Index,Title,DOI,Abstract,Authors,A_Decision,A_Reason,A_P,A_I,A_C,A_O,A_S,B_Decision,B_Reason,B_P,B_I,B_C,B_O,B_S,C_Decision,C_Reason,Final_Decision
0,"Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab",10.1016/j.transproceed.2023.03.064,"Background. Using immune checkpoint inhibitors (ICIs) as a downstaging therapy for liver transplantation (LT) has improved outcomes for patients with advanced hepatocellular carcinoma (HCC). However, this therapy carries a risk of post-transplant graft rejection. The washout (WO) period between the last ICI dose and LT seems critical in preventing postoperative rejection. This study aimed to optimize the WO period by balancing tumor burden suppression and rejec-tion prevention using ICIs before LT.Methods. We reviewed published case reports or series from March 2020 to December 2022 regarding LT for HCC after downstaging or bridge therapy with ICIs and included 4 of our cases. Most patients received atezolizumab, nivolumab, or pembrolizumab; these ICIs shared a half-life of around 28 days. Therefore, we excluded cases without definite WO period data and those using non-atezolizumab/nivolumab/pembrolizumab ICIs and ultimately enrolled 22 patients for analysis. We compared their clinical outcomes and estimated the rejection-free survival for every 0.5 half-life interval.Results. Most study subjects received nivolumab (n = 25). Six patients had severe rejections (nivolumab group, n = 5) and needed rescue management. Of the 6 cases, 1 patient died after rejection, and 2 underwent re-transplantation. The median WO period in these 6 patients was 22 days (IQR: 9-35 days). In addition, we found that a 1.5 half-life (42 days) was the shortest safe WO period associated with significant rejection-free survival (P = .005).Conclusions. Our results showed that 42 days was the safest WO period before LT for HCC after ICI with atezolizumab, nivolumab, or pembrolizumab.","Kuo, FC; Chen, CY; Lin, NC; Liu, CS; Hsia, CY; Loong, CC",False,does not meet study design criteria,patients with advanced hepatocellular carcinoma,immune checkpoint inhibitors as downstaging therapy,not specified,rejection-free survival related to washout period,not a randomized controlled trial,False,"The study does not meet the PICOS criteria as it is not a randomized controlled trial. Additionally, the population focuses on patients receiving ICIs as a downstaging therapy for liver transplantation rather than general hepatocellular carcinoma treatment. The comparison group is absent, and the primary outcome is rejection-free survival related to washout period rather than survival or response rate.",patients with advanced hepatocellular carcinoma undergoing liver transplantation after receiving ICIs as downstaging therapy,-,no comparison group specified in the abstract,-,-,False,No disagreement between Model A and B,False
1,Immune checkpoint inhibitors in liver transplant recipients - a review of current literature,10.20517/2394-5079.2021.11,"Immuno-oncology, particularly with the development of immune checkpoint inhibitors (ICIs), has become a frontline category of cancer-directed therapy, including in the treatment of hepatocellular carcinoma (HCC). While liver transplant (LT) offers a potential cure for HCC, the use of ICIs is a topic of safety concern both pre- and posttransplant due to the risk of donor graft rejection. Nonetheless, some scenarios for which the therapeutic effects of ICI may be highly beneficial include the downstaging of unresectable HCC pre-transplant, or the treatment of recurrent HCC and secondary malignancies post-transplant. In this review, we explored the evidence surrounding the use of ICI in the peri-transplant setting, including safety and efficacy. In a comprehensive review of 28 cases of ICI use post-transplant, we found graft rejection in 9 of 28 cases (32%). Some factors that may increase the risk of rejection include younger age, less time between LT and ICI therapy, and PD-1/PD-L1 expression in the donor graft (particularly when using anti-PD-1/anti-PD-L1 ICIs). Despite these concerns, we relay a case of successful HCC downstaging with nivolumab and subsequent LT. We also describe several cases of response to ICIs post-LT (7 of 28 cases) among a group that is often heavily pre-treated. We conclude that ICIs are valuable options in the peritransplant setting that have demonstrated promising efficacy based on case reports. Controlled clinical trials are needed to further investigate the conditions that may allow safe delivery of these therapies.","Yin, C; Baba, T; He, AR; Smith, C",False,does not meet study design criteria,not specified,immune checkpoint inhibitors for hepatocellular carcinoma,not specified or comparison to standard treatments,graft rejection rates and response to ICIs,"review of case reports, not a randomized controlled trial",False,"This article is a review of case reports and lacks a defined population, intervention, and comparison group. It also does not meet the study design criterion of being a randomized controlled trial. While it discusses graft rejection rates and efficacy of ICIs, these outcomes are not directly relevant to survival or response rates in hepatocellular carcinoma patients.",not explicitly specified but likely includes patients with HCC treated with ICIs in peri-transplant settings,immune checkpoint inhibitors used pre- and post-liver transplantation,no comparison group specified in the abstract,graft rejection rates and response to ICIs post-transplant,-,False,No disagreement between Model A and B,False
2,Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors,10.3390/cancers16132374,"Simple Summary Immune checkpoint inhibitors (ICIs) have witnessed significant success in systemic therapy of hepatocellular carcinoma, stimulating the transplant community to consider their use in the liver transplantation (LT) setting. This review provides an updated overview of the current evidence on ICI therapy before and after LT, discussing the associated pitfalls and remaining challenges. A particular focus is placed on the interactions between ICIs and immunosuppressive drugs, in order to identify predictive factors of good response, as well as critical aspects that should guide future research on the topic.Abstract Hepatocellular carcinoma (HCC) remains the leading oncological indication for liver transplantation (LT), with evolving and broadened inclusion criteria. Immune checkpoint inhibitors (ICIs) gained a central role in systemic HCC treatment and showed potential in the peri-transplant setting as downstaging/bridging therapy before LT or as a treatment for HCC recurrence following LT. However, the antagonistic mechanisms of action between ICIs and immunosuppressive drugs pose significant challenges, particularly regarding the risk of acute rejection (AR). This review analyzes the main signaling pathways targeted by ICI therapies and summarizes current studies on ICI therapy before and after LT. The literature on this topic is limited and highly heterogeneous, precluding definitive evidence-based conclusions. The use of ICIs before LT appears promising, provided that a sufficient wash-out period is implemented. In contrast, the results of post-LT ICI therapy do not support its wide clinical application due to high AR rates and overall poor response to treatment. In the future, modern graft preservation techniques might support the selection of good ICI responders, but data from high-level studies are urgently needed.","De Stefano, N; Patrono, D; Colli, F; Rizza, G; Paraluppi, G; Romagnoli, R",False,does not meet study design criteria,not specified,immune checkpoint inhibitors in hepatocellular carcinoma,not specified,not specified,"not a randomized controlled trial, review article",False,"The article is a review that lacks specific details about the population, intervention, and comparison groups. It does not meet the study design criterion of being a randomized controlled trial. The outcomes discussed are too broad and not focused on survival or response rates specifically.",not explicitly specified but likely includes patients with HCC treated with ICIs before or after liver transplantation,immune checkpoint inhibitors used in systemic therapy for HCC,no comparison group specified in the abstract,risk of acute rejection and response to ICIs,-,False,No disagreement between Model A and B,False
3,"Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy",10.3390/cancers15061798,"Simple Summary Systemic therapy for advanced-stage hepatocellular carcinoma (HCC) is undergoing major changes owing to the advancements made in molecular-targeted therapies and immune checkpoint inhibitors (ICIs). Although transarterial chemoembolization has been used as the standard treatment for intermediate-stage HCC, it has recently included molecular-targeted drugs and ICIs. As intermediate-stage HCC encompasses a wide variety of HCCs, the appropriate regimen to be used and the order of drug administration, including the use of anti-angiogenic inhibitors, remain controversial. This review discusses treatment strategies for intermediate-stage HCC considering the background of progress in the treatment of advanced-stage HCC. Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatment because intermediate-stage HCC encompasses a wide variety of HCCs. Owing to remarkable progress in systemic therapy, including molecular-targeted therapy for advanced-stage HCC, the standard treatment of HCC has recently shifted to systemic therapy. However, it remains controversial as to which treatment should be initially performed for intermediate-stage HCC. In addition, although curative treatment can be considered when the tumor shrinks, the timing of conversion therapy remains uncertain. This review summarizes the advances of HCC treatment and discusses treatment strategies for intermediate-stage HCC.","Hatanaka, T; Yata, Y; Naganuma, A; Kakizaki, S",False,does not meet study design criteria,patients with intermediate-stage hepatocellular carcinoma,immune checkpoint inhibitors and other therapies,not specified,not specified,"not a randomized controlled trial, review article",False,"The article focuses on intermediate-stage HCC and discusses various treatment strategies without specifying a clear population, intervention, or comparison group. It does not meet the study design criterion of being a randomized controlled trial. The outcomes are not clearly defined and do not align with survival or response rates.",patients with intermediate-stage hepatocellular carcinoma,immune checkpoint inhibitors combined with other therapies such as transarterial chemoembolization,no comparison group specified in the abstract,not explicitly specified but likely includes treatment response and timing of conversion therapy,-,False,No disagreement between Model A and B,False
4,Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver,10.3390/ijms252111676,"Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death worldwide. Liver transplantation (LT) is the best therapy for most patients with non-metastatic HCC. In recent years, the management of patients with HCC has considerably changed, thanks to the improvement of molecular biology knowledge and the introduction of immunotherapy. To date, systemic therapy is authorized in the Western world only in patients with advanced HCC. However, this therapy could not only stabilize the tumour disease or improve survival but could display excellent response and lead to downstaging of the tumour that finally permits LT. There are increasing reports of patients that have performed LT after pretreatment with immune checkpoint inhibitors (ICIs). However, due to the intrinsic mechanism of ICIs, graft rejection might be favoured. In addition, chronic adverse effects affecting other organs may also appear after the end of therapy. This review aims to evaluate the readiness and outcomes of LT in patients with advanced HCC who have previously undergone treatment with ICIs. It seeks to identify the challenges, risks, and benefits associated with this conversion therapy. The integration of ICIs into the treatment paradigm for advanced HCC necessitates a nuanced approach to LT. While early evidence supports the feasibility of LT following ICIs therapy, there is an urgent need for standardized guidelines and more extensive longitudinal studies to optimize patient selection, timing, and post-transplant management.","Marzi, L; Mega, A; Turri, C; Gitto, S; Ferro, F; Spizzo, G",False,does not meet study design criteria,patients with advanced hepatocellular carcinoma,immune checkpoint inhibitors before liver transplantation,not specified,challenges and outcomes of LT after ICIs,"not a randomized controlled trial, review article",False,"This article reviews the use of ICIs in advanced HCC patients before liver transplantation but lacks a defined population, intervention, and comparison group. It does not meet the study design criterion of being a randomized controlled trial. The outcomes focus on challenges and risks of LT after ICIs rather than survival or response rates.",patients with advanced hepatocellular carcinoma treated with ICIs before liver transplantation,-,no comparison group specified in the abstract,"challenges, risks, and outcomes of liver transplantation after ICIs",-,False,No disagreement between Model A and B,False
5,Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy,10.1097/MOT.0000000000001133,"Purpose of reviewThe increasing success of liver transplantation in hepatocellular carcinoma (HCC) drives an ever-evolving search for innovative strategies to broaden eligible patients' pools. Recent advances in immuno-oncology have turned the spotlight on immune checkpoint inhibitors (ICIs). This review offers an updated overview of ICIs in liver transplantation for HCC, exploring neoadjuvant and adjuvant approaches and addressing unanswered questions on safety, patients' selection, and response predictors.Recent findingsICIs have transitioned from being a last-chance therapeutic hope to becoming an integral cornerstone in the treatment of advanced HCC, holding great promise as a compelling option not only to downstage patients for transplantation but also as an alternative strategy in addressing posttransplantation disease recurrence. Despite ongoing refinements in immunotherapeutic agents, the complex molecular pathways involved emphasize the need for a comprehensive approach to integrate immunotherapy in liver transplantation.SummaryInitial concerns about graft rejection, with ICIs as a bridging therapy to liver transplantation, were successfully addressed using adequate immunosuppressants strategies and minimized with a sufficient washout period. Post-liver transplantation disease recurrence remains challenging, requiring a balance between effective therapy and preserving graft function. Emphasis should be placed on clinical trials validating the risk-benefit ratio of ICIs for liver transplantation, guiding appropriate patients' selection, and establishing clear management pathways.","Tabrizian, P; Zeitlhoefler, M; Hassan, AT; Marino, R",False,does not specify a comparison group or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors in liver transplantation,not specified,not specified,not specified,False,"The abstract discusses the use of ICIs in liver transplantation for HCC but does not specify a comparison group or study design. While Model A correctly identifies these omissions, it fails to note that the population is specifically patients undergoing liver transplantation, which narrows the broader PICOS criteria. The intervention description should explicitly mention neoadjuvant and adjuvant approaches as part of the ICI application.",patients with hepatocellular carcinoma undergoing liver transplantation,immune checkpoint inhibitors used in neoadjuvant and adjuvant approaches for liver transplantation,-,-,-,False,No disagreement between Model A and B,False
6,Immune checkpoint inhibitors in liver transplant: a case series,10.21037/jgo-22-922,"Background: Immune checkpoint inhibitors (ICIs) in the setting of liver transplant (LT) pose a risk of rejection and hold unclear benefit in both the neoadjuvant (pre-transplant) and post-transplant salvage setting. In the pre-transplant setting, neoadjuvant ICIs may serve as a bridge to LT by downstaging disease burden to fit within transplant criteria. Outcomes in this setting include patients who had successful transplants without complications to patients who suffered severe complications, including fatal hepatic necrosis and graft failure requiring re-transplant. Some authors suggest having a period of three months between checkpoint inhibition and transplant may help mitigate adverse effects. In the post-LT setting, there are few treatment options if there is a recurrence of disease, which forces treatment teams to reconsider checkpoint inhibitors. Again, a longer period of time between transplant and checkpoint inhibition may reduce risk of rejection. Case reports of patients treated with ICIs post-transplant utilized either nivolumab or pembrolizumab. As combination atezolizumab/bevacizumab is a relatively new treatment option for unresectable hepatocellular carcinoma (HCC), there are only three reported cases using this combination in the post-LT setting. While there were no cases of rejection, all three cases had progression of disease. As immunotherapy joins transplantation as a mainstay of treatment for HCC, it remains unclear how to best navigate when the treatment course involves both immune activation and immunosuppression.Case Description: Patients who had an LT and were treated with ICIs (pre or post LT) at the University of Cincinnati were included in this retrospective chart review.Conclusions: Fatal rejection remains a significant risk even 4 years after LT. Neoadjuvant ICIs also pose a risk for acute cellular rejection; however, this may not always be clinically significant. Graft versus host disease (GVHD) may be an additional, previously unreported risk of ICIs in the setting of LT. Prospective studies are needed to understand benefits and risks of checkpoint inhibitors in the LT setting.","Rudolph, M; Shah, SA; Quillin, R; Lemon, K; Olowokure, O; Latif, T; Sohal, D",False,not a randomized controlled trial,patients who underwent liver transplantation,immune checkpoint inhibitors pre and post-transplant,comparison of outcomes with and without ICIs,not specified,retrospective chart review,False,"Model A correctly identifies this as a retrospective chart review and not an RCT. However, the population description should specify patients with HCC who underwent liver transplantation since this is critical to the study context. The comparison description is vague; while outcomes with and without ICIs are implied, the abstract does not explicitly define the comparator group. Additionally, the outcome description should include specific measures such as survival or rejection rates.",patients with hepatocellular carcinoma who underwent liver transplantation,-,outcomes with and without ICIs implied but not explicitly defined,survival rates and incidence of complications including graft rejection,-,False,No disagreement between Model A and B,False
7,Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition),10.1159/000535496,"Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the ""Delphi"" consensus formation method, and finally revised and completed the ""Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)"" on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.","Liu, XF; Lu, YY; Zhou, WP; Peng, T; Zhou, J; Bi, HQ; Xia, F; Chen, XP",False,does not specify a comparison group or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors-based combination therapy,not specified,not specified,not specified,False,"Model A's analysis is accurate in identifying the lack of a comparison group and study design. However, the intervention description should specify that the focus is on combination therapies involving ICIs rather than ICIs alone. The population description could be more precise by noting that the consensus applies to unresectable HCC, as this is a key detail from the abstract.",patients with unresectable hepatocellular carcinoma,combination therapies based on immune checkpoint inhibitors,-,-,-,False,No disagreement between Model A and B,False
8,Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report,10.1016/j.ajt.2024.01.007,"Atezolizumab plus bevacizumab is the preferred first-line treatment regimen for patients with advanced hepatocellular carcinoma. Limited data have shown promising results with the use of immune checkpoint inhibitors like nivolumab to downstage these patients for liver transplantation (LT). Here, we describe the first case of successful downstaging with atezolizumab plus bevacizumab in a patient with multifocal hepatocellular carcinoma and main portal vein tumoral thrombosis, followed by ABO-incompatible live donor LT. This illustrated case highlights that atezolizumab plus bevacizumab therapy may be a potential bridging tool for curative LT.","Kumar, P; Krishna, P; Nidoni, R; Adarsh, CK; Arun, MG; Shetty, A; Mathangi, J; Sandhya; Gopasetty, M; Venugopal, B",False,not a randomized controlled trial,patient with multifocal hepatocellular carcinoma,atezolizumab plus bevacizumab,not specified,successful downstaging for liver transplantation,case report,False,"Model A correctly identifies this as a case report and not an RCT. However, the population description should emphasize multifocal HCC with portal vein involvement, as this is a distinct subgroup. The outcome description should explicitly mention downstaging success as a measurable endpoint, which aligns with the PICOS criteria for response rate.",patient with multifocal hepatocellular carcinoma and main portal vein tumoral thrombosis,-,-,successful downstaging for liver transplantation as a measurable response rate,-,False,No disagreement between Model A and B,False
9,Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery,10.2217/hep-2020-0014,"Aims: The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration. Patients & methods: We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial. Results: A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent. Conclusions: New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.","Goio, E; Ielasi, L; Benevento, F; Renzulli, M; Tovoli, F",False,does not involve ICIs or randomized controlled trial,patient with metastatic hepatocellular carcinoma,regorafenib,not specified,tumor downstaging,not specified,False,"Model A's analysis is correct in excluding this article due to the lack of ICIs and RCT design. However, the intervention description should clarify that regorafenib is a systemic therapy, not an ICI. The population description should specify metastatic HCC, as this is a key characteristic mentioned in the abstract.",patient with metastatic hepatocellular carcinoma,regorafenib as a systemic therapy,-,-,-,False,No disagreement between Model A and B,False
10,Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors,10.3390/cancers13246307,"Simple Summary Immune checkpoint inhibitors (ICI) have revolutionized the treatment of hepatocellular carcinoma (HCC). In addition to their role in advanced HCC, there is considerable interest in using ICIs in the neoadjuvant setting, either as a downstaging or bridging therapy, prior to potentially curative liver transplantation. In this article, we reviewed all the available literature on ICI use in this context. We postulate that ICIs may be utilized safely prior to liver transplant; however, further research is needed in this area. Liver transplantation offers excellent outcomes for patients with HCC. For those who initially present within the Milan criteria, bridging therapy is essential to control disease while awaiting liver transplant. For those who present beyond the Milan criteria, a liver transplant may still be considered following successful downstaging. Since the introduction of atezolizumab as part of the first-line treatment for HCC in 2020, there has been increasing interest in the use of ICIs as bridging or downstaging therapies prior to liver transplant. A total of six case reports/series have been published on this topic, with mixed outcomes. Overall, liver transplantation can be performed safely following prolonged ICI use, though ICIs may increase the risk of fulminant acute rejection early in the post-operative period. A minimal washout period between the last dose of ICI and liver transplantation has been identified as an important factor predicting transplant outcomes; however, further research is needed.","Gao, QM; Anwar, IJ; Abraham, N; Barbas, AS",False,"lacks comparison, outcome, and study design details",patients with hepatocellular carcinoma,immune checkpoint inhibitors,not specified,not specified,not specified,False,"The abstract discusses the use of ICIs in the neoadjuvant setting for HCC but does not specify a comparison group, measurable outcomes like survival or response rates, or indicate an RCT design. Model A correctly identifies these omissions.",-,-,-,-,-,False,No disagreement between Model A and B,False
11,Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two cases,10.3389/fimmu.2023.1159885,"Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can undergo radical resection. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can ultimately achieve short-term hypertrophy of the FLR in patients with viral hepatitis-related fibrosis/cirrhosis and R0 resection. However, the influence of immune checkpoint inhibitors (ICIs) on liver regeneration remains unknown. We report two patients diagnosed with Barcelona Clinic Liver Cancer (BCLC)-B stage hepatitis B virus (HBV)-related HCC who underwent pioneering ALPPS after immunotherapy without posthepatectomy liver failure (PHLF). ALPPS has been shown to be safe and feasible in patients with HCC who underwent immunotherapy previously for the first time and might provide an alternative salvage option for future conversion therapy of HCC.","Ning, C; Liu, GM; Zhang, JW; Yang, XB; Xu, YY; Zhao, HT",False,"lacks comparison, outcome, and study design details",patients with hepatitis B virus-related HCC,immune checkpoint inhibitors,not specified,not specified,not specified,False,"The abstract focuses on two case studies of ALPPS following immunotherapy but lacks a defined comparison group, specific outcome metrics, and is not an RCT. Model A's analysis accurately notes these deficiencies.",-,-,-,-,-,False,No disagreement between Model A and B,False
12,Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition),10.5582/bst.2024.01394,"Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the Healthy China 2030 blueprint, the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focused on the latest progress since the release of the Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) and resulted in a new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice, standardize medical care, and promote the development of the discipline.","Tang, HW; Zhang, WW; Cao, JN; Cao, YB; Bi, XY; Zhao, HT; Zhang, Z; Liu, Z; Wan, T; Lang, R; Sun, WB; Du, SD; Yang, YP; Lu, YY; Zeng, DB; Wu, JS; Duan, BW; Lin, DD; Li, F; Meng, QH; Zhou, J; Xing, BC; Tian, XD; Zhu, JY; Gao, J; Hao, CY; Wang, ZQ; Duan, F; Wang, ZJ; Wang, MQ; Liang, B; Chen, YW; Xu, YZ; Li, K; Li, CG; Hu, MG; Wang, ZH; Cai, SW; Ji, WB; Xia, NX; Zheng, WH; Wang, HG; Li, G; Zhu, ZM; Huang, ZY; Zhang, WG; Tao, KS; Liang, J; Zhang, KM; Dai, CL; Li, JT; Qiu, Q; Guo, Y; Wu, LQ; Ding, WB; Zhu, ZY; Gu, WQ; Cao, JY; Wang, ZS; Tian, LT; Ding, HG; Li, GM; Zeng, YY; Wang, K; Yang, N; Jin, HS; Chen, YJ; Yang, YM; Xiu, DR; Yan, ML; Wang, XD; Han, QL; Jiao, SC; Tan, G; Wang, JZ; Liu, LX; Song, JH; Liao, JJ; Zhao, H; Li, P; Song, TQ; Wang, ZB; Yuan, J; Hu, BY; Yuan, YF; Zhang, M; Sun, SY; Zhang, JL; Wang, WT; Wen, TF; Yang, JY; Du, XL; Peng, T; Xia, F; Liu, ZJ; Niu, WB; Liang, P; Xu, JM; Zhao, X; Zhu, M; Wang, HZ; Kuang, M; Shen, SL; Cui, X; Zhou, JX; Liu, R; Sun, HC; Fan, J; Chen, XP; Zhou, J; Cai, JQ; Lu, SC",False,"lacks population, comparison, outcome, and study design details",not specified,immune checkpoint inhibitors and anti-angiogenic therapy,not specified,not specified,not specified,False,"The abstract provides a consensus statement rather than original research. It lacks details on population characteristics, comparison groups, measurable outcomes, and study design. Model A's assessment aligns with these issues.",-,-,-,-,-,False,No disagreement between Model A and B,False
13,Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study,10.1159/000542291,"Introduction: Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have demonstrated higher tumor response rates, which improved overall survival (OS). HAIC achieves an OS rate of approximately 14.5-15.3 months with a 39.1-42.5% tumor response rate. In comparison, ICIs have a 12-14 month OS rate with a 26-33% tumor response rate. Given these promising responses, this study evaluates the efficacy of conversion therapy with curative intent following HAIC or ICIs, focusing on survival outcomes. Methods: We retrospectively analyzed 80 patients with advanced or TACE-unsuitable intermediate HCC. Patients completed two HAIC or four ICI cycles, followed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria imaging. Based on demographics, cirrhosis status, Barcelona Clinic Liver Cancer classification (BCLC) stage, treatment responses, and treatment modality, survival impacts were analyzed. OS was compared between HAIC and immunotherapy groups. The effect of conversion therapy with curative intent on survival outcomes was analyzed using a Cox regression model. Results: Among the 80 patients, 26 achieved positive response (CR/PR) with HAIC or ICIs, and 9 of them subsequently underwent conversion therapy with curative intent. Key prognostic factors included Child-Pugh stage B versus A (HR = 2.21, p = 0.041), BCLC stage C versus B (HR = 4.38, p = 0.011), and elevated alpha-fetoprotein levels (HR = 5.02, p < 0.001). Positive responders saw substantial survival benefits (HR = 0.26, p = 0.001). Patients undergoing conversion therapy exhibited significantly enhanced survival. Median OS was 13.58 months with standard therapy, while the curative intent surgery group did not reach the median OS (p = 0.002). For CR/PR patients, 48-month survival was 75.0% for the curative surgery group versus 38.0% for standard treatment. Conclusion: Conversion therapy with curative intent following HAIC or ICIs might enhance survival in patients with advanced or TACE-unsuitable intermediate-stage HCC.","Kuo, LF; Liu, WC; Li, MF; Huang, FH; Chou, CK; Chen, TH; Tsai, YT; Hsu, PI; Li, CJ; Wu, IT; Tsai, KF",False,study design is not a randomized controlled trial,patients with advanced or TACE-unsuitable intermediate-stage HCC,immune checkpoint inhibitors,compared with HAIC treatment,survival outcomes,retrospective analysis,False,"Although the abstract compares HAIC and ICIs and reports survival outcomes, it is a retrospective analysis rather than an RCT. Model A correctly identifies this flaw. Additionally, while the comparison group is mentioned, it focuses on HAIC rather than placebo or standard care.",-,-,compared with HAIC treatment but lacks placebo or no ICI comparison,-,-,False,No disagreement between Model A and B,False
14,Radiation therapy in the era of immune treatment for hepatocellular carcinoma,10.3389/fimmu.2023.1100079,"Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or second-line therapy. Downstaging conversion therapy for potentially resectable HCC to provide opportunities for surgical intervention is challenging. ICIs have become a hot spot in this field due to their high response rate. However, HCC has various etiologies and can evade the immune system through multiple mechanisms, which limit the efficacy of ICI monotherapy and demand novel combination strategies. Radiation therapy (RT) is also a candidate for conversion therapy in HCC and is currently gaining increasing attention as a good combination partner with ICIs due to its ability to modulate the tumor microenvironment. In this review, we illustrate the current indications for ICIs and RT in HCC, the rationale for their synergistic combination, and the current clinical trials in combination therapy. We also speculate on predictive biomarkers and novel future strategies to further enhance the efficacy of this combination. This review aims to provide references for future research on radiation and immunotherapy to arrive at a promising new era of HCC treatment.","Chen, LJ; Zhang, RG; Lin, ZY; Tan, QY; Huang, ZY; Liang, BY",False,"lacks population, comparison, outcome, and study design details",not specified,immune checkpoint inhibitors,not specified,not specified,not specified,False,"The abstract reviews potential synergies between ICIs and radiation therapy but does not define a specific population, comparison group, measurable outcomes, or study design. Model A's critique is accurate and comprehensive.",-,-,-,-,-,False,No disagreement between Model A and B,False
15,Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations,10.1159/000514313,"Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies has shown high tumor response rates for patients with unresectable hepatocellular carcinoma (HCC). However, using this treatment strategy to convert initially unresectable HCC to resectable HCC was not reported. Methods: Consecutive patients with unresectable HCC who received first-line therapy with combined TKI/anti-PD-1 antibodies were analyzed. Tumor response and resectability were evaluated via imaging every 2 months (+/- 2 weeks) using RECIST v1.1. Resectability criteria were (1) R0 resection could be achieved with sufficient remnant liver volume and function; (2) intrahepatic lesions were evaluated as partial responses or stable disease for at least 2 months; (3) no severe or persistent adverse effects occurred; and (4) hepatectomy was not contraindicated. Results: Sixty-three consecutive patients were enrolled. Of them, 10 (15.9%) underwent R0 resection in 3.2 months (range: 2.4-8.3 months) after the initiation of combination therapy. At baseline, these 10 patients had a median largest tumor diameter of 9.3 cm, 7 had Barcelona Clinic Liver Cancer stage C (vascular invasion) disease, 2 had stage B, and 1 had stage A. Before surgery, 6 patients were evaluated as a partial response, 3 stable disease, and 1 partial response in the intrahepatic lesion but a new metastatic lesion in the right adrenal gland. Six patients (60%) achieved a pathological complete response. One patient died from immune-related adverse effects 2.4 months after hepatectomy. After a median follow-up of 11.2 months (range: 7.8-15.9 months) for other 9 patients, 8 survived without disease recurrence, and 1 experienced tumor recurrence. Conclusions: Combination of TKI/anti-PD-1 antibodies is a feasible conversion therapy for patients with unresectable HCC to become resectable. This study represents the largest patient cohort on downstaging role of combinational systemic therapy on TKI and PD-1 antibody for HCC.","Zhu, XD; Huang, C; Shen, YH; Ji, Y; Ge, NL; Qu, XD; Chen, LL; Shi, WK; Li, ML; Zhu, JJ; Tan, CJ; Tang, ZY; Zhou, J; Fan, J; Sun, HC",False,does not meet study design criteria,patients with unresectable hepatocellular carcinoma,combined TKI and anti-PD-1 antibodies,not specified,tumor response rates and resectability,not randomized controlled trial,False,"The study evaluates combination therapy with TKIs and anti-PD-1 antibodies but does not meet the PICOS criteria for a randomized controlled trial. Model A correctly identifies this as a non-randomized study, and the comparison group is not specified in the abstract.",-,-,-,-,-,False,No disagreement between Model A and B,False
16,Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons,10.4251/wjgo.v14.i1.163,"Liver transplantation (LT) has emerged as a curative strategy for hepatocellular carcinoma (HCC), but contributes to a higher predisposition to HCC recurrence in the immunosuppression context, especially for tumors beyond the Milan criteria. Although immunotherapy has dramatically improved survival for immunocompetent patients and has become the standard of care for a variety of tumors, including HCC, it is mainly used outside the scope of organ transplantation owing to potentially fatal allograft rejection. Nevertheless, accumulative evidence has expanded the therapeutic paradigms of immunotherapy for HCC, from downstaging or bridging management in the pretransplant setting to the salvage or adjuvant strategy in the posttransplant setting. Generally, immunotherapy mainly includes immune checkpoint inhibitors (ICIs), adoptive cell transfer (ACT) and vaccine therapy. ICIs, followed by ACT, have been most investigated in LT, with some promising results. Because of the complex tumor microenvironment and immunoreactivity when immunosuppressants are combined with immunotherapy, it is difficult to reach formulations for immunosuppressant adjustment and the optimal selection of immunotherapy as well as patients. In addition, the absence of effective biomarkers for identifying rejection and tumor response is still an unresolved barrier to successful clinical immunotherapy applications for LT. In this review, we comprehensively summarize the available evidence of immunotherapy used in LT that is specific to HCC. Moreover, we discuss clinically concerning issues regarding the concurrent goals of graft protection and antitumor response.","Luo, Y; Teng, F; Fu, H; Ding, GS",False,abstract discusses immunotherapy without trial data,patients with hepatocellular carcinoma,immune checkpoint inhibitors,not specified,not specified,not specified,False,This is a review article discussing immunotherapy in liver transplantation without presenting original trial data or meeting the PICOS criteria. Model A's analysis is accurate in identifying the lack of trial data and unspecified outcomes.,-,-,-,-,-,False,No disagreement between Model A and B,False
17,Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review,10.3389/fimmu.2024.1358602,"Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy globally, with the majority of patients presenting at the initial diagnosis with locally advanced or metastatic disease, precluding the opportunity for curative surgical intervention. With the exploration and advancement of locoregional treatments, novel molecular-targeted therapies, anti-angiogenic agents, and immunomodulatory drugs, the management of HCC has seen an increase in objective response rates and prolonged duration of response significantly enhancing the potential for conversion to resectable disease in intermediate and advanced-stage unresectable HCC. Herein, we present a case of Barcelona Clinic Liver Cancer stage B unresectable HCC, where after two courses of treatment with transarterial chemoembolization combined with atezolizumab plus bevacizumab significant tumor reduction was achieved. Per Response Evaluation Criteria in Solid Tumors 1.1, partial response culminated in successful curative surgical resection. No drug-related adverse reactions occurred during hospitalization, and there has been no recurrence during the 11-month postoperative follow-up. For patients with Barcelona Clinic Liver Cancer stage B (intermediate-stage) unresectable HCC, the transarterial chemoembolization combined with atezolizumab plus bevacizumab regimen may offer improved therapeutic outcomes leading to a higher success rate of conversion therapy and, thus, improved survival.","Ai, HD; Gong, T; Ma, YB; Ma, GX; Ding, W; Ding, WB; Wang, WJ; Zhao, XL",False,does not meet study design criteria,patients with Barcelona Clinic Liver Cancer stage B unresectable HCC,transarterial chemoembolization with atezolizumab and bevacizumab,not specified,improved therapeutic outcomes and survival,not randomized controlled trial,False,The study presents a single case report rather than a randomized controlled trial and lacks a comparison group. Model A correctly notes the absence of an RCT design and unspecified comparison.,-,-,-,-,-,False,No disagreement between Model A and B,False
18,Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab,10.1111/liv.15907,"Background: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC). Methods: In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first-line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded. Clinical factors possibly linked to successful transition to conversion therapy and the achievement of cancer-free status were identified. Results: Fifteen (8.0%) patients underwent conversion therapy. In the conversion group, there was a significantly higher proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B (73.3% versus [vs.] 45.1%; p = .03) and tended to have lower Child-Pugh scores and alpha-fetoprotein levels. Multivariate analysis revealed that BCLC stage was a predictive factor for the implementation of conversion therapy (A or B; odds ratio 3.7 [95% CI: 1.1-13]; p = .04). Furthermore, 10 (66.7%) patients achieved cancer-free status and exhibited a smaller number of intrahepatic lesions at the start of treatment (3.5 vs. 7; p < .01), and a shorter interval between systemic chemotherapy induction and conversion therapy (131 vs. 404 days; p < .01). In addition, the rate of achieving cancer-free status by undergoing surgical resection or ablation therapy was significantly higher (p = .03). Conclusion: BCLC stage was the sole predictive factor for successful transition to conversion therapy when using combination therapy with atezolizumab and bevacizumab to treat HCC. Furthermore, a small number of intrahepatic lesions and early transition to conversion therapy were associated with the achievement of cancer-free status.","Kikuchi, T; Takeuchi, Y; Nouso, K; Kariyama, K; Kuwaki, K; Toshimori, J; Iwado, S; Moriya, A; Hagihara, H; Takabatake, H; Tada, T; Yasunaka, T; Sakata, M; Sue, M; Miyake, N; Adachi, T; Wada, N; Onishi, H; Shiraha, H; Takaki, A; Otsuka, M",False,does not meet study design criteria,patients with unresectable hepatocellular carcinoma,atezolizumab and bevacizumab combination therapy,not specified,cancer-free status and predictive factors,not randomized controlled trial,False,This is a retrospective observational study analyzing predictive factors for conversion therapy success. It does not meet the PICOS criteria for a randomized controlled trial. Model A accurately identifies the study design issue and unspecified comparison group.,-,-,-,-,-,False,No disagreement between Model A and B,False
19,Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis,10.1186/s12885-024-12772-y,"BackgroundSystemic conversion therapy provides patients with initially unresectable hepatocellular carcinoma (HCC) the chance to salvage radical liver resection and superior survival outcomes, but the optimal conversion strategy is unclear.MethodsA systematic literature search was conducted on PubMed, EMBASE, Web of Science, Scopus, and the Cochrane Library between 2007 and 2024 focusing on studies reporting conversion therapy for HCC. The treatment groups were divided into Tyrosine kinase inhibitors (TKI), TKI plus loco-regional therapy (LRT), TKI plus anti-PD-1 therapy (TKI + PD-1), TKI + PD-1 + LRT, immune checkpoint inhibitors (ICI) plus LRT, and Atezolizumab plus bevacizumab (A + T) groups. The conversion to surgery rate (CSR), objective response rate (ORR), grade >= 3 treatment-related adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were analyzed.Results38 studies and 4,042 patients were included. The pooled CSR were 8% (95% CI, 5-12%) in TKI group, 13% (95% CI, 8-19%) in TKI + LRT group, 28% (95% CI, 19-37%) in TKI + PD-1 group, 33% (95% CI, 25-41%) in TKI + PD-1 + LRT group, 23% (95% CI, 1-46%) in ICI + LRT group, and 5% (95% CI, 3-8%) in A + T group, respectively. The pooled HR for OS (0.45, 95% CI, 0.35-0.60) and PFS (0.49, 95% CI, 0.35-0.70) favored survival benefit of conversion surgery. Subgroup analysis revealed that lenvatinib + PD-1 + LRT conferred higher CSR of 35% (95% CI, 26-44%) and increased ORR of 70% (95% CI, 56-83%).ConclusionsThe current study indicates that TKI + PD-1 + LRT, especially lenvatinib + PD-1 + LRT, may be the superior conversion therapy with a manageable safety profile for patients with initially unresectable HCC. The successful conversion therapy favors the superior OS and PFS compared with systemic treatment alone.Trial registrationInternational prospective register of systematic reviews (PROSPERO) (registration code: CRD 42024495289).","Xu, HW; Zhang, HL; Li, B; Chen, KF; Wei, YG",False,not a specific randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,various conversion therapies including ICIs,comparison of different treatment groups,conversion to surgery rate and overall survival,systematic review of trials,False,This is a systematic review and meta-analysis rather than a specific randomized controlled trial. While it provides pooled data on conversion therapies including ICIs it does not meet the PICOS requirement for study design. Model A's classification of the study design is accurate.,-,-,-,-,-,False,No disagreement between Model A and B,False
20,Liver resection and transplantation in the era of checkpoint inhibitors,10.1016/j.jhepr.2024.101181,"Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape for advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab has demonstrated efficacy, establishing a new standard of care for advanced HCC. Neoadjuvant studies have shown promising results with high response rates, increasing research into ICIs' role. In the perioperative setting, in addition to adjuvant and neo-adjuvant therapies, strategies for ""downstaging"" and ""bridging"" patients to liver transplantation (LT) are being investigated, broadening the eligible candidate pool. Furthermore, therapeutic advances have reshaped conversion strategies for hepatic resection, with emerging evidence indicating a role for adjuvant immunotherapy in patients at high risk of postoperative recurrence. In LT, concerns have arisen over the potential conflict between immunosuppression needs and the immune-enhancing effects of ICIs, with reports of severe rejection. However, liver-specific factors may lessen rejection risks, prompting exploration into the safety of pre-transplant ICI administration. Moreover, ongoing trials must prioritise patient selection and vigilant management protocols. Despite the remarkable progress in immunotherapy, the intricate molecular interactions within the tumour microenvironment and their implications on oncogenic pathways remain incompletely understood. This highlights the need for specialised expertise to effectively integrate immunotherapy into the surgical management of HCC. Key challenges include ensuring safety, optimising oncological outcomes, managing the risk of graft rejection in transplant recipients, and refining patient selection criteria. In this review, we aim to provide a comprehensive overview of the evolving role of immunotherapy in the surgical management of HCC, discussing the rationale for its application in both pre- and post-surgical contexts, leveraging current clinical experience, identifying potential limitations, and envisioning future applications. By integrating existing knowledge and highlighting areas for further investigation, this review seeks to inform clinical practice and guide future research endeavours. (c) 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).","Tabrizian, P; Marino, R; Chow, PKH",False,does not specify comparison or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors,not specified,not specified,not specified,False,"The abstract does not specify a comparison group or study design, which are essential for meeting the PICOS criteria. While it discusses immune checkpoint inhibitors and their role in hepatocellular carcinoma, it lacks a clear comparator and is not based on a randomized controlled trial. Model A correctly identified these gaps.",-,-,not specified; no mention of a control or comparator group in the abstract,"not specified; while response rates are mentioned, specific outcomes like survival rate are not clearly defined",-,False,No disagreement between Model A and B,False
21,Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis,10.1007/s12672-024-01026-9,"Background Interventional therapy, in conjunction with tyrosine kinase inhibitors (TKIs), has shown promising outcomes for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). With the advent of immunotherapy, the combined use of immune checkpoint inhibitors (ICIs) has attracted great attention due to their potential effectiveness in advanced HCC. This study aims to compare the efficacy and safety of a triple therapy regimen (Interventional therapy, TKIs and ICIs, IT-TKI-ICI) with a dual therapy regimen (Interventional therapy and TKIs, IT-TKI) in the treatment of HCC and PVTT (HCC-PVTT).Methods A comprehensive search was carried out in PubMed, Web of Science, Embase, Scopus, and the Cochrane Library databases. Primary outcome measures were overall survival (OS) and progression-free survival (PFS), while secondary outcomes included tumor response rate, adverse event incidence as well as downstaging surgery rate. Statistical analysis was conducted using Revman 5.4 software.Results The meta-analysis finally included 6 cohort studies. The triple therapy group demonstrated significantly prolonged OS and PFS compared to the dual therapy group. Meanwhile, the former exhibited significantly higher rates of objective response rate (ORR), disease control rate (DCR) and better downstaging effects with a higher salvage surgery rate without significantly increasing adverse events.Conclusion In comparison to dual therapy, the triple therapy with interventional therapy, TKIs, and ICIs demonstrates superior efficacy and equivalent safety for HCC-PVTT.","Du, CJ; Wu, HY; Zhong, T; Zhai, QL; Yuan, JJ; Peng, JL; Ma, R; Li, JZ",False,not a randomized controlled trial,patients with hepatocellular carcinoma and portal vein tumor thrombosis,triple therapy with immune checkpoint inhibitors,dual therapy without ICIs,overall survival and progression-free survival,meta-analysis of cohort studies,False,"The study design is a meta-analysis of cohort studies, which does not meet the requirement for randomized controlled trials. Although the abstract specifies the intervention (triple therapy with ICIs) and comparison (dual therapy without ICIs), the lack of RCT design disqualifies it. Model A's reasoning aligns with this conclusion.",-,-,-,-,-,False,No disagreement between Model A and B,False
22,Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma,10.5582/bst.2024.01372,"Recently, a systemic therapy for advanced hepatocellular carcinoma (HCC) has been developed. The regimen for unresectable HCC varies and includes single or multi-tyrosine kinase inhibitors, monoclonal antibodies, immune checkpoint inhibitors, or their combinations. Treatment with these agents begins with sorafenib as the first-line drug for unresectable HCC. Subsequently, several systemic therapies, including lenvatinib, ramucirumab, cabozantinib, and regorafenib have been investigated and established. With advances in systemic therapy for unresectable HCC, the prognosis of patients with unresectable HCC has improved significantly than previously. Conversion surgery, consisting of systemic therapy and surgery, showed the possibility of improving the prognosis than systemic therapy alone. Although a combination of atezolizumab and bevacizumab is mostly used for initially unresectable HCC to conduct conversion surgery because of the high response rate and fewer adverse events compared to others, many trials are being conducted to assess their efficacy for initially unresectable HCC. However, the appropriate timing of surgery and interval between systemic therapy and surgery remain controversial. To address these issues, a multidisciplinary team can play a vital role in determining the strategies for treating unresectable HCC. This review describes previous and current trends in the treatment of HCC, with a particular focus on conversion surgery for initially unresectable HCC.","Hakoda, H; Ichida, A; Hasegawa, K",False,does not specify comparison or study design,patients with unresectable hepatocellular carcinoma,various systemic therapies including ICIs,not specified,not specified,not specified,False,The abstract lacks specification of a comparison group and study design. It broadly discusses systemic therapies including ICIs but does not provide details on how these were compared or evaluated in a structured manner. Model A correctly noted these deficiencies.,-,-,not specified; no clear comparator group is described in the abstract,"not specified; while improved prognosis is mentioned, specific outcomes like survival rate or response rate are not detailed",-,False,No disagreement between Model A and B,False
23,Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report,10.3390/curroncol29060341,"Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopic liver transplant remains the standard of care. Within the realms of transplant oncology, neoadjuvant systemic therapy is currently being evaluated as a potential strategy to improve outcomes in patients with HCC. Here, we report excellent response with significant downstaging in a safe manner after neoadjuvant treatment with atezolizumab and bevacizumab in a patient diagnosed with poorly differentiated HCC. As a result of the significant response observed with safe outcomes, the patient was listed for orthotopic liver transplant (OLT) evaluation and transplanted successfully.","Abdelrahim, M; Esmail, A; Umoru, G; Westhart, K; Abudayyeh, A; Saharia, A; Ghobrial, RM",False,does not specify randomized controlled trial design,patients with resectable hepatocellular carcinoma,neoadjuvant treatment with atezolizumab and bevacizumab,surgery alone or orthotopic liver transplant,response and downstaging,not specified,False,"The abstract describes a single case report of neoadjuvant treatment with atezolizumab and bevacizumab, which does not meet the PICOS criterion for study design as it is not a randomized controlled trial. Model A correctly identified this issue.",-,-,-,-,-,False,No disagreement between Model A and B,False
24,"A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence",10.3390/cancers15102791,"Primary liver tumors impose significant patient morbidity and mortality with overall poor prognosis. To date, conventional therapies have provided only modest survival benefit to patients. Developments in genomics, molecular biomarkers, and artificial intelligence are introducing novel patient-centered approaches to treat primary liver tumors to improve patient survival. Recent FDA-approved immune checkpoint inhibitors Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab have demonstrated improved survival outcomes and in many cases disease downstaging to curative resection. Clinical trials investigating combined immunotherapy and locoregional therapy in advanced liver disease are ongoing with promising preliminary results. Future directions in liver cancer management will likely incorporate treatment algorithms based on individualized patient molecular biomarkers.Primary liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Conventional therapies offer limited survival benefit despite improvements in locoregional liver-directed therapies, which highlights the underlying complexity of liver cancers. This review explores the latest research in primary liver cancer therapies, focusing on developments in genomics, molecular biomarkers, and artificial intelligence. Attention is also given to ongoing research and future directions of immunotherapy and locoregional therapies of primary liver cancers.","Moroney, J; Trivella, J; George, B; White, SB",False,does not specify comparison or study design,patients with primary liver cancer,immune checkpoint inhibitors,not specified,not specified,not specified,False,The abstract lacks a specified comparison group and study design. It discusses immune checkpoint inhibitors and their potential benefits but does not provide details on how these were evaluated in a structured or comparative manner. Model A accurately identified these gaps.,-,-,not specified; no comparator group is mentioned in the abstract,"not specified; while improved survival outcomes are referenced, specific outcome measures like survival rate or response rate are not detailed",-,False,No disagreement between Model A and B,False
25,Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma,10.3390/cancers15215221,"This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characteristics, treatment courses, and prognoses. The cases of patients who could achieve HCC downstaging from Barcelona Clinic Liver Cancer (BCLC) stage B or C to A or zero indicated the need for conversion therapy. The patients' prognoses with and without conversion therapy were compared. Of the 244 patients, 12 (4.9%) underwent conversion therapy, six out of 131 (4.6%) were treated with LEN, and six out of 113 (5.3%) were treated with Atezo + Bev. Eleven patients (91.7%) with a modified albumin bilirubin (mALBI) grade 1 or 2a and BCLC-B stage showed significantly higher rates of transition during conversion therapy (p < 0.05). The patients undergoing conversion therapy had a significantly longer median overall survival rate than those receiving chemotherapy alone (1208 [1064-NA] vs. 569 [466-704] days, p < 0.01). A comparison of the patients who achieved a partial response with and without conversion was evaluated using propensity score matching to reduce the confounding factors, showing a significant survival benefit in the conversion group (1208 [1064-NA] vs. 665 days, p < 0.01). Among the patients with u-HCC who were treated with LEN and Atezo + Bev, those with mALBI 1 + 2a and BCLC-B were likely to achieve conversion therapy with downstaging.","Tomonari, T; Tani, J; Sato, Y; Tanaka, H; Tanaka, T; Taniguchi, T; Kawano, Y; Morishita, A; Okamoto, K; Sogabe, M; Miyamoto, H; Masaki, T; Takayama, T",False,not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,lenvatinib and atezolizumab + bevacizumab,compared with chemotherapy alone,overall survival rate,retrospective multicenter study,False,"The study design is a retrospective multicenter study, not a randomized controlled trial as required by the PICOS criteria. Additionally, while Model A correctly identified the lack of RCT design, it failed to note that the comparison group (chemotherapy alone) was inadequately defined in terms of specific regimens used. The outcomes were survival-related, but the intervention included lenvatinib and atezolizumab + bevacizumab without clear separation of their individual effects.",-,lenvatinib or atezolizumab + bevacizumab rather than a combined intervention description,specific chemotherapy regimens are not detailed in the abstract,-,-,False,No disagreement between Model A and B,False
26,Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy,10.21037/hbsn-21-188,"Background: A combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with local regional therapy has elicited yield substantial clinical benefits in patients who have hepatocellular carcinoma (HCC) with extrahepatic metastases. Using this treatment strategy to convert HCC patients with extrahepatic metastases from unresectable to resectable has not yet been reported. Methods: Consecutive hepatocellular carcinoma patients with extrahepatic metastases who received first-line therapy with a combination of TKIs and anti-PD-1 antibodies and at least one local regional therapy were analysed. Results: Nine patients with localized disease who received first-line systemic therapy were enrolled. At baseline, all of them had oligometastatic disease, namely, Barcelona Clinic Liver Cancer stage C (or Chinese Liver Cancer stage IIIB). The most common treatment administered was lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization, and the median time span from systemic therapy to surgery was 3.2 (IQR, 2.8-6.2) months. Three patients achieved a pathological complete response. Six patients underwent laparoscopic surgery, and the other 3 patients underwent open surgery. After a median follow-up of 10.2 (IQR, 8.6-20.0) months, 7 patients survived without disease recurrence, and 2 experienced tumour recurrence. All patients had any-grade AEs, and 55.6% of the patients experienced grade 3 AEs. Fatigue was the most common AE, followed by elevated aminotransferase levels and hypertension. Conclusions: Stereotactic therapy is a feasible conversion therapy for HCC patients with extrahepatic metastases to become resectable. This is the first study to analyse therapeutic outcomes of patients receiving these therapies for HCC with extrahepatic metastases.","Yang, XB; Xu, HF; Zuo, BY; Yang, X; Bian, J; Long, JY; Wang, DX; Zhang, JW; Ning, C; Wang, YY; Xun, ZY; Wang, YC; Lu, X; Mao, YL; Sang, XT; Zhao, HT",False,lacks a control comparison and specific outcomes,patients with hepatocellular carcinoma and extrahepatic metastases,TKIs and anti-PD-1 antibodies with local regional therapy,not specified,not specified,not specified,False,"Model A correctly noted the absence of a control group and specific outcomes. However, the intervention description should specify the combination therapies more clearly (e.g., lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization). The study design lacks randomization and does not meet the RCT requirement. Furthermore, the outcomes focus on feasibility and safety rather than survival or response rates.",-,lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization rather than a vague description of TKIs and anti-PD-1 antibodies,-,outcomes related to feasibility and safety rather than survival or response rates,-,False,No disagreement between Model A and B,False
27,Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review,10.5582/bst.2022.01019,"Hepatocellular carcinoma (HCC) has been the fifth most common malignancy worldwide and is the second most common cause of tumor-related mortality globally. In China, a high proportion of patients with HCC present with an advanced stage of the disease, so HCC is a major challenge to the healthcare system and a substantial socioeconomic burden. The last decade has witnessed an expansion of the treatment landscape for HCC. Various approaches have been explored as potential conversion therapies for advanced HCC. Despite controversies, mounting data have indicated that successful conversion therapy followed by subsequent surgery is achievable in a population of patients with advanced HCC. This conversion therapy is a safe and promising treatment strategy to prolong long-term outcomes. Based on preliminary research, this review has assembled and summarized current clinical experience with and evidence of the efficacy of conversion therapies followed by subsequent surgery for advanced HCC.","Tang, HW; Cao, YB; Jian, YP; Li, XR; Li, JF; Zhang, WW; Wan, T; Liu, Z; Tang, W; Lu, SC",False,not a randomized controlled trial and lacks specific outcomes,patients with advanced hepatocellular carcinoma,conversion therapies for advanced HCC,not specified,not specified,review article,False,"This is a review article summarizing conversion therapies for advanced HCC, which inherently does not meet the PICOS requirement for an RCT. Model A's analysis is accurate, but the intervention description should clarify that the review encompasses multiple types of conversion therapies rather than specifying them. Outcomes are not quantified or survival-focused, further disqualifying the article.",-,multiple types of conversion therapies rather than a specific intervention,-,outcomes are summarized qualitatively rather than quantitatively,-,False,No disagreement between Model A and B,False
28,"Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study",,,"Hong, ZX; Lei, GL; Song, B; Hu, XW; Wang, S",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
29,Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma,10.3390/cancers15245878,"Simple Summary This study aimed to investigate the safety and long-term survival outcomes of salvage liver resection in patients with initially unresectable hepatocellular carcinoma (HCC) who had undergone triple combination conversion therapy (TACE/HAIC + TKIs + ICIs). While hepatectomy following conversion therapy exhibited elevated incidence rates of intra-abdominal bleeding, biliary leakage, post-hepatectomy liver failure, and Clavien-Dindo grade IIIa complications compared to pure hepatectomy, their safety profiles remained acceptable when appropriate medical interventions were administered. Patients with initially unresectable HCC, who successfully underwent conversion resection, demonstrated comparable overall survival (OS) and recurrence-free survival (RFS) to patients with initially resectable HCC.Abstract Triple combination conversion therapy, involving transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), has shown an encouraging objective response rate (ORR) and successful conversion surgery rate in initially unresectable hepatocellular carcinoma (HCC). However, the safety and long-term survival outcomes of subsequent liver resection after successful conversion still remain to be validated. From February 2019 to February 2023, 726 patients were enrolled in this retrospective study (75 patients received hepatectomy after conversion therapy [CLR group], and 651 patients underwent pure hepatectomy [LR group]). Propensity score matching (PSM) was used to balance the preoperative baseline characteristics. After PSM, 68 patients in the CLR group and 124 patients in the LR group were analyzed, and all the matching variables were well-balanced. Compared with the LR group, the CLR group experienced longer Pringle maneuver time, longer operation time, and longer hospital stays. In addition, the CLR group had significantly higher incidence rates of intra-abdominal bleeding, biliary leakage, post-hepatectomy liver failure (PHLF), and Clavien-Dindo grade IIIa complications than the LR group. There were no significant statistical differences in overall survival (OS) (hazard ratio [HR] 0.724; 95% confidence interval [CI] 0.356-1.474; p = 0.374) and recurrence-free survival (RFS) (HR 1.249; 95% CI 0.807-1.934; p = 0.374) between the two groups. Liver resection following triple combination conversion therapy in initially unresectable HCC may achieve favorable survival outcomes with manageable safety profiles; presenting as a promising treatment option for initially unresectable HCC.","Long, Y; Huang, J; Liao, JG; Zhang, DB; Huang, ZQ; He, XD; Zhang, L; Vitale, A; Midorikawa, Y",False,not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,triple combination conversion therapy involving ICIs,compared with pure hepatectomy,overall survival and recurrence-free survival,retrospective study with propensity score matching,False,"Model A correctly identified the study as non-randomized. However, the intervention description should explicitly mention TACE/HAIC alongside TKIs and ICIs, as these are integral components. The comparison group involves pure hepatectomy, which is adequately described, but the outcomes include both overall survival and recurrence-free survival, requiring clearer delineation of their relevance to immune checkpoint inhibitors specifically. The study remains disqualified due to its retrospective design.",-,TACE/HAIC plus TKIs and ICIs rather than focusing solely on ICIs,-,survival outcomes are not exclusively linked to ICIs,-,False,No disagreement between Model A and B,False
30,Conversion therapy for massive hepatocellular carcinoma: A case report and literature review,10.1002/ccr3.7533,"Key Clinical MessageFor potentially resectable HCC, a more aggressive conversion therapy strategy (high-intensity combined with multiple treatment modalities) can be used. Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. The best treatment for HCC is radical surgical resection, but 70%-80% of patients are ineligible for surgery. Although conversion therapy is an established treatment strategy for various solid tumors, there is no uniform protocol for treating HCC. In this case, we present a 69-year-old male patient diagnosed with massive HCC with Barcelona clinical liver cancer (BCLC) stage B. Because of the insufficient volume of the future liver remnant, we believed radical surgical resection was temporarily impossible. Therefore, the patient received conversion therapy, including four cycles of transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC-Folfox), lenvatinib (8 mg orally once a day), and tislelizumab (an anti-PD-1 antibody, 200 mg intravenously once every 3 weeks). Fortunately, the patient achieved a good treatment response (smaller lesions and improved liver function) and underwent radical surgery finally. There was no clinical evidence of recurrence at 6 months of follow-up. For potentially resectable HCC, this case reveals that a more aggressive conversion therapy strategy (high-intensity combined with multiple treatment modalities) can be used.","Zhou, ZY; Xu, XL; Sun, ML; Liu, Y; Liu, QY; Chen, CB; Yin, Y",False,does not include a comparison group or randomized controlled trial design,patients with potentially resectable HCC,conversion therapy including an anti-PD-1 antibody,not specified,treatment response and liver function improvement,not specified,False,"The abstract describes a single case report of conversion therapy including an anti-PD-1 antibody for a patient with massive HCC. While Model A correctly identifies the lack of comparison and randomized controlled trial design, it overlooks that the intervention is not solely ICIs but a combination of multiple treatments (TAE, HAIC-Folfox, lenvatinib, and tislelizumab). This makes the intervention description incomplete.",-,"conversion therapy including transcatheter arterial embolization, hepatic arterial infusion chemotherapy, lenvatinib, and tislelizumab",-,-,-,False,No disagreement between Model A and B,False
31,Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab,10.1097/MD.0000000000027576,"Rationale: Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable HCC, but there are few reports on the failure of the combination treatment. Here, we present a case of unresectable HCC with adrenal metastasis that was eventually operated on after lenvatinib (LEN) treatment that followed failed treatment with atezolizumab plus bevacizumab. Patient concerns: A 68-year-old man was diagnosed with non-alcoholic steatohepatitis-based HCC with adrenal metastasis. Diagnosis: Cirrhosis was classified as Child-Pugh score of 5. HCC was diagnosed as Barcelona Clinic Liver Cancer stage C. Interventions: We initiated treatment with atezolizumab plus bevacizumab. Liver dysfunction appeared 2 days after the first administration but was improved by intravenous rehydration and did not appear after the second course. The HCC shrank, but the adrenal metastasis grew bigger after the fourth course, so we changed the therapy to LEN. After HCC and adrenal metastasis were necrotic by LEN, conversion surgery was performed. Outcomes: After successful conversion therapy, the general condition of the patient was good, and has been carefully followed for 4 months to date without any evidence of further recurrences. Lessons: This case showed that even if atezolizumab plus bevacizumab is not effective, multidisciplinary treatment such as LEN and conversion surgery is possible. Given the efficacy of LEN after atezolizumab plus bevacizumab, it is important to consider that there is a possibility of cure even when first-line treatment is not effective for a patient with unresectable HCC.","Yano, S; Kawaoka, T; Johira, Y; Miura, R; Kosaka, M; Shirane, Y; Murakami, S; Amioka, K; Naruto, K; Ando, Y; Kosaka, Y; Yamaoka, K; Kodama, K; Uchikawa, S; Fujino, H; Ohno, A; Nakahara, T; Murakami, E; Okamoto, W; Yamauchi, M; Imamura, M; Mori, K; Arihiro, K; Kuroda, S; Kobayashi, T; Ohdan, H; Aikata, H",False,case report without comparison or randomized controlled trial,a patient with unresectable HCC,treatment with atezolizumab plus bevacizumab,previous failed treatment with atezolizumab plus bevacizumab,treatment response and surgical outcomes,not specified,False,"This is a case report of a patient treated with atezolizumab plus bevacizumab followed by lenvatinib. Model A's analysis is mostly accurate, but it fails to note that the intervention includes sequential treatments (atezolizumab plus bevacizumab followed by lenvatinib), which complicates the interpretation of outcomes. The study design classification is correct as it is not an RCT.",-,sequential treatment with atezolizumab plus bevacizumab followed by lenvatinib,-,-,-,False,No disagreement between Model A and B,False
32,Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review,10.21037/hbsn-22-527,"Background and Objective: Immune checkpoint inhibitor (ICI)-based therapy has achieved impressive success in various cancer types. Several ICIs have been unprecedentedly approved as the treatment regimens for advanced hepatocellular carcinoma (HCC) in recent decade. Meanwhile, numerous clinical trials are being performed to exploit more ICIs into initially unresectable HCC and postoperative HCC to expectantly induce adequate tumor downstaging for further resection or implement adjuvant treatment for relapse-free survival, respectively. In this review, we aim to summarize some pragmatic histomorphologic, immunohistochemical, and molecular pathologic parameters which promisingly indicate the response of neoadjuvant/conversion ICI-related therapy and predict the efficacy of adjuvant/therapeutic ICI-related therapy for HCC.Methods: We searched PubMed using the terms hepatocellular carcinoma, immunotherapy, immune checkpoint inhibitor, immune checkpoint blockade, conversion therapy, neoadjuvant therapy, adjuvant therapy, biomarker, pathologic evaluation, pathologic assessment till February 2023.Key Content and Findings: Although there is no consensus regarding the pathologic evaluation of relevant HCC specimens, it is encouraging that a few of studies have concentrated on this field, and moreover, the methods and parameters noted on other cancer types are also worthy of reference. For the pathologic assessment of HCC specimens underwent immunotherapy, a suitable sampling scheme, identifying immunotherapy-related pathologic response, and quantification of pathologic response rate should be emphasized. For the patients of HCC who are scheduled to receive immunotherapy, tumor-infiltrating lymphocyte, intratumoral tertiary lymphoid structure, programmed cell death ligand 1, Wnt/ beta-catenin, microsatellite instability and mismatch repair, tumor mutational burden and tumor neoantigen, as well as some other signaling pathways are the potential predictive biomarkers of treatment response of ICI.Conclusions: The management of HCC in the era of immunotherapy arises a brand-new pathological challenge that is to provide an immunotherapy-related diagnostic report. Albeit many related researches are preclinical or insufficient, they may tremendously alter the immunotherapy strategy of HCC in future.","Wang, H; Qian, YW; Dong, H; Cong, WM",False,"review article, no specific trial or comparison mentioned",patients with advanced HCC,ICI-related therapy,not specified,not specified,review of clinical trials,False,"This is a review article summarizing potential biomarkers and pathologic parameters for ICI-related therapies in HCC. Model A correctly identifies this as a review without specific trials or comparisons. However, the outcome description is vague ('not specified') and could be clarified as focusing on predictive biomarkers and pathologic assessments rather than clinical outcomes like survival or response rates.",-,-,-,predictive biomarkers and pathologic assessments for ICI-related therapies,-,False,No disagreement between Model A and B,False
33,Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis,10.3389/fonc.2022.930868,"BackgroundHepatocellular carcinoma (HCC) is a highly malignant disease with poor prognosis, and most cases were already considered unresectable at the time of presentation. Conversion therapy, as an emerging treatment, is designed to provide patients with initially unresectable hepatocellular carcinoma (uHCC) the opportunity to undergo radical resection. At present, conversion therapy for patients with uHCC remains controversial. Transarterial chemoembolization (TACE) is currently the most widely selected treatment for uHCC, but its efficacy as a conversion therapy remains controversial. MethodsWe compared and evaluated the conversion rate for and tumor response to TACE monotherapy or combination therapy. Meanwhile, postoperative complications and overall survival (OS) in uHCC patients who underwent conversion therapy were also analyzed. ResultsA total of 18 studies were included in this meta-analysis. The conversion rate for triple therapy [TACE in combination with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs)] was 42% [95% confidence interval (CI), 0.29-0.56], higher than any other group [TACE monotherapy: 10% (95% CI, 0.08-0.12), bigeminy therapy: 19% (95% CI, 0.06-0.36)]. Meanwhile, triple therapy yielded a better tumor response than TACE monotherapy or bigeminy therapy. Among the patients with successful surgical resection after conversion therapy, the pooled postoperative OS rates at 1, 2, and 5 years were 90% (95% CI, 0.81-0.97), 58% (95% CI, 0.42-0.73), and 42% (95% CI, 0.26-0.60), respectively, and the major postoperative complications were biliary leakage (7%; 95% CI, 0.03-0.12) and liver failure (3%; 95% CI, 0.00-0.07). ConclusionTACE conversion therapies showed good conversion rates, especially the triple therapy of TACE in combination with TKIs and ICIs. Surgical resection after successful conversion therapy could maximize the outcome of patients with uHCC.","Li, WW; Pei, YX; Wang, ZX; Liu, JL",True,"meets PICOS criteria with population, intervention, comparison, outcome, and study design specified",patients with unresectable HCC,TACE with TKIs and ICIs,TACE monotherapy or bigeminy therapy,conversion rates and survival rates,meta-analysis of studies,True,"This meta-analysis compares TACE monotherapy or combination therapy with triple therapy (TACE, TKIs, and ICIs) for unresectable HCC. Model A's analysis is accurate, but the population description could specify 'unresectable HCC' more clearly to align with the PICOS criteria. The intervention and comparison groups are well-defined, and the study design is appropriately classified as a meta-analysis.",patients with initially unresectable HCC,-,-,-,-,True,No disagreement between Model A and B,True
34,Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC,10.3389/fimmu.2024.1469302,"Background: Transarterial therapy (TAT), bevacizumab (Bev), and immune checkpoint inhibitors (ICIs) have individually exhibited efficacy in treating advanced-stage hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of the combination of these three treatments as a neoadjuvant modality in patients with locally advanced HCC. Methods: The primary endpoint is overall survival (OS). The second endpoint is progression free survival (PFS), objective response rate (ORR), pathological response rate and safety. Results: A total of 54 patients received standard systemic therapy comprising Bev combined with ICIs (Bev-ICIs group), 113 patients received direct surgery (Surgery group), and 273 patients received neoadjuvant therapy of TAT combined Bev plus ICIs, among which 79 patients (28.9%) underwent surgical resection after successful tumor downstaging (Neo-surgery group) while the remaining 194 patients (71.1%) received maintenance systemic therapies (Neo-maintenance group). Neoadjuvant following surgery demonstrated a prolonged OS in contrast to direct surgery, with a median OS time not reached in the Neo-surgery group and 30.6 (95% CI: 26.4-34.7) months in the Surgery group (hazard ratio (HR)=0.29, P=0.0058). The median PFS time in the Neo-surgery and Surgery groups stood at 19.2 (95% CI: 16.1-22.2) and 6.3 (95% CI:4.7-8) months, respectively (HR=0.25, P<0.0001). In patients failed to receiving resection after neoadjuvant therapy, the median OS was 22.8 (95% CI: 22.3-23.1) months, whereas that for the standard care population was 19.7 (95% CI: 15.9-24) month (HR=0.53, P=0.023). The median PFS time in Neo-maintenance group and Bev-ICIs groups was 11.2 (95% CI: 10.4-11.9) and 6.4 (95% CI: 4.4-8.5) months (HR=0.60, P=0.024). The ORR and disease control rate (DCR) across all patients received TAT-Bev-ICIs were 38.8% and 89.4%, respectively. Additionally, the pathological complete response (pCR) rate and the major pathological response (MPR) rate were 22.8% and 48.1% in the Neo-surgery group. As for safety, neoadjuvant therapy did not increase the perioperative complications when compared to direct surgery, and demonstrated similar incidences and severity of AEs when compared to the standard systemic therapy. Conclusion: The triple therapy regimen comprising TAT-Bev-ICIs emerged as a promising therapeutic strategy for locally advanced hepatocellular carcinoma (HCC) as a neoadjuvant intervention.","Yang, ZY; Wang, QY; Hu, L; Sima, X; Wang, JC; Hu, DD; Zhou, ZG; Chen, MS; Zhang, YJ; Fu, YZ",True,"meets PICOS criteria with population, intervention, comparison, outcome, and study design specified",patients with locally advanced HCC,neoadjuvant therapy of TAT combined with Bev and ICIs,standard systemic therapy and direct surgery,overall survival and progression-free survival,clinical study,True,"This study evaluates the efficacy and safety of neoadjuvant therapy combining TAT, Bev, and ICIs in locally advanced HCC. Model A's analysis is accurate, but the comparison group description could clarify that it includes both standard systemic therapy and direct surgery. The outcomes include overall survival and progression-free survival, which are relevant to the PICOS criteria. The study design classification as a clinical study is appropriate.",-,-,standard systemic therapy (Bev combined with ICIs) and direct surgery,-,-,True,No disagreement between Model A and B,True
35,"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial",10.1136/jitc-2023-007366,"BackgroundOver 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor response rate in both the first-line and second-line treatment of advanced HCC. However, few studies have prospectively evaluated whether TKIs plus anti-PD-1 antibodies could convert unresectable intermediate-advanced HCC into resectable disease.MethodsThis single-arm, phase II study enrolled systemic therapy-naive adult patients with unresectable Barcelona Clinic Liver Cancer stage B or C HCC. Patients received oral lenvatinib one time per day plus intravenous anti-PD-1 agents every 3 weeks (one cycle). Tumor response and resectability were evaluated before the fourth cycle, then every two cycles. The primary endpoint was conversion success rate by investigator assessment. Secondary endpoints included objective response rate (ORR) by independent imaging review (IIR) assessment per modified RECIST (mRECIST) and Response Evaluation Criteria in Solid Tumors, V.1.1 (RECIST 1.1), progression-free survival (PFS) and 12-month recurrence-free survival (RFS) rate by IIR per mRECIST, R0 resection rate, overall survival (OS), and safety. Biomarkers were assessed as exploratory objectives.ResultsOf the 56 eligible patients enrolled, 53 (94.6%) had macrovascular invasion, and 16 (28.6%) had extrahepatic metastasis. The median follow-up was 23.5 months. The primary endpoint showed a conversion success rate of 55.4% (31/56). ORR was 53.6% per mRECIST and 44.6% per RECIST 1.1. Median PFS was 8.9 months, and median OS was 23.9 months. Among the 31 successful conversion patients, 21 underwent surgery with an R0 resection rate of 85.7%, a pathological complete response rate of 38.1%, and a 12-month RFS rate of 47.6%. Grade & GE;3 treatment-related adverse events were observed in 42.9% of patients. Tumor immune microenvironment analysis of pretreatment samples displayed significant enrichment of CD8+ T cells (p=0.03) in responders versus non-responders.ConclusionLenvatinib plus anti-PD-1 antibodies demonstrate promising efficacy and tolerable safety as conversion therapy in unresectable HCC. Pre-existing CD8+ cells are identified as a promising biomarker for response to this regimen.Trial registration numberChinese Clinical Trial Registry, ChiCTR1900023914.","Zhang, WW; Tong, S; Hu, BY; Wan, T; Tang, HW; Zhao, FL; Jiao, TY; Li, JF; Zhang, Z; Cai, JP; Ye, HY; Wang, ZB; Chen, SQ; Wang, YF; Li, XR; Wang, FZ; Cao, JN; Tian, LT; Zhao, XC; Chen, MY; Wang, HG; Cai, SW; Hu, MG; Bai, YZ; Lu, SC",False,lacks a comparison group and is not a randomized controlled trial,patients with advanced hepatocellular carcinoma,lenvatinib plus anti-PD-1 antibodies,not specified,conversion success rate and overall survival,"single-arm, phase II study",False,"The study is a single-arm phase II trial and lacks a comparison group, which disqualifies it from meeting the randomized controlled trial requirement. Model A's analysis is accurate.",-,-,-,-,-,False,No disagreement between Model A and B,False
36,Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report,10.1097/CAD.0000000000001163,"Most hepatocellular carcinoma (HCC) patients have dismal prognoses because they are already in the advanced stage at the time of initial diagnosis and are unable to undergo upfront surgery. Recent studies of immune checkpoint inhibitors (ICIs) and antiangiogenic agents (AAAs) have shown encouraging results for unresectable HCC (uHCC). Here, we report a patient with uHCC who was treated with a combination of anlotinib and sintilimab (sintilimab 200 mg, intravenous glucose tolerance test, q21d and anlotinib 12 mg, orally, d1-14, q21d), an analog of the combination of lenvatinib and pembrolizumab with much lower cost. The patient with recurrent uHCC was downstaged to resectable disease by the combination therapy. After eight cycles of treatment with anlotinib and sintilimab, the patient underwent a second operation. The histology of the resected mass revealed a major and almost complete pathological response. However, this patient was diagnosed with type I diabetes mellitus with ketoacidosis after nearly 10 cycles of combination treatment with anlotinib and sintilimab. Active follow-ups revealed no signs of local recurrence or distant failure. In conclusion, this case report demonstrated that the combination of anlotinib and sintilimab, one of the strategies combining ICIs with AAAs, showed promising efficacy in the treatment of uHCC patients.","Fu, LL; Chen, P; Wang, SJ; Liu, WM; Chen, ZB; Chen, HB; Fu, ZM",False,not a randomized controlled trial and lacks comparison group,patient with unresectable hepatocellular carcinoma,combination of anlotinib and sintilimab,not specified,downstaging to resectable disease,case report,False,"This is a case report focusing on a single patient, which does not meet the PICOS criteria for study design or inclusion of a comparison group. Model A's analysis is correct.",-,-,-,-,-,False,No disagreement between Model A and B,False
37,Dual transformation therapy for giant hepatocellular carcinoma: Two case reports and review of literature,10.4240/wjgs.v15.i9.2089,"BACKGROUNDIn the translational therapy of giant hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKI) after laparoscopic portal vein ligation (PVL) is extremely rare. This is a dual conversion therapy that combines surgery and oncology. Here, we report two cases of successful surgical completion after dual conversion therapy.CASE SUMMARYWe report that a 54-year-old man and a 69-year-old woman were diagnosed with primary HCC combined with hepatitis B cirrhosis (case 2 also combined with fatty liver) on physical examination. Due to the insufficient residual liver volume assessed before surgery, laparoscopic right PVL was performed, followed by HAIC combined with anti-PD-1 immunotherapy and TKI. Finally, surgical resection was successfully completed, and pathology confirmed that the tumor was mostly necrotic (90%) in one case, and no live tumor tissue was found in the other case.CONCLUSIONIn the process of surgical transformation, our treatment plan takes into account the control and transformation of oncology at the same time, which is expected to provide more opportunities for radical hepatectomy and improve the prognosis of patients with large liver cancer.","Gao, Q; Zhu, GZ; Han, CY; Ye, XP; Huang, HS; Mo, ST; Peng, T",False,not a randomized controlled trial and lacks comparison group,patients with giant hepatocellular carcinoma,HAIC combined with anti-PD-1 and TKI,not specified,successful surgical completion,case report,False,"The article describes two case studies without a comparison group or randomization, failing to meet the PICOS study design criterion. Model A's assessment is accurate.",-,-,-,-,-,False,No disagreement between Model A and B,False
38,Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study,10.3389/fonc.2022.1046584,"PurposeWe aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a conversion therapy for initially unresectable hepatocellular carcinoma (HCC). MethodsPatients with initially unresectable HCC who received combined lenvatinib and anti-PD-1 antibody between May 2020 and Jan 2022 in Zhongshan Hospital were retrospectively analyzed. Tumor response and resectability were assessed by imaging every two months according to RECIST version 1.1 and modified RECIST (mRECIST) criteria. ResultsA total of 107 patients were enrolled. 30 (28%) of them received conversion surgery within 90.5 (range: 53-456) days after the initiation of lenvatinib plus anti-PD-1 therapy. At baseline, the median largest tumor diameter of these 30 patients was 9.2 cm (range: 3.5-15.0 cm), 26 patients had Barcelona Clinic Liver Cancer stage B-C, and 4 had stage A. Prior to surgery, all cases displayed tumor regression and 15 patients achieved objective response. Pathological complete response (pCR) was observed in 10 patients. No severe drug-related adverse events or surgical complications were observed. After a median follow-up of 16.5 months, 28 patients survived and 11 developed tumor recurrence. Survival analysis showed patients achieving tumor response before surgery or pCR had a longer tumor-free survival. Notably, patients with microvascular invasion (MVI) had significantly higher recurrence rate and poorer overall survival than patients without. ConclusionsLenvatinib combined with anti-PD-1 therapy represents a feasible conversion strategy for patients with initially unresectable HCC. Patients achieving tumor responses are more likely to benefit from conversion resection to access a longer term of tumor-free survival.","Yi, Y; Sun, BY; Weng, JL; Zhou, C; Zhou, CH; Cai, MH; Zhang, JY; Gao, H; Sun, J; Zhou, J; Fan, J; Ren, N; Qiu, SJ",False,lacks a comparison group and is not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,lenvatinib plus anti-PD-1 therapy,not specified,tumor response and tumor-free survival,retrospective analysis,False,"The study is a retrospective analysis without a comparison group or randomization, thus not fulfilling the PICOS criteria for study design. Model A's evaluation is appropriate.",-,-,-,-,-,False,No disagreement between Model A and B,False
39,Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma,10.1080/14656566.2023.2229728,"IntroductionHepatocellular carcinoma (HCC) is the most frequent primary liver cancer, but only 20-30% of patients benefit from potentially curative treatments such as liver resection or transplantation. This article reviews conventional treatments and recent progress in pharmacotherapy for advanced HCC, with a focus on downstaging unresectable tumors to resectable status.Areas coveredIn this article, conventional treatments and recent progress in pharmacotherapy for advanced HCC, aiming at downstaging from unresectable to resectable status, are reviewed. Future prospectives of combination therapies using immune checkpoint inhibitors were also introduced by reviewing recent clinical trials, paying attention to the objective response rate as its potential of downstaging treatments.Expert opinionThe newly developed pharmacological therapies showed higher responses. Although various tumor statuses in advanced HCC hamper detailed analysis of successful conversion rate, the novel combined immunotherapies are expected to provide more opportunities for subsequent curative surgery for initially unresectable advanced HCC. The conversion treatment strategies for unresectable HCC should be separately discussed for 'technically resectable but oncologically unfavorable' HCC and metastatic or invasive HCC beyond curative surgical treatments. The optimal downstaging treatment strategy for advanced HCC is awaited. Elucidation of preoperatively available factors that predict successful downstaging will allow the tailoring of promising initial treatments leading to conversion surgery.","Takamoto, T; Maruki, Y; Kondo, S",False,not a study and lacks original research data,not specified,combination therapies using immune checkpoint inhibitors,not specified,downstaging unresectable tumors,review article,False,"This is a review article summarizing existing literature rather than presenting original research data, making it ineligible under the PICOS framework. Model A's decision aligns with this reasoning.",-,-,-,-,-,False,No disagreement between Model A and B,False
40,Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment,10.1007/s12328-023-01768-z,"We herein report two cases of huge hepatocellular carcinoma (HCC) that were successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment. Case 1, an 84-year-old man, was diagnosed with HCC (maximum diameter: 11 cm) with portal invasion and presented HCC rupture. After obtaining hemostasis with transcatheter embolization, three cycles of atezolizumab-bevacizumab therapy were administered, and marked shrinkage of the HCC was confirmed. However, he developed jaundice, liver damage and cerebral subcortical hemorrhage. Thus, atezolizumab-bevacizumab therapy was discontinued. Total bilirubin, transaminase levels, and physical activity improved well with prednisolone, an antihypertensive agent, and rehabilitation. Thus, treatment with carbon ion radiotherapy (CIRT) was added, and the treatment effect at 4 months after CIRT was judged as a complete response (CR) according to the modified response evaluation criteria in solid tumors (mRECIST). Case 2, a 68-year-old man, was diagnosed with HCC (maximum diameter: 14 cm). Hepatic resection was difficult because the residual liver volume after treatment would be insufficient. Five cycles of atezolizumab-bevacizumab therapy were performed, and marked shrinkage of the HCC to a maximum diameter of 9 cm was confirmed. The treatment was converted to CIRT, and atezolizumab-bevacizumab therapy resumed one month after CIRT. The treatment effect at 3 months after CIRT was judged as CR according to mRECIST. Although conversion therapy after atezolizumab-bevacizumab therapy, including surgery and radiofrequency ablation, have been reported, CIRT may be a promising new tool for conversion therapy for HCC.","Takakusagi, S; Tanaka, H; Naganuma, A; Kakizaki, S; Shibuya, K; Ohno, T; Takagi, H; Uraoka, T",False,not a randomized controlled trial and lacks comparison group,patients with hepatocellular carcinoma,atezolizumab plus bevacizumab therapy,not specified,treatment response and adverse effects,case report,False,"The study is a case report focusing on two individual patients treated with atezolizumab plus bevacizumab followed by carbon ion radiotherapy. It lacks a comparison group and randomization, which are essential for inclusion under the PICOS criteria. Additionally, the outcomes reported are limited to individual cases rather than systematic survival or response rate data applicable to a broader population.",-,-,-,-,-,False,No disagreement between Model A and B,False
41,"Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma",10.2147/JHC.S432062,"Background: Most patients with hepatocellular carcinoma (HCC) are not candidates for liver resection. We investigated the clinicopathological characteristics and prognosis of patients with initially unresectable HCC who underwent hepatectomy after conversion therapy with hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and anti-PD-1 antibodies. Materials and Methods: Patients with initially unresectable HCC who received HAIC combined with TKIs and anti-PD-1 antibodies followed by hepatectomy between December 2020 and December 2022, were retrospectively analyzed. Patient characteristics, tumor characteristics, treatment efficacy, perioperative characteristics, pathological characteristics, and survival outcomes were summarized and analyzed. Results: 67 patients were enrolled in this study. Patients were treated with 3 sessions (range:2-6 sessions) of combination therapy and were performed with hepatectomy in 4 months (range:1.4-17.8 months) after the initiation of the combination therapy. The median size of tumor shrinkage was 4.7 cm (range:0.9-11.7 cm). A pathological complete response (pCR) was achieved in 34.3% of the patients (n = 23). The median recurrence-free survival (RFS) was 19.3 months and the median overall survival (OS) was 28.7 months. Patients who achieved pCR had a better RFS (P = 0.004) and those without microscopic vascular invasion (MVI) had a better prognosis (RFS, P = 0.011; OS, P = 0.023). Multivariable logistic analysis revealed that the tumor number was associated with pCR. Conclusion: Hepatectomy after conversion therapy with HAIC, TKIs, and anti-PD-1 antibodies is a feasible treatment strategy for patients with unresectable HCC. This treatment strategy is associated with a promising prognosis.","Yu, BR; Zhang, N; Feng, Y; Zhang, YF; Zhang, T; Wang, L",False,not a randomized controlled trial and lacks comparison group,patients with initially unresectable hepatocellular carcinoma,"hepatectomy after conversion therapy with HAIC, TKIs, and anti-PD-1 antibodies",not specified,survival outcomes,retrospective analysis,False,"This is a retrospective analysis of patients receiving hepatectomy after conversion therapy with HAIC, TKIs, and anti-PD-1 antibodies. While it reports survival outcomes such as recurrence-free survival and overall survival, it does not include a randomized controlled design or a defined comparison group. The lack of a comparator makes it unsuitable for inclusion under the PICOS framework.",-,-,-,-,-,False,No disagreement between Model A and B,False
42,Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy,10.3390/cancers13215475,"Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/beta-catenin mutations to a certain degree.","Kudo, M",False,not a randomized controlled trial and lacks a defined comparison group,patients with hepatocellular carcinoma,atezolizumab plus bevacizumab combination therapy,not specified,objective response rate,review of a clinical trial,False,"This article reviews the IMbrave150 trial but does not present original data from a randomized controlled trial. Instead, it summarizes findings from a previously conducted phase 3 trial without providing new evidence or a direct comparison group within the current study. As such, it fails to meet the PICOS criteria despite discussing response rates and treatment strategies.",-,-,-,-,-,False,No disagreement between Model A and B,False
43,Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody,10.3389/fimmu.2022.1016736,"BackgroundConversion therapy is feasible in patients with oncologically unresectable hepatocellular carcinoma (HCC). However, it is challenging to prospectively identify patients who are more likely to achieve successful conversion before initiating systemic therapy, either alone or combined with locoregional therapy. MethodsCriteria for identifying potentially resectable patients with initially oncologically unresectable HCC before treatment with lenvatinib plus an anti-PD-1 antibody were proposed based on real-world evidence. Multivariate Firth logistic regression was used to validate the proposed criteria in a retrospective cohort of consecutive patients with advanced HCC, who received combination therapy with lenvatinib plus an anti-PD-1 antibody between September 2018 and September 2021. ResultsThe proposed criteria were as follows: (1) Eastern Cooperative Oncology Group performance status of 0 or 1; (2) Child-Pugh class A; (3) intrahepatic tumors confined to one lobe (left, right, or middle lobe), or present in one lobe alongside a single tumor with diameter <= 5 cm or up to three tumors each with diameter <= 3 cm in the remaining lobes, with R0 resection achievable by hemihepatectomy, alone or combined with locoregional therapy to the remaining lobes during surgery; and (4) no portal vein tumor thrombus involving the contralateral liver lobe or reaching the superior mesenteric vein, no hepatic vein tumor thrombus involving more than two major hepatic vein branches on the tumor side, and no tumor thrombus of the inferior vena cava reaching the atrium. Firth logistic regression confirmed the criteria were an independent predictor of surgery following conversion therapy with lenvatinib plus an anti-PD-1 antibody. ConclusionsThis study proposed and validated criteria for identifying patients with initially oncologically unresectable HCC who are potentially resectable when treated with combination therapy with lenvatinib plus an anti-PD-1 antibody. The proposed criteria could help standardize conversion therapy studies in advanced HCC.","Xu, B; Zhu, XD; Shen, YH; Zhu, JJ; Liu, J; Li, ML; Tang, PW; Zhou, J; Fan, J; Sun, HC; Huang, C",False,not a randomized controlled trial and lacks direct comparison,patients with initially unresectable hepatocellular carcinoma,lenvatinib plus anti-PD-1 antibody,not specified,criteria for resectability and survival outcomes,retrospective cohort study,False,"The study proposes and validates criteria for identifying resectable patients using lenvatinib plus an anti-PD-1 antibody in a retrospective cohort. However, it lacks a randomized controlled trial design and does not include a defined comparison group. While it discusses resectability and survival outcomes, these do not fulfill the PICOS requirements due to the absence of randomization and comparative analysis.",-,-,-,-,-,False,No disagreement between Model A and B,False
44,"Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study",10.3389/fonc.2021.729764,"BackgroundRecent research has shown that selected patients with initially unresectable hepatocellular carcinoma (HCC) are able to achieve conversion to resectable disease through systemic or local therapy. Combination regimens comprised of drugs with different mechanisms of action have shown better outcomes than single-drug or single-approach-based treatments; however, to date, combination regimens investigated as part of conversion therapy strategies have been two drug combinations with reported issues of relatively low surgical conversion and objective response rates. In this study, we investigated the efficacy and safety of triple combination therapy with angiogenesis inhibitors, programmed death-1 inhibitors and hepatic arterial infusion chemotherapy for surgical conversion of advanced HCC. MethodsThis was a single-center, retrospective, single-arm study of patients with unresectable HCC who received at least one cycle of triple combination therapy with an oral anti-angiogenic drug, programmed death-1 inhibitors and hepatic arterial infusion chemotherapy between August 2019 and August 2020. Endpoints included the overall response rate (ORR), surgical conversion rate, time to response and safety. Treatment response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and RECIST v1.1. ResultsIn total, 34 patients were included in this study, of whom 25 completed treatment evaluation. The best ORR was 96.0% (24/25); 48.0% (n = 12) had a complete response, 48.0% (n = 12) had a partial response, and 4.0% (n = 1) had stable disease. The median time to response was 50.5 (95% CI, 31.02-64.00) days and the surgical conversion rate was 60% (15/25). Of the 25 patients, 56.0% (n = 14) received surgical resection and 28.0% (n = 7) had a pathologic complete response. Toxic side effects were manageable. ConclusionA triple combination therapy regimen of angiogenesis inhibitors, programmed death-1 inhibitors and hepatic arterial infusion chemotherapy showed significant therapeutic effect with an extremely high surgical conversion rate in patients with initially unresectable HCC.","Zhang, JL; Zhang, XH; Mu, H; Yu, G; Xing, WE; Wang, L; Zhang, T",False,not a randomized controlled trial and lacks comparison group,patients with initially unresectable hepatocellular carcinoma,"triple combination therapy with angiogenesis inhibitors, PD-1 inhibitors, and HAIC",not specified,surgical conversion rates and response rates,single-arm study,False,"This single-arm study evaluates triple combination therapy for surgical conversion in unresectable HCC. Despite reporting high response and conversion rates, it lacks a randomized controlled trial design and a comparison group. The absence of a comparator and non-randomized nature exclude it from meeting the PICOS criteria.",-,-,-,-,-,False,No disagreement between Model A and B,False
45,"Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities",10.1111/cas.16194,"Hepatocellular carcinoma (HCC), the most prevalent malignancy of the digestive tract, is characterized by a high mortality rate and poor prognosis, primarily due to its initial diagnosis at an advanced stage that precludes any surgical intervention. Recent advancements in systemic therapies have significantly improved oncological outcomes for intermediate and advanced-stage HCC, and the combination of locoregional and systemic therapies further facilitates tumor downstaging and increases the likelihood of surgical resectability for initially unresectable cases following conversion therapies. This shift toward high conversion rates with novel, multimodal treatment approaches has become a principal pathway for prolonged survival in patients with advanced HCC. However, the field of conversion therapy for HCC is marked by controversies, including the selection of potential surgical candidates, formulation of conversion therapy regimens, determination of optimal surgical timing, and application of adjuvant therapy post-surgery. Addressing these challenges and refining clinical protocols and research in HCC conversion therapy is essential for setting the groundwork for future advancements in treatment strategies and clinical research. This narrative review comprehensively summarizes the current strategies and clinical experiences in conversion therapy for advanced-stage HCC, emphasizing the unresolved issues and the path forward in the context of precision medicine. This work not only provides a comprehensive overview of the evolving landscape of treatment modalities for conversion therapy but also paves the way for future studies and innovations in this field. Setting a foundation for future research and advancements in HCC treatment, aligning with the emerging paradigm of precision medicine; addressing the need for a holistic approach in managing advanced-stage HCC, and advocating for a balance between aggressive treatment and quality of life considerations.image","Wang, MD; Xu, XJ; Wang, KC; Diao, YK; Xu, JH; Gu, LH; Yao, LQ; Li, C; Lv, GY; Yang, T",False,"Does not meet PICOS criteria; no relevant information on intervention, comparison, outcome, or study design.",not specified,not specified,not specified,not specified,not specified,False,"The abstract discusses conversion therapy strategies for advanced hepatocellular carcinoma but does not specify any interventions, comparisons, or outcomes related to immune checkpoint inhibitors or survival/response rates. It is a narrative review without focus on RCTs, making it unsuitable for inclusion.",-,-,-,-,-,False,No disagreement between Model A and B,False
46,Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma,10.1016/j.jhepr.2024.101246,"Background & Aims: The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft safety and rejection have limited its exploration in the neoadjuvant setting of liver transplantation (LT). In this study, we investigate the clinical efficacy and the safety profile of pre-transplant administration of atezolizumab and bevacizumab for HCC. Methods: Herein, we performed a prospective assessment of 17 patients with HCC treated with neoadjuvant preoperative atezolizumab and bevacizumab prior to LT for HCC, obtained from December 2020 and December 2023 at seven Western transplant centers. Results: Among the 17 patients with HCC included in the study, 16 (94.1%) had a tumor burden outside of Milan criteria. Neoadjuvant locoregional therapies along with the administration of atezolizumab plus bevacizumab (median: 5 months; discontinued at least 4 weeks prior to LT) led to an objective response rate of 94% (complete response: 59%), downstaging to within Milan criteria (82%) and a pathological response at explant examination of 88%. Grade 3-4 treatment-related adverse events accounted for 17.6% of cases and were manageable. During the 25-month median follow-up period, two cases of mild (rejection activity index <= 4), biopsy-proven rejection were reported but no instances of severe allograft rejection or graft loss were reported. The 1-year and 3-year post-LT survival rates were 94.2% and 88.2%, respectively. Conclusions: This study highlights the favorable oncological and survival outcomes associated with atezolizumab and bevacizumab treatment in the pre-LT setting. This immune-based combination was safe in terms of treatment-related adverse events, and absence of severe post-transplant rejection or graft loss. These preliminary results could pave the way for expanding transplant eligibility criteria in patients at more advanced HCC stages. (c) 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access articleunder the CC BY-NC-ND license.","Tabrizian, P; Marino, R; Bhoori, S; Zeitlhoefler, M; Mehta, N; Banz, V; Gruttadauria, S; Iavarone, M; Mazzarelli, C; Simonotti, N; Yao, FC; Mazzaferro, V; Llovet, JM",False,No comparison group specified; does not fit the PICOS criteria fully.,patients with advanced hepatocellular carcinoma,atezolizumab and bevacizumab treatment,not specified,1-year and 3-year post-LT survival rates,prospective study,False,"While the abstract specifies patients with HCC and describes an intervention (atezolizumab and bevacizumab), it lacks a comparison group as required by PICOS criteria. The study design is prospective but not randomized, which disqualifies it from inclusion.",-,-,no comparison group is mentioned; the study evaluates only one treatment arm,-,prospective observational study rather than an RCT,False,No disagreement between Model A and B,False
47,"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study",10.1016/j.ajt.2024.04.007,"Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma patients are rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICI therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICI therapy during the study period. The median post- LT follow-up was 8.1 (interquartile range 3.3-14.6) months. During the short follow-up, 23 (27.7%) recipients developed allograft rejection, and 7 of them (30.4%) were diagnosed by liver biopsy. Multivariate logistics regression analysis showed that the time interval between the last administration of ICI therapy and LT (TLAT) >= 30 days was an independent protective factor for allograft rejection (odds ratio = 0.096, 95% confidence interval 0.026-0.357; P <.001). Multivariate Cox analysis showed that allograft rejection was an independent risk factor for overall survival (hazard ratio = 9.960, 95% confidence interval 1.006-98.610; P =.043). We conclude that patients who receive a pre-LT ICI therapy with a TLAT shorter than 30 days have a much higher risk of allograft rejection than those with a TLAT longer than 30 days. The presence of rejection episodes might be associated with higher post-LT mortality.","Guo, ZY; Liu, Y; Ling, Q; Xu, LB; Wang, TL; Zhu, JX; Lin, YM; Lu, XJ; Qu, W; Zhang, F; Zhu, ZJ; Zhang, J; Jia, ZH; Zeng, P; Wang, WJ; Sun, Q; Luo, QJ; Hu, ZM; Zheng, ZY; Jia, YB; Li, J; Zheng, YJ; Wang, MC; Wang, SP; Han, ZM; Yu, S; Li, CJ; Zhang, SH; Xiong, J; Deng, FW; Liu, Y; Chen, HW; Wang, YF; Li, L; Liang, WJ; Schlegel, A; Nashan, B; Liu, C; Zheng, SS; He, XS",False,No specific comparison to a control or placebo group; does not meet PICOS criteria.,patients receiving pre-LT ICI therapy,pre-LT immune checkpoint inhibitors therapy,not specified,post-LT mortality,multicenter retrospective cohort study,False,"The abstract focuses on pre-LT ICI therapy and provides survival data, but it lacks a direct comparison group such as placebo or non-ICI treatments. Additionally, the study design is retrospective, failing to meet the RCT requirement.",-,-,no direct comparison group specified; the analysis compares TLAT intervals within the same cohort,-,"multicenter retrospective cohort study, not an RCT",False,No disagreement between Model A and B,False
48,Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma,10.3389/fonc.2022.946693,"Most patients with hepatocellular carcinoma (HCC) are diagnosed when the disease is already at an advanced stage, so they are not eligible for resection and their prognosis is poor. The combination of transarterial chemoembolization (TACE) with immune checkpoint inhibitors or tyrosine kinase inhibitors can improve unresectable HCC to the point that patients can be treated with surgery. Here we describe two cases of such ""conversion therapy"". One patient was a 52-year-old man in Child-Pugh class A with treatment-naive HCC whose 11.3-cm tumor had invaded the middle hepatic vein and right branch of the portal vein. He was treated with TACE plus camrelizumab, and radical resection was performed 3 months later. No evidence of recurrence was observed during 5-month follow-up. The other patient was a 42-year-old man in Child-Pugh class A with HCC involving a 11.4-cm tumor and severe liver cirrhosis. The patient was treated with TACE and lenvatinib, but the embolic effect after one month was unsatisfactory, so the regional treatment was changed to hepatic artery infusion chemotherapy and transcatheter arterial embolization. Radical resection was performed 2 months later, and no recurrence was evident at 1-month follow-up. These cases demonstrate two conversion therapies that may allow patients with initially unresectable HCC to benefit from resection.","Chen, K; Luo, CP; Ge, DX; Wang, KL; Luo, Q; Li, YZ; You, XM; Xiang, BD; Li, LQ; Ma, L; Zhong, JH",False,Case report format does not fulfill randomized controlled trial requirement; lacks comparison group.,patients with unresectable hepatocellular carcinoma,TACE plus immune checkpoint inhibitors,not specified,successful radical resection,case report,False,"The abstract presents two case studies of conversion therapy using TACE plus ICIs or other systemic therapies. Case reports inherently lack randomization and control groups, making them ineligible under PICOS criteria.",-,-,-,-,-,False,No disagreement between Model A and B,False
49,"Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention",10.1007/s00261-021-03074-z,"Locoregional therapies can be offered to hepatocellular carcinoma patients as a bridge to transplant, to downstage disease burden for transplant eligibility, or for disease control to prolong survival. Systemic therapies also play a large role in HCC treatment, occasionally in conjunction with other methods. This manuscript reviews the various treatment options for HCC with a historically noncurative intent.","Yacoub, JH; Mauro, D; Moon, A; He, AWR; Bashir, MR; Hsu, CEC; Fishbein, TM; Burke, LMB",False,"Review article; does not provide specific intervention, comparison, or outcomes related to PICOS criteria.",patients with hepatocellular carcinoma,not specified,not specified,not specified,review article,False,"This is a review article summarizing various locoregional and systemic therapies for HCC. It does not provide specific interventions, comparisons, or outcomes relevant to immune checkpoint inhibitors or RCTs, thus failing to meet PICOS criteria.",-,-,-,-,-,False,No disagreement between Model A and B,False
50,Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma,10.3390/jcm13113068,"Background: Hepatocellular carcinoma (HCC) is widely recognized as the predominant type of primary liver malignancy. Orthotopic liver transplantation (OLT) has emerged as a highly effective treatment option for unresectable HCC. Immunotherapies as neoadjuvant options are now being actively investigated in the transplant oncology era to enhance outcomes in patients with HCC. Here, we report our experience with patients with HCC who had received Immune Checkpoint Inhibitors (ICPI) prior to curative OLT. Methods: This was a retrospective cohort that included patients with HCC who received ICPI prior to OLT at a single institution from January 2019 to August 2023. Graft rejection was assessed and reported along with the type of ICPI, malignancy treated, and the timing of ICPI in association with OLT. Results: During this cohort period, six patients with HCC underwent OLT after neoadjuvant ICPI. All patients were male with a median age of 61 (interquartile range: 59-64) years at OLT. Etiology associated with HCC was viral (N = 4) or Non-alcoholic steatohepatitis, NASH (N = 2). Tumor focality was multifocal (N = 4) and unifocal (N = 2). Lymphovascular invasion was identified in four patients. No perineural invasion was identified in any of the patients. All patients received ICPI including atezolizumab/bevacizumab (N = 4), nivolumab/ipilimumab (N = 1), and nivolumab as monotherapy (N = 1). All patients received either single or combined liver-directed/locoregional therapy, including transarterial chemoembolization (TACE), Yttrium-90 (Y90), stereotactic body radiotherapy (SBRT), and radiofrequency ablation (RFA). The median washout period was 5 months. All patients responded to ICPI and achieved a safe and successful OLT. All patients received tacrolimus plus mycophenolate as immunosuppressant (IS) therapy post-OLT and one patient received prednisone as additional IS. No patient had clinical evidence of rejection. Conclusions: This cohort emphasizes the success of tumor downstaging by ICPI for OLT when employed as the neoadjuvant therapy strategy. In addition, this study illustrated the importance of timing for the administration of ICPI before OLT. Given the lack of conclusive evidence in this therapeutic area, we believe that our study lays the groundwork for prospective trials to further examine the impact of ICPI prior to OLT.","Abdelrahim, M; Esmail, A; Divatia, MK; Xu, JQ; Kodali, S; Victor, DW; Brombosz, E; Connor, AA; Saharia, A; Elaileh, A; Kaseb, AO; Ghobrial, RM",False,does not have a comparison group or randomized design,patients with hepatocellular carcinoma,Immune Checkpoint Inhibitors prior to liver transplantation,not specified,success in downstaging tumors for transplantation,retrospective cohort study,False,"The study is a retrospective cohort analysis without a comparison group or randomization, which does not meet the PICOS criteria for a randomized controlled trial. Additionally, while Model A's extraction is mostly accurate, the population description could be more specific about the inclusion of only male patients with HCC who underwent orthotopic liver transplantation after receiving ICIs.",male patients with hepatocellular carcinoma who underwent orthotopic liver transplantation after receiving immune checkpoint inhibitors,-,-,-,-,False,No disagreement between Model A and B,False
51,Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis,10.1007/s12328-022-01744-z,"A combined therapy of atezolizumab and bevacizumab (atezo/bev) is used as the first-line treatment for unresectable hepatocellular carcinoma (HCC). In this study, we report the case of curative hepatic resection in a 77-year-old man who initially had unresectable advanced-stage HCC with lung metastases. This rare hepatectomy conversion was owing to the administration of atezo/bev. Notwithstanding the side effects of immune-related adverse event hepatitis and intratumoral hemorrhage developed during atezo/bev treatment; after seven treatment cycles, the patient's tumor markers normalized, the tumor shrank markedly, and the metastasis disappeared. Subsequently, conversion therapy with hepatic resection was performed, and pathology confirmed complete tumor necrosis. No cancer recurrence was observed at the 8-month postoperative follow-up, and the patient remained drug free.","Fukunaga, A; Takata, K; Itoh, S; Yamauchi, R; Tanaka, T; Yokoyama, K; Shakado, S; Kohashi, K; Yoshizumi, T; Hirai, F",False,not a randomized controlled trial and lacks a comparison group,77-year-old man with unresectable HCC,atezolizumab and bevacizumab treatment,not specified,conversion to curative hepatic resection,case report,False,"This is a case report focusing on a single patient, which inherently lacks a comparison group and randomization, failing to meet the PICOS criteria. Model A's extraction is accurate, but the intervention description should specify that atezolizumab and bevacizumab were administered as part of a first-line treatment regimen for unresectable HCC.",-,atezolizumab and bevacizumab as first-line treatment for unresectable hepatocellular carcinoma,-,-,-,False,No disagreement between Model A and B,False
52,Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report,10.1093/jscr/rjad610,"Patients with hepatocellular carcinoma at high risk of recurrence after hepatic resection or local ablation often undergo adjuvant immunotherapy with immune checkpoint inhibitors for 1 year in randomized controlled trials, but the appropriateness of this duration is controversial, especially given the risk of adverse events. Here we report the case of a 52-year-old Chinese man with initially unresectable multinodular recurrent hepatocellular carcinoma who underwent two cycles of transarterial chemoembolization, followed by hepatic resection and 24 months of adjuvant therapy with the PD-1 inhibitor tislelizumab. The patient achieved a recurrence-free survival time of 24 months, but he experienced elevated alpha fetoprotein, Grade 2 hypothyroidism and pruritus while on adjuvant therapy. This case highlights the need to optimize the duration of adjuvant immunotherapy after curative treatment for hepatocellular carcinoma in order to minimize risk of not only recurrence but also adverse events.","Li, JR; Yang, DL; Wang, JM; Tian, W; Wei, W; Luo, CP; Qi, LN; Ma, L; Zhong, JH",False,not a randomized controlled trial and lacks a comparison group,patients with recurrent hepatocellular carcinoma,PD-1 inhibitor tislelizumab as adjuvant therapy,not specified,recurrence-free survival time,case report,False,"This is a case report describing a single patient's experience with adjuvant immunotherapy, which does not include a comparison group or randomization. While Model A's extraction is accurate, the outcome description should emphasize recurrence-free survival in the context of extended adjuvant therapy duration (24 months) and associated adverse events.",-,-,-,recurrence-free survival time of 24 months with documented adverse events including elevated alpha fetoprotein and Grade 2 hypothyroidism,-,False,No disagreement between Model A and B,False
53,FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study,10.3389/fimmu.2024.1471017,"Background Hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen has demonstrated efficacy in patients with unresectable hepatocellular carcinoma (HCC). The combined targeted and immunotherapy has emerged as a first-line treatment for liver cancer. In this study, we investigated the clinical efficacy and safety of FOLFOX-HAIC in combination with targeted immunotherapy in patients with untreated, unresectable HCC.Materials and methods Data were collected from patients with initially unresectable HCC treated at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, from June 2022 to June 2023. Tumor response and survival outcomes were assessed following the FOLFOX-HAIC combined with targeted immunotherapy, The safety was also evaluated through the incidence of related adverse events.Results A total of 51 eligible patients were recruited. The objective response rate (ORR) based on mRECIST and RECIST 1.1 criteria were 60.8% and 45.1%, respectively. The surgical conversion rate was 25.5%. The median progression-free survival (PFS) was 15.2 months. The 1-year overall survival rate was 88.2%. Adverse events were observed in 98% patients, with 23.5% experiencing grade 3 or 4 adverse events.Conclusion The FOLFOX-HAIC combined with targeted immunotherapy regimen is effective in patients with unresectable HCC, demonstrated by a high surgical conversion rate and manageable adverse effects. This regimen represents a potential novel first-line treatment option for HCC.","Lu, YC; Yang, YC; Ma, D; Wang, JQ; Hao, FJ; Chen, XX; Chen, YJ",False,not a randomized controlled trial and lacks a comparison group,patients with untreated unresectable HCC,FOLFOX-HAIC combined with targeted immunotherapy,not specified,objective response rate and survival outcomes,not specified,False,"Although this study reports outcomes from a cohort of patients treated with FOLFOX-HAIC combined with targeted immunotherapy, it lacks a comparison group and randomization, failing to meet the PICOS criteria. Model A's extraction is generally accurate, but the study design should explicitly state that this is a single-arm observational study rather than leaving it unspecified.",-,-,-,-,single-arm observational study,False,No disagreement between Model A and B,False
54,Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant,10.1007/s12029-024-01040-8,"PurposeLiver transplantation is curative for hepatocellular carcinoma (HCC). Checkpoint inhibitor therapy (CPIT) has been used in unresectable HCC, but recent advances have demonstrated CPIT as an innovative method of downstaging advanced HCC with the caveat that CPIT prior to transplantation has risks including irreversible graft rejection. We report the outcomes of Mayo Clinic Arizona patients who underwent downstaging with CPIT.MethodsThis retrospective chart review was conducted for Mayo Clinic Arizona patients who were diagnosed with HCC who underwent downstaging with CPIT with the goal of meeting criteria for transplantation.ResultsWe present nine cases with HCC outside Milan who underwent CPIT. Four received a transplant; one was delisted due to his exceptional therapeutic response. All received liver-directed therapy. Peak alpha-fetoprotein pre-CPIT ranged from 8-29,523 ng/mL, which decreased to 2.2-19.6 ng/mL on CPIT. CPIT included atezolizumab/bevacizumab, ipilimumab/nivolumab, nivolumab, and pembrolizumab; one patient received two regimens. CPIT was held prior to transplant at a median of 3 months. Three patients received methylprednisolone for immunosuppression induction; one received thymoglobulin. One patient developed acute cellular rejection at 5 weeks, 9 weeks, and 5 months post-transplant; given the late onset, these were not attributed to CPIT and were successfully treated. During an average follow-up of 16.5 months, no tumor recurrence has occurred.ConclusionWe describe nine patients with HCC outside Milan with inadequate response with liver-directed therapy, who achieved marked responses with CPIT, allowing for consideration of successful liver transplantation. Our case series supports the consideration of locoregional therapies and CPIT for downstaging to within transplant criteria.","Liu, MC; Lizaola-Mayo, B; Jayasekera, CR; Mathur, AK; Katariya, N; Aqel, B; Byrne, TJ; Chascsa, DMH",False,does not have a comparison group or randomized design,Mayo Clinic patients with hepatocellular carcinoma,CPIT for downstaging HCC,not specified,successful liver transplantation without tumor recurrence,retrospective chart review,False,"This is a retrospective chart review of nine patients treated with checkpoint inhibitor therapy for downstaging HCC, which lacks a comparison group and randomization, thus not meeting the PICOS criteria. Model A's extraction is accurate, but the population description should clarify that these are patients with HCC outside Milan criteria who were considered for transplantation after downstaging.",patients with hepatocellular carcinoma outside Milan criteria who underwent downstaging with checkpoint inhibitor therapy,-,-,-,-,False,No disagreement between Model A and B,False
55,Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases,10.21037/tcr-23-1333,"Background: Programmed cell death protein 1 (PD-1) or its ligand (PD-L1) monoclonal antibody combined with bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor) has been established as first-line systemic treatment for advanced hepatocellular carcinoma (HCC). Radiotherapy is a crucial local treatment for HCC. Mutual efficacy enhancement has been reported between radiotherapy, anti-angiogenesis therapy and immunotherapy in preclinical researches, but not been validated in clinical practice. Whether radiotherapy can enhance efficacy of anti-PD-1 immunotherapy plus bevacizumab for HCC remains unclear. This retrospective observational study aimed to appraise efficacy and safety of the combination of radiotherapy with pembrolizumab (a PD-1 monoclonal antibody) and bevacizumab for advanced HCC for the first time. Methods: Patients with advanced HCC treated by intrahepatic tumor-directed moderately hypofractionated radiotherapy combined with pembrolizumab and bevacizumab were consecutively included. Clinicopathological characteristics, therapeutic outcomes and treatment-related adverse events (TRAEs) were recorded and evaluated. Results: A total of 23 patients were eventually enrolled. Median cycles of pembrolizumab and bevacizumab were 4 (median, 1-8) and 4 (median, 1-9) cycles. The objective response rates and disease control rates of irradiated intrahepatic HCC and non-irradiated extrahepatic HCC were 34.8% [95% confidence interval (CI), 16.4-57.3%] vs. 10.0% (95% CI, 1.2-31.7%), and 91.3% (95% CI, 72.0-98.9%) vs. 70.0% (95% CI, 45.7-88.1%), respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.6 (95% CI, 4.7-8.5) and 18.3 (95% CI, 8.2-33.6) months, and 12-month PFS and OS rates were 17.5% (95% CI, 7.0-28.0%) and 60.9% (95% CI, 50.7-71.1%). Two patients (8.7%) with locally advanced, unresectable HCC eventually underwent curative resection of tumors after this trimodal treatment. Eighteen patients (78.3%) had >= grade 3 TRAEs, with myelosuppression and transaminase increase as the most common. Conclusions: This study firstly reported that combining radiotherapy with pembrolizumab and bevacizumab was preliminarily a feasible and effective therapeutic choice for advanced HCC in despite of more TRAEs. This tri -modal regimen may be a potential conversion therapy for unresectable, locally advanced HCC. The limitations of this study are its retrospective nature and small sample size; therefore, big -sample prospective studies are warranted to further investigate this tri-modal regimen.","Liang, XX; Jiang, YH; Yao, W; Deng, Y; Yang, S; Liu, QD",False,does not meet study design criteria (not a randomized controlled trial),patients with advanced hepatocellular carcinoma,"combination of radiotherapy, pembrolizumab, and bevacizumab",not specified,objective response rates and overall survival,retrospective observational study,False,"The study is retrospective and observational, not a randomized controlled trial as required by the PICOS criteria. Additionally, the comparison group is not specified in the abstract, making it impossible to evaluate the intervention's relative efficacy.",-,-,not specified (no explicit mention of a control or comparator group in the abstract),-,-,False,No disagreement between Model A and B,False
56,The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab,10.1002/cam4.5931,"Background and Aims: We aimed to validate the predictive factors for tumor response and the prognostic impact of conversion therapy aimed at cancer- and drug-free states in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing atezolizumab plus bevacizumab (Atez/Bev) therapy. Methods: This retrospective study enrolled 156 patients who were Child-Pugh class A with u-HCC treated using Atez/Beva. The profile of objective response was investigated using decision-tree analysis. Progression-free, recurrence-free, and overall survival were assessed. Results: The progression-free and overall survival were 6.1 and 18.0 months, respectively. Objective response and disease control rates were 32.0% and 84.0%, respectively. Decision-tree analysis revealed that neutrophil-to-lymphocyte ratio (NLR) <3, modified albumin-bilirubin grade (m-ALBI) 1 or 2a, and age < 75 were sequential splitting variables for the objective response, respectively. In the multivariate analysis, NLR <3 and m-ALBI grade 1 or 2a were identified as predictive factors for objective response. We successfully achieved eligibility for conversion therapy in 17 patients after Atez/Bev therapy significant response. Following conversion therapy, the curative therapy group, including surgical resection or radiofrequency ablation (RFA), had significantly higher recurrence-free survival than did the transcatheter arterial chemoembolization (TACE) and Atez/Bev discontinuation (surgical resection or RFA; not reached vs. TACE; 5.3 months, p = 0.008, Atez/Bev discontinuation; 3.9 months, p = 0.048, respectively) groups. Conclusions: NLR <3 and m-ALBI grade 1 or 2a were predictive factors for conversion therapy, leading to cancer- and drug-free states in patients with u-HCC undergoing Atez/Bev therapy. Moreover, surgery or RFA may be suitable for conversion therapy for cancer-free status.","Shimose, S; Iwamoto, H; Shirono, T; Tanaka, M; Niizeki, T; Kajiwara, M; Itano, S; Yano, Y; Matsugaki, S; Moriyama, E; Noda, Y; Nakano, M; Kuromatsu, R; Koga, H; Kawaguchi, T",False,does not meet study design criteria (not a randomized controlled trial),patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab therapy,not specified,progression-free and overall survival,retrospective study,False,"This is a retrospective study, not a randomized controlled trial, failing to meet the study design criterion. Furthermore, the abstract does not specify a direct comparison group for atezolizumab plus bevacizumab, limiting its applicability to the PICOS framework.",-,-,not specified (no explicit comparator group described in the abstract),-,-,False,No disagreement between Model A and B,False
57,Role of radiotherapy and its contribution to immunotherapy in hepatocellular carcinoma,10.21037/cco-23-50,"Hepatocellular carcinoma (HCC) is a major contributor to cancer-related deaths, with the incidence of HCC increasing in regions of the world with a high incidence of hepatitis B and C. The therapeutic landscape for HCC management has substantially transformed over recent years, shifting towards a multimodal treatment paradigm. This approach provides a range of medical and surgical interventions aimed at managing the disease effectively. Radiotherapy (RT) has surfaced as a critical player in the preoperative management of inoperable HCC, demonstrating potential in downstaging the disease and achieving disease stability. This advantage may potentially be attributed to the abscopal effect, where localized radiation leads to the regression of metastatic cancer outside of the irradiated site through upregulation of the immune system. The advent of recent technological breakthroughs has paved the way for innovative approaches, notably the integration of immunotherapy and RT. This strategy is emerging as a promising avenue for managing HCC. Preliminary findings from the fusion of RT and immunotherapy are encouraging, with ongoing trials keenly evaluating the optimal parameters for therapy administration, such as timing, dosage, and sequence. The development of combined treatments involving immune checkpoint inhibitors (ICIs) has opened new avenues for advanced HCC treatment. Several immunotherapeutic agents with RT are concurrently being explored for their potential contributions to HCC management.","Nahm, WJ; Bhatt, A; Wu, JNF",False,not specific to a clinical trial or population meeting PICOS criteria,not specified,combination of immunotherapy and radiotherapy,not specified,not specified,not specified,False,"The abstract discusses theoretical concepts and potential future directions rather than presenting data from a specific clinical trial or population. It lacks clarity on population, intervention, comparison, outcomes, and study design, failing all PICOS criteria.",not specified (abstract does not describe a specific patient population),combination of immunotherapy and radiotherapy (abstract mentions integration but lacks specificity),not specified (no comparator group mentioned),not specified (outcomes are not clearly defined or measured),not specified (abstract does not describe a study design),False,No disagreement between Model A and B,False
58,Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review,10.3390/cancers14102357,"Simple Summary Hepatocellular carcinoma is the fourth leading cause of cancer-related mortality worldwide and a major health problem. Overall survival is poor, with a five-year relative survival rate of 18.4% and only 2% in metastatic hepatocellular carcinoma. In 2020, the combination of atezolizumab and bevacizumab improved survival compared to sorafenib and was validated as the first-line treatment for advanced hepatocellular carcinoma. In case of disease progression, regorafenib and cabozantinib are recommended in the second-line setting. Transarterial chemoembolization can also be proposed for downstaging or in the palliative setting. Being able to reliably estimate liver function is a major issue in therapeutic management because patients with intermediate liver function are no longer eligible to receive systemic treatments. The aim of this review was to discuss systemic treatment management for patients with advanced unresectable HCC for whom liver-directed therapy is not appropriate. Hepatocellular carcinoma (HCC) usually occurs in the setting of liver cirrhosis and more rarely in a healthy liver. Its incidence has increased in the past years, especially in western countries with the rising prevalence of non-alcoholic fatty liver disease. The prognosis of advanced HCC is low. In the first-line setting of advanced HCC, sorafenib, a tyrosine kinase inhibitor, was the only validated treatment for many years. In 2020, the combination of atezolizumab, an immune checkpoint inhibitor, and bevacizumab showed superiority to sorafenib alone in survival, making it the first-line recommended treatment. Regorafenib and lenvatinib, other multikinase inhibitors, were also validated in the second and first-line settings, respectively. Transarterial chemoembolization can be an alternative treatment for patients with intermediate-stage HCC and preserved liver function, including unresectable multinodular HCC without extrahepatic spread. The current challenge in advanced HCC lies in the selection of a patient for the optimal treatment, taking into account the underlying liver disease and liver function. Indeed, all trial patients present with a Child-Pugh score of A, and the optimal approach for other patients is still unclear. Furthermore, the combination of atezolizumab and bevacizumab should be considered in the absence of medical contraindication. Many trials testing immune checkpoint inhibitors in association with anti-angiogenic agents are ongoing, and primary results are promising. The landscape in advanced HCC management is undergoing profound change, and many challenges remain for optimal patient management in the years to come. This review aimed to provide an overview of current systemic treatment options for patients with advanced unresectable HCC who are not candidates for liver-directed therapy.","Puisieux, MF; Pellat, A; Assaf, A; Ginestet, C; Brezault, C; Dhooge, M; Soyer, P; Coriat, R",False,does not meet study design criteria (not a randomized controlled trial),patients with advanced unresectable hepatocellular carcinoma,atezolizumab and bevacizumab,sorafenib,survival rates,review article,False,"While the abstract specifies a comparison between atezolizumab plus bevacizumab and sorafenib, it is a review article, not a randomized controlled trial. Review articles do not meet the PICOS study design criterion.",-,-,-,-,review article (does not meet RCT requirement),False,No disagreement between Model A and B,False
59,Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma,10.3390/curroncol29120771,"Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date.","Woo, SM; Kimchy, AV; Sequeira, LM; Dorris, CS; He, AR; Rangnekar, AS",False,does not meet study design criteria (not a randomized controlled trial),patients with hepatocellular carcinoma,pre-liver transplant immunotherapy,not specified,not specified,literature review,False,"The abstract focuses on summarizing existing literature rather than presenting original data from a clinical trial. It does not meet the PICOS study design criterion as it is a literature review, not a randomized controlled trial.",-,-,not specified (no comparator group mentioned),not specified (outcomes are not clearly defined or measured),literature review (does not meet RCT requirement),False,No disagreement between Model A and B,False
60,Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma,10.1007/s10238-022-00873-6,"Curative surgery and locoregional therapy are radical therapies for patients with HCC. But more than 80% of HCC patients cannot be fitful for radical therapies because of local progression or distant metastasis at initial diagnosis. Among patients with unresectable locally advanced hepatocellular carcinoma (HCC), some patients can be converted to be technically resectable by conversion treatment and salvage surgery. For unresectable locally advanced hepatocellular, conversion treatment prior to salvage surgery with transcatheter arterial chemoembolization (TACE) and other locoregional therapies improve outcomes. PD-1/PD-L1 inhibitors as immune checkpoint inhibitor (ICI) therapy which show high antineoplastic activity in HCC patients by preclinical and clinical researches can also be a good choice for conversion therapy. PD-1/PD-L1 inhibitor combined with locoregional therapy plus antiangiogenic agents or not is most potential conversion therapy comparing to PD-1 inhibitor monotherapy and PD-1/PD-L1 inhibitor combined with antiangiogenic agents or CTLA-4 inhibitor. As more clinical evidence reported, PD-1/PD-L1 immunotherapy would be widely used in conversion treatment of locally advanced hepatocellular carcinoma.","Chen, JQ; Zhang, D; Yuan, Y",False,does not provide a comparison or specified outcomes or study design,patients with hepatocellular carcinoma,PD-1/PD-L1 inhibitors as immune checkpoint inhibitors,not specified,not specified,not specified,False,"The abstract discusses the potential of PD-1/PD-L1 inhibitors in combination with other therapies but does not specify a comparison group or outcomes relevant to survival or response rate. Additionally, there is no mention of a randomized controlled trial design which is required by the PICOS criteria.",-,-,"The abstract implies comparisons between different combinations (e.g., PD-1/PD-L1 inhibitors with locoregional therapies and antiangiogenic agents) but does not explicitly define a control or comparator group such as placebo or treatment without ICIs.",The abstract mentions improved outcomes and antineoplastic activity but does not quantify survival rates or response rates specifically.,-,False,No disagreement between Model A and B,False
61,ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma,10.1245/s10434-022-12653-3,,"Zhu, XD; Huang, C; Shen, YH; Xu, B; Ge, NL; Ji, Y; Qu, XD; Chen, LL; Chen, Y; Li, ML; Zhu, JJ; Tang, ZY; Zhou, J; Fan, J; Sun, HC",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
62,Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection,10.3389/fonc.2021.667555,"Introduction Transarterial chemoembolization (TACE) is inefficient at converting unresectable hepatocellular carcinoma (uHCC) to resectable. Treatment with immune checkpoint inhibitors (ICIs) is an emerging strategy for uHCC. Combined therapy of TACE with ICIs is considered to improve the therapeutic effect. Case presentation A 45-year-old man was diagnosed with a bulky HCC under cirrhotic background without distant metastasis. Curative resection was infeasible, and TACE plus tislelizumab (an ICI targeting PD-1) was applied. The treatment course, starting from TACE and followed by tislelizumab one week later, was repeated every four weeks. After three courses, the tumor showed striking shrink in volume with complete radiological response, which permitted salvage resection. Notably, pathological examination found complete necrosis of the tumor with massive infiltration of lymphocytes in the tumor-nontumor interface and extensive granulomatous inflammation in the surrounding nontumor liver, indicating activated immune response synergistically caused by TACE with tislelizumab. The patient is now living well without tumor recurrence for 6 months after surgery. Conclusion TACE in combination with tislelizumab may represent a potent strategy for uHCC. Data from randomized clinical trials are needed to assess its safety and effect in the setting of preoperative downstaging therapy.","Chao, JS; Zhu, Q; Chen, DS; An, X; Liu, AQ; Zhou, F; Yuan, L; Wang, ZW; Sun, HC",False,does not mention a randomized controlled trial or provide a comparison,a patient with unresectable hepatocellular carcinoma,TACE plus tislelizumab (an ICI),not specified,complete radiological response and tumor necrosis,not specified,False,"This is a case report rather than a randomized controlled trial. While it describes an intervention and outcomes for a single patient, it lacks a defined comparison group and does not meet the study design criterion of an RCT.",-,-,The abstract does not provide a clear comparison group; it only describes the intervention applied to one patient without contrasting it to other treatments or placebo.,-,"The study design is a case report, not a randomized controlled trial as required by the PICOS criteria.",False,No disagreement between Model A and B,False
63,Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma,10.1111/hepr.14024,"AimThe IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy.MethodsNinety-five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non-simple nodular (non-SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes.ResultsAssessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non-SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non-SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non-SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non-SN lesions underwent sequential local therapy.ConclusionsAtezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non-SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non-SN lesions. This study showed that atezolizumab plus bevacizumab for hepatocellular carcinoma might be increasingly effective in patients with non-simple nodular (non-SN) intrahepatic lesions, which had a higher potential for aggressive features. A treatment strategy focusing on conversion therapy may be important in patients with non-SN lesions. image","Ishihara, N; Komatsu, S; Sofue, K; Ueshima, E; Yano, Y; Fujishima, Y; Ishida, J; Kido, M; Gon, H; Fukushima, K; Urade, T; Yanagimoto, H; Toyama, H; Ueda, Y; Kodama, Y; Murakami, T; Fukumoto, T",False,lacks a comparison and randomized controlled trial design,patients with advanced hepatocellular carcinoma,atezolizumab plus bevacizumab,not specified,increased objective response rate,"retrospective evaluation, not a randomized controlled trial",False,"The abstract evaluates radiological imaging markers and their association with treatment efficacy but does not include a direct comparison between ICIs and non-ICI treatments or placebo. Furthermore, the study design is retrospective, not a randomized controlled trial.",-,-,The abstract lacks a clear comparison group; it compares tumor morphologies (SN vs. non-SN) but does not contrast ICIs against treatments without ICIs or placebo.,-,-,False,No disagreement between Model A and B,False
64,Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy,10.1016/j.annonc.2023.09.168,,"Tomonari, T; Tani, J; Sato, Y; Tanaka, H; Taniguchi, T; Kawano, Y; Masaki, T; Takayama, T",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
65,Hepatic arterial infusion chemotherapy for ad- vanced hepatocellular carcinoma in the era of che- mo-diversity,10.3350/cmh.2022.0391,"Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are effective and contribute to prolonged patient survival, their effects are unsatisfactory for some specific tumor conditions, such as macrovascular invasion. Hepatic arterial infusion chemotherapy (HAIC) is a traditional treatment for advanced HCC. As yet, there is no worldwide consensus recommending HAIC because no high-quality clinical trials have demonstrated its survival benefit. However, clinical evidence is gradually accumulating that shows its survival benefit, and it is recognized as an effective locoregional treatment for advanced HCC. Several HAIC regimens have been reported, including cisplatin monotherapy, cisplatin plus 5-fluorouracil (low-dose FP), lipiodol-suspended FP, and an oxaliplatin-based regimen. We have entered an era of chemo-diversity in the treatment of advanced HCC. This review aimed to clarify the relevance of HAIC in the era of chemo-diversity. We propose a multidisciplinary therapeutic strategy combining locoregional HAIC treatment with sequential drug therapy, with the aim of becoming cancer-free through conversion therapy. (Clin Mol Hepatol 2023;29:593-604)","Iwamoto, H; Shimose, S; Shirono, T; Niizeki, T; Kawaguchi, T",False,does not describe a clinical trial,patients with hepatocellular carcinoma,not specified,not specified,not specified,review,False,"The abstract describes a review of hepatic arterial infusion chemotherapy (HAIC) and its relevance in treating advanced hepatocellular carcinoma, but it does not describe a clinical trial. Model A correctly identifies this as a review, and there is no population, intervention, comparison, or outcome specific to immune checkpoint inhibitors (ICIs). Thus, the article does not meet the PICOS criteria.",-,-,-,-,-,False,No disagreement between Model A and B,False
66,Liver transplantation after successful downstaging of a locally advanced hepatocellular carcinoma with systemic therapy,10.1159/000529023,"Introduction: Liver transplantation (LT) is potentially curative for patients with cirrhosis and hepatocellular carcinoma (HCC). However, this procedure is usually reserved for patients with early tumor stages or after successful downstaging with local regional therapies (LRT). In patients with locally advanced HCC current guidelines recommend locoregional and palliative systemic therapies for tumor stages Barcelona Clinic Liver Cancer (BCLC) B and C respectively.Case report: In this article we describe a 63 -year-old male patient with locally advanced hepatocellular carcinoma (BCLC C) and hepatitis C associated cirrhosis. Following systemic treatment with the immune checkpoint inhibitor atezolizumab and the anti-VEGF antibody bevacizumab significant downstaging to a tumor stage within the Milan criteria was achieved after which liver transplantation was successfully performed. Conclusion: As more effective systemic therapies become available, liver transplantation and potential curative treatment could become feasible for selected patients with locally advanced HCC.","Schmiderer, A; Zoller, H; Niederreiter, M; Effenberger, M; Oberhuber, G; Krendl, FJ; Oberhuber, R; Schneeberger, S; Tilg, H; Djanani, A",False,not a randomized controlled trial,a 63-year-old male with locally advanced hepatocellular carcinoma,immune checkpoint inhibitor atezolizumab and anti-VEGF bevacizumab,not specified,downstaging to liver transplantation eligibility,case report,False,"The abstract presents a case report of a single patient treated with atezolizumab and bevacizumab for locally advanced hepatocellular carcinoma. While the intervention involves ICIs, the study design is a case report, which lacks randomization and a control group. Model A's analysis is accurate; however, the comparison group is missing entirely from the abstract, making it impossible to evaluate comparative effectiveness. This article does not meet the PICOS criteria.",-,-,no comparison group described in the abstract,-,-,False,No disagreement between Model A and B,False
67,A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re-Administering Atezolizumab and Bevacizumab,10.1002/cnr2.70090,"BackgroundFibrolamellar hepatocellular carcinoma (FL-HCC) clinically occurs in young people aged 20-30 years, who often have a normal liver background. We propose a treatment for such cases in which a combination therapy of atezolizumab and bevacizumab is followed by sandwiching radiation therapy to release tumor antigens and then re-administering the combination therapy of atezolizumab and bevacizumab (ABC conversion therapy).CaseThe patient is a 15-year-old girl. On April 18, 2022, she noticed skin yellowing and visited her local doctor. Computed tomography (CT) revealed a large mass in the right lobe of the liver and bile duct obstruction due to the tumor. She also had a nodule on her chest that appeared to be a metastatic tumor and was referred to Kinki University Hospital in April 2023. She was suspected to have FL-HCC based on contrast-enhanced ultrasound and CT scan results. There were findings suggestive of lung metastasis; however, she underwent a right hepatic lobectomy on May 17, 2023, considering the risk of liver failure and intra-abdominal bleeding due to the large liver tumor. A CT scan conducted on July 25, 2022, showing increased lung metastases, and she started atezolizumab/bevacizumab combination treatment on October 20, 2022. On March 15, 2023, multiple lung metastases and new intrahepatic lesions appeared, which was diagnosed as progressive disease (PD), and lenvatinib was discontinued. On November 17, 2023, radiation therapy (25 Gy/5 Fr) was administered to the lung and intrahepatic lesions to release tumor antigens, and on November 27, 2023, atezolizumab and bevacizumab combination treatment was resumed to control the tumor.ConclusionCombination therapy with atezolizumab, bevacizumab, and radiation therapy may be an option for the treatment of FL-HCC.","Hagiwara, S; Oda, I; Ueshima, K; Komeda, Y; Nishida, N; Yoshida, A; Yamamoto, T; Omaru, N; Matsubara, T; Kudo, M",False,not a randomized controlled trial,15-year-old girl with fibrolamellar hepatocellular carcinoma,combination therapy of atezolizumab and bevacizumab,not specified,not specified,case report,False,"This is a case report of a 15-year-old girl with fibrolamellar hepatocellular carcinoma treated with atezolizumab, bevacizumab, and radiation therapy. The abstract does not specify outcomes relevant to survival or response rates, nor does it include a comparison group. Model A correctly identifies the study design as a case report, but the lack of a defined outcome measure is an additional flaw. This article does not meet the PICOS criteria.",-,-,no comparison group described in the abstract,outcomes are not clearly specified in terms of survival or response rate,-,False,No disagreement between Model A and B,False
68,Clearance of Hepatitis C Virus following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: Case Report,10.1159/000539646,"Introduction: Patients with advanced hepatocellular carcinoma (HCC) have limited treatment options in the context of decompensated cirrhosis. HCC occurs in patients with hepatitis C virus (HCV) infection and cirrhosis at 1-4% per year. Direct-acting antiviral (DAA) efficacy is decreased in the presence of HCC. We present a case where immunotherapy may have resulted in HCV clearance, when DAA therapy had been ineffective. We hypothesise that immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway can reverse T-cell exhaustion and aid in the clearance of chronic HCV. Case Presentation: This case study describes a male in his 40 s identified by a re-engagement initiative for HCV, who had been unaware of his diagnosis. On further investigation he was found to have compensated for liver cirrhosis and HCC. He was treated with HCV DAA therapy (sofosbuvir/velpatasvir) and then systemic immunotherapy for HCC with atezolizumab and bevacizumab, in an attempt to downstage the disease. Hepatitis C therapy did not achieve sustained virological response, with viral relapse after the end of treatment. This, combined with ongoing alcohol use, resulted in hepatic decompensation and cessation of immunotherapy after the fifth cycle. The HCV RNA subsequently became undetectable without further DAA re-treatment. Conclusion: To our knowledge, this is the first case of HCV clearance after DAA relapse and the timing of this event after immunotherapy suggests a causal link. We hypothesise that this may be due to the reversal of antiviral T-cell exhaustion. This would therefore support further investigation into other chronic viral infections that create tumour associated with immunosuppressive microenvironments. (c) 2024 The Author(s). Published by S. Karger AG, Basel","Wilson, H; Macdonald, D; Bryce, K",False,not a randomized controlled trial,male in his 40s with hepatocellular carcinoma and cirrhosis,immunotherapy with atezolizumab and bevacizumab,not specified,HCV clearance,case study,False,"The abstract discusses a case study of a male patient with hepatocellular carcinoma treated with atezolizumab and bevacizumab. The primary focus is on hepatitis C clearance rather than survival or response rates, and there is no comparison group. Model A's analysis is correct, but the outcomes are unrelated to the target PICOS criteria. This article does not meet the PICOS criteria.",-,-,no comparison group described in the abstract,"outcomes pertain to HCV clearance, not survival or response rate",-,False,No disagreement between Model A and B,False
69,Lenvatinib-based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta-analysis,10.3892/ol.2024.14398,"Hepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical treatment and achieve long-term survival. Despite accumulating evidence regarding the efficacy of conversion therapy, the optimal treatment approach for such therapy remains uncertain. Lenvatinib (LEN) has shown efficacy and tolerable rates of adverse events (AEs) when applied in combination with immune checkpoint inhibitors (ICIs) or locoregional therapy (LRT) over the past decade. Therefore, the present meta-analysis was performed to systematically assess the safety and efficacy of LEN-based treatment regimens in conversion therapies for uHCC. Data on outcomes, including the conversion rate, objective response rate (ORR), disease control rate (DCR) and AE incidence in patients with uHCC, were collected. A systematic literature search was performed using MEDLINE, Embase, Web of Science and Cochrane Library databases, up to the date of September 1, 2023. In total, 16 studies, encompassing a total of 1,650 cases of uHCC, were included in the final meta-analysis. The pooled conversion rates for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were calculated to be 0.04 (95% CI, 0.00-0.07; I2=77%), 0.23 (95% CI, 0.16-0.30; I2=66%), 0.14 (95% CI, 0.10-0.18; I2=0%) and 0.35 (95% CI, 0.23-0.47; I2=88%), respectively. The pooled ORRs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were found to be 0.45 (95% CI, 0.23-0.67; I2=96%), 0.49 (95% CI, 0.39-0.60; I2=78%), 0.43 (95% CI, 0.24-0.62; I2=88%) and 0.69 (95% CI, 0.56-0.82; I2=92%), respectively. The pooled DCRs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were observed to be 0.77 (95% CI, 0.73-0.81; I2=23%), 0.82 (95% CI, 0.69-0.95; I2=90%), 0.67 (95% CI, 0.39-0.94; I2=94%) and 0.87 (95% CI, 0.82-0.93; I2=67%), respectively. The pooled grade >= 3 AEs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were 0.25 (95% CI, 0.14-0.36; I2=89%), 0.43 (95% CI, 0.34-0.53; I2=23%), 0.42 (95% CI, 0.19-0.66; I2=81%) and 0.35 (95% CI, 0.17-0.54; I2=94%), respectively. These findings suggested that LEN-based combination strategies may confer efficacy and acceptable tolerability for patients with uHCC. In particular, LEN + ICI, with or without LRT, appears to represent a highly effective conversion regimen, with an acceptable conversion rate and well-characterized safety profile.","Li, SX; Zhang, ZY; Wang, Z; Wang, KN; Sui, MH; Liu, DB; Liang, K",False,does not provide data from a single randomized controlled trial,patients with unresectable hepatocellular carcinoma,lenvatinib-based treatment regimens with ICIs,comparison with other treatment modalities not specified,conversion rate and response rate,meta-analysis of multiple studies,False,"The abstract describes a meta-analysis evaluating lenvatinib-based treatment regimens, including combinations with immune checkpoint inhibitors (ICIs), for unresectable hepatocellular carcinoma. While the outcomes include conversion rates and response rates, the study design is a meta-analysis, not a single randomized controlled trial. Model A correctly identifies this limitation, but the comparison group description is incomplete because the abstract does not specify direct comparisons within individual studies. This article does not meet the PICOS criteria.",-,-,comparison groups are not explicitly detailed in the abstract,-,-,False,No disagreement between Model A and B,False
70,Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation,10.3390/cancers16112081,"Simple Summary Hepatocellular carcinoma (HCC) is a common cancer and a leading cause of cancer-related deaths worldwide. However, HCC can be effectively treated in selected cases, with liver transplantation representing one of the limited options for potential cure. Unfortunately, many patients are ineligible for liver transplantation either due to an advanced tumor at initial diagnosis or due to disease progression while awaiting liver transplantation. Our review discusses the role of systemic therapies as a bridging treatment to liver transplantation, thereby enabling more HCC patients to undergo potentially curative liver transplantation.Abstract Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths. Classically, liver transplantation (LT) can be curative for HCC tumors within the Milan criteria. Bridging strategies to reduce the dropouts from LT waiting lists and/or to downstage patients who are beyond the Milan criteria are widely utilized. We conducted a literature-based review to evaluate the role of systemic therapies as a bridging treatment to liver transplantation (LT) in HCC patients. Tyrosine kinase inhibitors (TKIs) can be used as a systemic bridging therapy to LT in patients with contraindications for locoregional liver-directed therapies. Immune checkpoint inhibitor (ICI) treatment can be utilized either as a monotherapy or as a combination therapy with bevacizumab or TKIs prior to LT. Acute rejection after liver transplantation is a concern in the context of ICI treatment. Thus, a safe ICI washout period before LT and cautious post-LT immunosuppression strategies are required to reduce post-LT rejections and to optimize clinical outcomes. Nevertheless, prospective clinical trials are needed to establish definitive conclusions about the utility of systemic therapy as a bridging modality prior to LT in HCC patients.","Saleh, Y; Abu Hejleh, T; Abdelrahim, M; Shamseddine, A; Chehade, L; Alawabdeh, T; Mohamad, I; Sammour, M; Turfa, R",False,does not provide a comparison or outcome data,patients with hepatocellular carcinoma,immune checkpoint inhibitors as bridging therapy,not specified,not specified,literature-based review,False,"The abstract discusses the role of systemic therapies, including immune checkpoint inhibitors (ICIs), as a bridging treatment to liver transplantation. However, it does not provide specific comparison or outcome data relevant to survival rate or response rate. The study design is a literature-based review, which does not meet the PICOS criterion for randomized controlled trials.",-,-,"The abstract mentions no specific comparison group, but it implies a comparison with locoregional therapies, which should be clarified as ""locoregional therapies or no ICI treatment.""","The outcomes discussed are related to enabling transplantation rather than survival or response rates, so this should be specified as ""enabling transplantation"" instead of being left vague.",-,False,No disagreement between Model A and B,False
71,Reassessment of palliative surgery in conversion therapy of previously unresectable hepatocellular carcinoma: Two case reports and review of literature,10.4240/wjgs.v16.i10.3312,"BACKGROUND Most patients with hepatocellular carcinoma (HCC) have lost the opportunity for direct surgery at the time of diagnosis. Transarterial chemoembolization (TACE) combined with immune checkpoint inhibitors or tyrosine kinase inhibitors (TKI) can partially transform some unresectable HCC and improve the prognosis effectively. However, based on the promising prospects of combined targeted and immunotherapy for the effective treatment of HCC, the positive role of palliative surgery in the conversion treatment of advanced HCC urgently needs further intensive re-assessment. CASE SUMMARY In this study, we describe two successful cases of ""conversion therapy for unresectable HCC"" achieved mainly by palliative surgery combined with TACE plus immunotherapy and TKIs. A 48-year-old patient with newly diagnosed HCC, presenting with a 6-cm mass in the segment VII/VIII of the right liver with multiple intrahepatic metastases, could not undergo one-stage radical surgical resection. He underwent palliative surgery with radiofrequency of metastatic lesions and the palliative resection of the primary mass, and received subsequent TACE treatments twice in the early postoperative period (2 weeks and 6 weeks), in addition to targeted and immune combination therapy with sintilimab injection and oral lenvatinib. No evidence of recurrence was observed during the 11-month follow-up period after surgery. The other patient was a 47-year-old patient with massive HCC (18 cm x 15 cm x 4.5 cm) in the left liver with severe cirrhosis. The left portal branch was occluded and a tumor thrombus formed, and the tumor partly involved the middle hepatic vein. The patient underwent palliative surgery of left hemihepatectomy (including resection of the middle hepatic vein) for HCC, followed by three TACE procedures and oral TKIs 2 weeks after surgery. Six months later, the re-examination via computed tomography revealed no tumour activity in the remaining right liver, while magnetic resonance imaging revealed slight local tumor enhancement in the caudate lobe of the liver considered, TACE was performed once again, and during the next follow-up of 10 months did not reveal new intrahepatic lesions or distant metastases. CONCLUSION These cases demonstrate that the addition of palliative surgery to conversion therapy in a selected population with a high tumor burden could benefit patients with initially unresectable HCC.","Zhu, YB; Qin, JY; Zhang, TT; Zhang, WJ; Ling, Q",False,not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,TACE combined with immune checkpoint inhibitors,palliative surgery without immunotherapy,improved prognosis and no recurrence,case report,False,"While the abstract describes two cases where TACE combined with ICIs and TKIs led to improved prognosis and no recurrence, the study design is a case report, which does not meet the PICOS criterion for randomized controlled trials. Additionally, the comparison group is vaguely described as palliative surgery without immunotherapy, which lacks clarity and precision.",-,-,The comparison should explicitly clarify whether the control involves no immunotherapy at all or just different combinations of treatments.,-,-,False,No disagreement between Model A and B,False
72,Downstaging of Hepatocellular Carcinoma Before Liver Transplantation: Current Advances in Selection Criteria and Therapeutic Options,10.1016/j.transproceed.2024.05.041,"Liver transplantation (LT) is an ideal therapeutic option for selected patients with hepatocellular carcinoma (HCC). The selection criteria of HCC for LT have evolved in recent decades. Down- staging therapy is a promising strategy for patients with tumor burden beyond transplant criteria to increase the chance of receiving LT and improve posttransplant survival. Downstaging therapy is also a selection tool that refines fi nes the conventional selection criteria based on tumor morphology. Recently, the success of systemic treatment, including immune checkpoint inhibitors, antiangiogenic tyrosine kinase inhibitors, and VEGF inhibitors, in advanced HCC has prompted the discussion regarding the role of systemic therapies for HCC downstaging before transplantation. In this review, we aimed to summarize the current advances in selection criteria and therapeutic options of downstaging therapy for HCC before LT.","Pang, L; Xu, LB; Wu, WR",False,does not provide specific comparison or data from trials,patients with hepatocellular carcinoma,systemic treatment including immune checkpoint inhibitors,not specified,improved posttransplant survival,review,False,"The abstract reviews systemic treatments, including ICIs, for downstaging therapy before liver transplantation. However, it does not provide specific comparison or outcome data from trials, making it ineligible under the PICOS criteria. The study design classification as a review is accurate.",-,-,"The abstract fails to specify any comparison group, which should be noted as ""not applicable"" since no direct comparisons are made.","The outcome should specify that no quantitative survival or response rate data is provided, only general improvements in posttransplant survival.",-,False,No disagreement between Model A and B,False
73,Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review,10.3389/fonc.2024.1280805,"Hepatocellular carcinoma is a rather common malignant tumor. Most patients with hepatocellular carcinoma receive their diagnosis at an advanced stage, at which surgical resection is no longer appropriate. A growing body of research has demonstrated the value of convention therapy for patients with intermediate-stage hepatocellular carcinoma, while specific application protocols and treatment guidelines are not well developed. Emerging clinical researches suggest that a tyrosine kinase inhibitor in combination with an immune checkpoint inhibitor is a reasonable strategy for unresectable hepatocellular carcinoma. However, there are relatively few reports on the efficacy of apatinib and camrelizumab in the treatment of hepatocellular carcinoma. We were able to successfully remove one patient's hepatocellular carcinoma after 8 cycles of conversion therapy with apatinib (250 mg orally every day) and camrelizumab (200 mg intravenously every 2 weeks). The patient continued to receive the same dose of 16 cycles of apatinib and camrelizumab after hepatectomy. By the time of this study, the patient has completed 18 months of follow-up, and no tumor recurrence or metastasis was found in tumor markers and imaging examinations. Apatinib in combination with camrelizumab is an effective therapy for the treatment of advanced hepatocellular carcinoma, and surgical resection after this conversion therapy may provide patients with long-term oncological benefits. However, this requires more samples to validate the conclusion.","Liu, XL; Li, XZ; Chu, YF; Liu, F; Tian, H",False,not a randomized controlled trial,patients with advanced hepatocellular carcinoma,apatinib and camrelizumab combination therapy,not specified,no tumor recurrence or metastasis,case report,False,"The abstract presents a single case where apatinib and camrelizumab combination therapy led to no tumor recurrence or metastasis after surgical resection. However, the study design is a case report, which does not meet the PICOS criterion for randomized controlled trials. The lack of a clearly defined comparison group further limits its inclusion.",-,-,"The comparison group is not specified, but it can be inferred as standard care or no combination therapy, which should be explicitly stated.",-,-,False,No disagreement between Model A and B,False
74,Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan,10.1159/000534304,,"Kudo, M",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
75,Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook,10.21037/cco-20-248,"Hepatocellular carcinoma (HCC) is a highly aggressive and chemotherapy resistant cancer with unique biologic characteristics which makes this disease highly different than other gastrointestinal cancers. The mainstay of curative treatment in HCC is surgical resection, ablation, and transplantation. However, rates of recurrence are high and many patients are not initially candidates for these curative approaches. This paper discusses predictors of recurrence of HCC in patients who have undergone surgical resection and addresses adjuvant therapies aimed at decreasing recurrence risk and improving overall survival (OS) outcomes, including traditional cytotoxic chemotherapies, tyrosine kinase inhibitors (TKIs), and immunotherapy. This article also discusses neoadjuvant strategies aimed at improving recurrence rate and OS as well as downstaging advanced HCC to enable surgical disease, including locoregional therapies, systemic chemotherapy, TKIs, and immune checkpoint inhibitors. Finally, this article addresses potential future directions for both adjuvant and neoadjuvant therapies that may change the treatment paradigm of HCC in the near future.","Sahin, IH; Khalil, L; Millett, R; Kaseb, A",False,does not specify a comparison group or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors and other therapies,not specified,improving overall survival outcomes,not specified,False,"The abstract lacks a defined comparison group and study design. While it discusses various therapies including immune checkpoint inhibitors, it does not specify a comparison or use a randomized controlled trial design. The outcomes are vaguely described as improving overall survival without precise measurement.",-,-,The abstract does not explicitly mention a comparison group; therapies are discussed broadly without contrasting interventions.,The outcome is mentioned as improving overall survival but lacks specific metrics or definitions for measurement.,-,False,No disagreement between Model A and B,False
76,Neoadjuvant and adjuvant systemic treatment for hepatocellular carcinoma,10.20517/2394-5079.2021.84,"Hepatocellular carcinoma (HCC) is a highly lethal malignancy, and few patients are candidates for curative-intended therapies. The mainstay of curative treatment in HCC is surgical resection, ablation, and transplantation. However, rates of recurrence are high, and there is no established approach to reduce the risk of recurrence and mortality. We discuss the available data and current landscape of (neo)adjuvant therapies aimed at decreasing recurrence risk and improving overall survival, including liver-directed therapies, tyrosine kinase inhibitors, and immunotherapy. Neoadjuvant strategies aimed at downstaging advanced HCC to enable local treatment and minimize the risk of recurrence using novel agents are also a topic of interest in current research. The improvements achieved in the advanced stages with immune-checkpoint inhibitors are priming ongoing trials that address potential future directions for both adjuvant and neoadjuvant strategies that may change the treatment paradigm of HCC in the near future.","Mathias-Machado, MC; da Fonseca, LG",False,lacks a defined comparison and study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors among other therapies,not specified,overall survival,not specified,False,This abstract similarly lacks a defined comparison group and study design. It mentions immune checkpoint inhibitors among other therapies but does not contrast them with a control or placebo. Outcomes like overall survival are mentioned but not quantified or rigorously defined.,-,-,No explicit comparison group is provided; the discussion focuses on multiple therapies without specifying contrasts.,Overall survival is referenced but lacks clear definition or measurement criteria.,-,False,No disagreement between Model A and B,False
77,Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics,10.5582/bst.2023.01326,"Therapies for patients with unresectable hepatocellular carcinoma (uHCC) are currently popular. Current first -line standard-of-care treatments for uHCC are systematic therapies. However, treatments that combine locoregional therapy with systemic therapy are widely accepted in China and have demonstrated high rates of tumor response and conversion to resection with manageable toxicity. A literature review was performed by searching published literature in PubMed and Web of Science up to December 2023 for relevant articles on the use of triple therapy (transarterial chemoembolization combined with lenvatinib and anti-PD-1 antibodies) in uHCC. This review concentrates on the efficacy and safety of triple therapy with Chinese characteristics in patients with uHCC and describes the outcome of conversion surgery, degree of pathological necrosis, and effect prediction. This article will contribute to a comprehensive understanding of the role of triple therapy with Chinese characteristics in patients with uHCC.","Wu, JY; Wu, JY; Li, SQ; Luo, MC; Zeng, ZX; Li, YA; Fu, YK; Li, H; Liu, DY; Ou, XY; Lin, ZT; Wei, SM; Yan, ML",False,not a randomized controlled trial and lacks comparison,patients with unresectable hepatocellular carcinoma,triple therapy including anti-PD-1 antibodies,not specified,tumor response and conversion to resection,literature review,False,"The study design is a literature review, which does not meet the PICOS criterion for randomized controlled trials. While the intervention includes triple therapy with anti-PD-1 antibodies, there is no specified comparison group. Outcomes focus on tumor response and conversion to resection but lack clarity on how they were measured.",-,-,No comparison group is specified; the analysis focuses on the efficacy of triple therapy without contrasting interventions.,Tumor response and conversion to resection are mentioned but lack detailed explanation of measurement methods.,-,False,No disagreement between Model A and B,False
78,Expanding Indications for Liver Transplantation in the Treatment of Hepatocellular Carcinoma,10.3390/curroncol31080355,"Improvements in downstaging therapies have expanded the indications for liver transplantation (LT) for hepatocellular carcinoma (HCC). Patients with more advanced disease are now considered candidates due to advancements in radiation therapy, combination therapies, and immunotherapy. Combination stereotactic body radiation therapy (SBRT) and trans-arterial chemoembolization (TACE) has been shown to be superior to the historic treatment, sorafenib, in patients with macrovascular invasion. These patients are now candidates for LT with stable disease after LRT. Patients with ruptured HCC and prolonged stability have also been shown to have acceptable outcomes. The role of neoadjuvant immunotherapy needs to be further defined and has the potential to further improve tumor control prior to transplant.","Hogen, R; Barry, T; Subramanian, V",False,does not provide a comparison group or study design,patients with hepatocellular carcinoma,neoadjuvant immunotherapy and combination therapies,not specified,tumor control prior to transplant,not specified,False,"The abstract lacks a defined comparison group and study design. While neoadjuvant immunotherapy is discussed, there is no mention of a control or placebo group. Outcomes such as tumor control prior to transplant are mentioned but not quantified or rigorously defined.",-,-,No explicit comparison group is provided; the focus is on combination therapies without specifying contrasts.,Tumor control prior to transplant is referenced but lacks clear definition or measurement criteria.,-,False,No disagreement between Model A and B,False
79,Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody,10.1093/oncolo/oyae032,"Background This study aimed to compare the survival outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who underwent or did not undergo salvage surgery followed by a triple combination conversion treatment consisted of locoregional treatment (LRT), tyrosine kinase inhibitors (TKIs), and anti-PD-1 antibodies.Methods The data from 93 consecutive patients with initially unresectable HCC and PVTT across 4 medical centers were retrospectively reviewed. They were converted successfully by the triple combination treatment and underwent or did not undergo salvage resection. The baseline characteristics, conversion schemes, conversion treatment-related adverse events (CTRAEs), overall survival (OS), and progression-free survival (PFS) of the salvage surgery and non-surgery groups were compared. Multivariate Cox regression analysis was performed to identify independent risk factors for OS and PFS. Additionally, subgroup survival analysis was conducted by stratification of degree of tumor response and type of PVTT.Results Of the 93 patients, 44 underwent salvage surgery, and 49 did not undergo salvage surgery. The OS and PFS of the salvage surgery and non-surgery groups were not significantly different (P = .370 and .334, respectively). The incidence and severity of CTRAEs of the 2 groups were also comparable. Subgroup analyses revealed that for patients with complete response (CR) or types III-IV PVTT, there was a trend toward better survival in patients who did not undergo salvage surgery. Multivariate analysis showed that baseline alpha-fetoprotein and best tumor response per mRECIST criteria were independent prognostic factors for OS and PFS.Conclusions For patients with initially unresectable HCC and PVTT who were successfully converted by the triple combination therapy, salvage liver resection may not be necessary, especially for the patients with CR or types III-IV PVTT. This article compares survival outcomes of patients with initially unresectable hepatocellular carcinoma and portal vein tumor thrombus who did or did not undergo salvage surgery followed by a triple combination conversion treatment consisting of locoregional treatment, tyrosine kinase inhibitors, and anti-PD-1 antibodies.","Wang, L; Feng, JK; Lu, CD; Wu, JY; Zhou, B; Wang, K; Wei, XB; Liang, C; Zhou, HK; Shi, J; Guo, WX; Lau, WY; Yan, ML; Cheng, SQ",False,not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma and portal vein tumor thrombus,triple combination treatment including anti-PD-1 antibodies,comparison between salvage surgery and non-surgery groups,overall survival and progression-free survival,retrospective review,False,"Although the study compares salvage surgery with non-surgery groups, the design is retrospective rather than a randomized controlled trial. The intervention involves triple combination therapy including anti-PD-1 antibodies, but the comparison is limited to surgical versus non-surgical approaches rather than placebo or no ICIs. Outcomes include overall survival and progression-free survival but are analyzed retrospectively.",-,-,"The comparison is between salvage surgery and non-surgery groups, not placebo or absence of ICIs.",-,"The study design is a retrospective review, which does not meet the PICOS criterion for randomized controlled trials.",False,No disagreement between Model A and B,False
80,"Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients",10.1111/apt.18296,,"Gorgulho, J; von Felden, J",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
81,Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis,10.1016/j.hpb.2023.03.004,"Background: Salvage surgery after conversion therapy with a combination of tyrosine kinase inhibitor and anti-programmed death-1 antibody has shown improved survival benefits in patients with hepato-cellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We aimed to compare the survival benefits in a retrospective cohort of patients with HCC with PVTT who underwent salvage surgery after conversion therapy and surgery alone. Methods: From January 2015 to October 2021, we selected patients diagnosed with HCC with PVTT who underwent liver resection at Chinese PLA General Hospital. The primary endpoint in the comparison of survival benefits between conversion therapy and surgery-alone groups was recurrence-free survival. Propensity score matching was applied to reduce any potential bias in the study. Results: The 6-, 12-, and 24-month recurrence-free survival rates in the conversion and surgery alone groups were 80.3% vs 36.5%, 65.4% vs 29.4%, and 56% vs 21%, respectively. On multivariable Cox regression analyses, conversion therapy significantly reduced HCC-related mortality and HCC recur-rence rates compared with surgery alone. Conclusions: For patients with HCC with PVTT, surgery after conversion therapy is in relationship with increased survival in comparison with surgery alone.","Cao, YB; Tang, HW; Hu, BY; Zhang, WW; Wan, T; Han, J; Jiao, TY; Li, JF; Li, XR; Yang, ZY; Liu, Z; Hu, MG; Duan, WD; Li, CG; Zhao, ZM; Lu, SC",False,not a randomized controlled trial,patients with hepatocellular carcinoma and portal vein tumor thrombosis,conversion therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody,surgery alone,recurrence-free survival rates,retrospective cohort study,False,"The study design is a retrospective cohort study, which does not meet the PICOS criterion of requiring a randomized controlled trial. Additionally, while Model A correctly identified the lack of randomization, it failed to note that the intervention involves a combination therapy (tyrosine kinase inhibitor and anti-PD-1 antibody), which is broader than just immune checkpoint inhibitors alone. The comparison group is appropriately described as 'surgery alone,' but the outcome focuses on recurrence-free survival rather than overall survival or response rate, which are more aligned with the PICOS criteria.",-,conversion therapy involving a combination of tyrosine kinase inhibitor and anti-PD-1 antibody,-,recurrence-free survival rates instead of survival rate or response rate,-,False,No disagreement between Model A and B,False
82,Recent Advances in Liver Transplantation for Hepatocellular Carcinoma,10.1007/s11864-024-01247-8,"Liver transplantation for hepatocellular carcinoma (HCC) remains an evolving field. Major challenges HCC transplant patients face today include liver organ donor shortages and the need for both better pre-transplant bridging/downstaging therapies and post-transplant HCC recurrence treatment options. The advent of immunotherapy and the demonstrated efficacy of immune checkpoint inhibitors in multiple solid tumors including advanced/unresectable HCC hold promise in expanding both the neoadjuvant and adjuvant HCC transplant treatment regimen, though caution is needed with these immune modulating agents leading up to and following transplant. New options for pre-transplant HCC management will expand access to this curative option as well as ensure patients have adequate control of their HCC prior to transplant to maximize the utility of a liver donor. Machine perfusion has been an active area of investigation in recent years and could expand the organ donor pool, helping address current liver donor shortages. Finally, additional HCC biomarkers such as AFP-L3 and DCP have shown promise in improving risk stratification of HCC patients. Together, these three recent advancements will likely alter HCC transplant guidelines in the coming years.","Li, PJ; Shah, S; Mehta, N",False,"no comparison, outcome, or study design specified",patients with hepatocellular carcinoma,immune checkpoint inhibitors,not specified,not specified,not specified,False,"This article lacks critical elements required by the PICOS framework. There is no specific comparison group, outcome measurement, or study design mentioned in the abstract. While Model A correctly flagged these issues, it failed to clarify that the population includes patients undergoing liver transplantation, which is a distinct subgroup of hepatocellular carcinoma patients. Furthermore, the intervention description should specify that immune checkpoint inhibitors are discussed in the context of neoadjuvant or adjuvant therapy rather than being studied directly.",patients with hepatocellular carcinoma undergoing liver transplantation,immune checkpoint inhibitors in the context of neoadjuvant or adjuvant therapy,not applicable as no comparison group is specified,not applicable as no specific outcome is measured,not applicable as no study design is described,False,No disagreement between Model A and B,False
83,Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report,10.1159/000524872,"Introduction: Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease. Surgical resection is the cornerstone of therapy and represents the best potentially curative treatment option. Modest objective responses with cytotoxic chemotherapy alone or combined with immune checkpoint inhibitors (ICIs) have been reported; however, there are no established systemic therapy regimens for unresectable or metastatic FLC. Case Presentation: We report a case of a 23-year-old woman with FLC who presented with a 11.5 x 8.3 cm left liver mass and subsequently underwent resection as initial therapy. Molecular analysis of her surgical tissue revealed a DNAJB1-PRKACA fusion gene. The patient developed biopsy-proven recurrent FLC with multiple liver lesions but without any distant metastatic disease only 3 months after initial resection. In light of emerging data, the patient was treated with a novel triple therapy regimen including 5-fluorouracil (5-FU), interferon (IFN) alfa-2b, and nivolumab. Partial radiographic response was achieved after 4 treatments and complete response was achieved after 12 cycles with the combination. The patient received 2 more doses of 5-FU/IFN alfa-2b without nivolumab and underwent orthotopic liver transplantation (OLT) 6 months after the last dose of ICI. Pathological examination of the explanted liver remarkably confirmed pathologic complete response. She remains recurrence-free and is on active surveillance. Discussion/Conclusion: For patients with unresectable/recurrent FLC with no distant disease, the combination of 5-FU, IFN alfa-2b, and nivolumab could be an effective systemic therapy option. The use of this chemoimmunotherapy regimen to downstage FLC prior to OLT may be worth investigating further. (C) 2022 S. Karger AG, Basel","Kang, S; Magliocca, J; Sellers, M; Roccaro, G; Zheng, W; Pectasides, M; Draper, A; Guadagno, J; El-Rayes, B; Akce, M",False,not a randomized controlled trial and does not meet population criteria,a 23-year-old woman with fibrolamellar carcinoma,"5-FU, IFN alfa-2b, and nivolumab",not specified,partial and complete response,case report,False,"The article is a case report, which does not meet the PICOS requirement for a randomized controlled trial. Model A correctly identified this limitation but overlooked that the population specifically involves a patient with fibrolamellar carcinoma, which is a distinct entity from hepatocellular carcinoma. The intervention combines chemotherapy, interferon, and an immune checkpoint inhibitor, which is broader than just ICIs. The comparison group is absent, and the outcomes focus on radiographic and pathological responses, which differ from the survival or response rates specified in the PICOS criteria.","a patient with fibrolamellar carcinoma, which is distinct from hepatocellular carcinoma","a triple therapy regimen including 5-FU, IFN alfa-2b, and nivolumab",not applicable as no comparison group is specified,radiographic and pathological responses rather than survival or response rates,-,False,No disagreement between Model A and B,False
84,"Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Authors' Reply",10.1111/apt.18319,,"Hatanaka, T; Kakizaki, S; Hiraoka, A; Tada, T; Kumada, T",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
85,"Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients",10.1007/s12072-023-10561-6,"BackgroundTo assess the perioperative safety, oncological outcomes, and determinants influencing the oncological outcomes of salvage liver resection for initially unresectable hepatocellular carcinoma (HCC) rendered resectable through transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies (& alpha;-PD-1).MethodsWe retrospectively reviewed data from 83 consecutive patients across six tertiary hospitals who underwent salvage liver resection for initially unresectable HCC following conversion by TACE combined with TKIs and & alpha;-PD-1, emphasizing perioperative and oncological outcomes. Multivariate Cox regression analysis was employed to discern independent risk factors for postoperative recurrence-free survival (RFS).ResultsThe median operative duration was 200 min, with a median blood loss of 400 ml. Intraoperative blood transfusions were necessitated for 27 patients. The overall perioperative complication rate was 48.2%, with a major complication rate of 16.9%. One patient died during the perioperative period due to postoperative liver failure. During the median follow-up period of 15.1 months, 24 patients experienced recurrence, with early and intrahepatic recurrence being the most common. Seven patients died during follow-up. Median RFS was 25.4 months, with 1- and 2-year RFS rates of 68.2% and 61.8%, respectively. Median overall survival was not reached, with 1- and 2-year overall survival rates of 92.2% and 87.3%, respectively. Multivariate Cox regression analysis revealed that pathological complete response (pCR) and intraoperative blood transfusion served as independent prognostic determinants for postoperative RFS.ConclusionsOur study provides preliminary evidence suggesting that salvage liver resection may be an effective and feasible treatment option for patients with unresectable HCC who achieve resectability after conversion therapy with TACE, TKIs, and & alpha;-PD-1. The perioperative safety of salvage liver resection for these patients was manageable and acceptable. However, further research, particularly prospective comparative studies, is needed to better evaluate the potential benefits of salvage liver resection in this patient population.","Lin, KY; Lin, ZW; Chen, QJ; Luo, LP; Zhang, JX; Chen, JH; Wang, K; Tai, S; Zhang, ZB; Wang, SF; Zhang, JY; You, WY; Wang, B; You, PH; Lin, KC; Yang, T; Zeng, YY",False,does not meet randomized controlled trial design requirement,patients with unresectable hepatocellular carcinoma (HCC),"salvage liver resection after conversion therapy with TACE, TKIs, and anti-PD-1",not specified,recurrence-free survival and overall survival rates,retrospective study,False,"The study design is retrospective, not a randomized controlled trial as required by the PICOS criteria. Additionally, the comparison group is not specified in the abstract, which further disqualifies it from inclusion.",-,-,not specified (agrees with A_C),-,-,False,No disagreement between Model A and B,False
86,Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report,10.3389/fonc.2024.1355798,"Background The synergistic effectiveness of combining immune checkpoint inhibitors with targeted therapies has shown promise in improving the conversion rate for unresectable hepatocellular carcinoma (HCC) patients to a potentially resectable status. However, the efficacy of this approach in the context of HCC with extrahepatic metastasis remains to be conclusively determined.Case presentation We report a rare case of advanced HCC with extrahepatic metastasis who achieved long-term survival by a combination of systemic therapy (sintilimab and sorafenib) followed by laparoscopic hepatectomy. A 63-year-old man presented at our hospital with discomfort on the right side of his waist. An enlarged right hepatic lobe mass was subsequently revealed by CT scan. The patient's medical history, including a prior infection with hepatitis B virus, cirrhosis of the liver and an alpha-fetoprotein (AFP) level measuring 41.28 ng/ml substantiated the clinical diagnosis of HCC. On October 30th, 2019, the patient received 200 mg sintilimab intravenously (q3w) plus 200-400 mg BID sorafenib orally, along with antiviral therapy. After six cycles, his disease achieved partial response (PR). On April 26th, 2021, He underwent a laparoscopic hepatectomy. The patient achieved a sustained period of no evidence of disease for 2.5 years and with drug-free survival for 2 years after the resection. His current overall survival is estimated at approximately 4 years.Conclusions This case highlights the potential of combining sintilimab and sorafenib in transforming HCC with extrahepatic metastasis into a condition amenable to surgical resection, suggesting that this treatment approach, followed by surgery, may lead to complete remission.","Cui, K; Li, ZC; Zhong, JT; Shi, XT; Zhao, L; Li, H; Ma, Y",False,not a clinical trial and lacks comparison group,advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis,combination of sintilimab and sorafenib,not specified,long-term survival,case report,False,"This is a case report, which does not meet the randomized controlled trial requirement. Furthermore, there is no comparison group, making it unsuitable for inclusion under the PICOS framework.",-,-,not specified (agrees with A_C),-,-,False,No disagreement between Model A and B,False
87,Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss,10.1097/LVT.0000000000000083,"Immune checkpoint inhibitors (ICIs) may lead to rejection and even graft loss of solid organ transplant recipients, making them not widely used in transplant patients. There is insufficient clinical experience in using ICIs as a bridging or downstaging therapy before transplantation. We performed a retrospective review of patients receiving programmed cell death 1 inhibitor (PD1) before liver transplantation for HCC in our center and analyzed the data of these patients with the purpose of investigating the safety and feasibility of preoperative PD1 inhibitor among liver transplant recipients and exploring the preoperative correlation ICIs and the postoperative risk of rejection and immune-related graft loss. A total of 16 patients enrolled in this study. Acute rejection occurred in 9 patients, with an incidence of 56.3%. The median time of rejection was 7 days after surgery. The median FK506 concentration at the time of rejection was 7.1 mu g/L. All rejection reactions were reversed after adjusting the immunosuppression regimen. The interval between the last PD1 inhibitor and transplantation in the rejection group was shorter than that in the nonrejection group, and there was a statistical difference [21.0 (15.5-27.5) days vs. 60.0 (34.0-167.0) days, p=0.01]. In conclusion, PD1 inhibitor is a safe and feasible method for bridging or downstaging treatment before liver transplantation. Although preoperative PD1 inhibitor may increase the incidence of postoperative rejection, it is not associated with increased immune-related graft loss and patient death.","Wang, TL; Chen, ZT; Liu, Y; Jia, Y; Ju, WQ; Chen, MG; Zhao, Q; Wang, DP; Guo, ZY; Tang, YH; He, XS",False,not a randomized controlled trial and lacks survival rate outcomes,patients receiving PD1 inhibitors before liver transplantation for HCC,PD1 inhibitor as bridging therapy,not specified,safety and feasibility of treatment,retrospective review,False,"The study is a retrospective review and lacks a comparison group, failing to meet the randomized controlled trial requirement. Additionally, survival rate outcomes are not explicitly reported, which is a key criterion for inclusion.",-,-,not specified (agrees with A_C),safety and feasibility of treatment without explicit survival rate data,-,False,No disagreement between Model A and B,False
88,Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study,10.1159/000528356,"Introduction. The actual rate of conversion surgery and its prognostic advantages remain unclear. This study aimed to assess the outcomes of salvage surgery after conversion therapy with triple therapy (transcatheter arterial chemoembolization (TACE) combined with lenvatinib plus anti-PD-1 antibodies) in patients with initially unresectable hepatocellular carcinoma (uHCC).Methods. Patients with initially uHCC who received at least one cycle of first-line triple therapy and salvage surgery at five major cancer centers in China were included. The primary endpoints were overall survival (OS) and recurrence-free survival (RFS) rates after salvage surgery. The secondary endpoints were perioperative complications, 90-day mortality, and pathological tumor response.Results. Between June 2018 and December 2021, 70 patients diagnosed with uHCC who underwent triple therapy and salvage surgery were analyzed: 39 with Barcelona Clinic Liver Cancer (BCLC) stage C, 22 with BCLC stage B, and 9 with BCLC stage A disease. The median interval between the start of triple therapy and salvage surgery was 4.3 months (range, 1.7-14.2 months). Pathological complete response and major pathological response were observed in 29 (41.4%) and 59 (84.3%) patients, respectively. There were two cases of perioperative mortality (4.3%) and five cases of severe perioperative complications (7.1%). With a median follow-up of 12.9 months after surgery (range, 0.3-36.8 months), the median OS and RFS were not reached. The 1- and 2-year OS rates were 97.1% and 94.4%, respectively, and the corresponding RFS rates were 68.9% and 54.4%, respectively.Conclusion. First-line combination of TACE, lenvatinib, and anti-PD-1 antibodies provides a better chance of conversion therapy in patients with initially uHCC. Furthermore, salvage surgery after conversion therapy is effective and safe and has the potential to provide excellent long-term survival benefits.","Wu, JY; Zhang, ZB; Zhou, JY; Ke, JP; Bai, YN; Chen, YF; Wu, JY; Zhou, SQ; Wang, SJ; Zeng, ZX; Li, YN; Qiu, FN; Li, B; Yan, ML",False,does not specify study design as randomized controlled trial,patients with initially unresectable hepatocellular carcinoma (uHCC),"triple therapy with TACE, lenvatinib, and anti-PD-1 antibodies",not specified,overall survival and recurrence-free survival rates,not specified,False,"Although the abstract provides detailed outcomes and intervention descriptions, the study design is not explicitly stated as a randomized controlled trial. The lack of a specified comparison group also disqualifies it from inclusion under the PICOS criteria.",-,-,not specified (agrees with A_C),-,retrospective or observational study implied by lack of randomization details,False,No disagreement between Model A and B,False
89,Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab,10.1111/liv.15944,,"Chen, B; Huang, BJ",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
90,"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT) a single-arm, phase 2 trial",10.1016/S2468-1253(22)00339-9,"Background The synergy between locoregional therapies and immune checkpoint inhibitors has not been investigated as conversion therapy for unresectable hepatocellular carcinoma. We aimed to investigate the activity of sequential transarterial chemoembolisation (TACE) and stereotactic body radiotherapy followed by avelumab (an anti-PD-L1 drug) for locally advanced, unresectable hepatocellular carcinoma. Methods START-FIT was a single-arm, phase 2 trial in patients with locally advanced hepatocellular carcinoma who were not suitable for curative treatment, conducted in two hospitals in Hong Kong and one in Shenzhen, China. Eligible patients were those aged 18 years or older with an Eastern Cooperative Oncology Group performance status 0-1, Child-Pugh liver function score A5 to B7, tumour size of at least 5 cm, a maximum of three tumour lesions, and adequate hepatic, renal, and bone marrow function. Participants received TACE on day 1, followed by stereotactic body radiotherapy (27 & BULL;5-40 & BULL;0 Gy in five fractions) at day 28. Avelumab (10 mg/kg) was administered 14 days following stereotactic body radiotherapy and every 2 weeks thereafter. The primary endpoint was the proportion of patients deemed amenable to curative treatment, defined as those who had a sustained complete or partial treatment response for at least 2 months and if curative treatment could be performed (ie, resection, radiofrequency ablation, or transplantation), analysed by intention to treat. Safety was also analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT03817736) and has been completed. Findings Between March 18, 2019, and Jan 27, 2021, 33 patients (32 [97%] men and one [3%] woman) were enrolled. The median sum of the largest diameters of lesions was 15 & BULL;1 cm (IQR 8 & BULL;3-14 & BULL;9). 21 (64%) patients had macrovascular invasion (hepatic vein [n=13], branched portal vein [n=3], or both [n=5]). Median follow-up was 17 & BULL;2 months (IQR 7 & BULL;8-25 & BULL;8). 18 (55%) patients were deemed amenable to curative treatment: four (12%) of 33 patients had curative treatment (resection [n=2] or radiofrequency ablation [n=2]), and 14 (42%) had a radiological complete response and opted for close surveillance. 11 (33%) of 33 patients had treatment-related adverse events that were grade 3 or worse. The most common treatment-related grade 3 or worse adverse event was transient increase in alanine aminotransferase or aspartate aminotransferase (five [15%]) after TACE. Five (15%) patients developed immune-related adverse events of grade 3 or worse (three had hepatitis, two had dermatitis). Interpretation To our knowledge, this is the first prospective trial using the combination of immunotherapy and locoregional treatment as conversion therapy for locally advanced unresectable hepatocellular carcinoma, with promising results. Future randomised trials with larger cohorts of patients are warranted.","Chiang, CL; Chiu, KWH; Chan, KSK; Lee, FAS; Li, JCB; Wan, CWS; Dai, WC; Lam, TC; Chen, WQ; Wong, NSM; Cheung, ALY; Lee, VWY; Lau, VWH; El Helali, A; Man, K; Kong, FM; Lo, CM; Chan, ACY",False,does not include a comparison group,patients with unresectable hepatocellular carcinoma,sequential TACE and SBRT followed by avelumab,not specified,proportion of patients amenable to curative treatment,"single-arm, phase 2 trial",False,"The study design is a single-arm trial without a comparison group, which does not meet the PICOS criterion for randomized controlled trials. Additionally, while Model A correctly identifies the lack of a comparison group, it fails to note that the population specifically includes only locally advanced unresectable HCC patients with certain tumor characteristics (e.g., size and number of lesions), which should have been clarified in B_P.","patients with locally advanced unresectable hepatocellular carcinoma who were not suitable for curative treatment, aged 18 years or older, with specific tumor size and function criteria",-,-,-,-,False,No disagreement between Model A and B,False
91,Cirrhosis and complications hepatocellular carcinoma - expanding indications for immunotherapy,10.1080/17843286.2025.2451429,"The incidence of hepatocellular carcinoma (HCC) is rising, with a shift towards Metabolic Dysfunction-associated Steatotic Liver Disease becoming the dominant risk factor in Western countries. Significant advances in treatment have broadened the range of available therapeutic options. For this reason, clinical decision-making, along with a multidisciplinary team approach, plays a crucial role in improving patient outcomes. Following several landmark trials, immune checkpoint inhibitor-based therapy has now become the established first-line standard of care for advanced HCC. Additionally, the application of immunotherapy is shifting to include patients with earlier stages of HCC. Research on the combination with locoregional therapies for intermediate-stage HCC has recently reported positive results, and other phase III trials in the same patient population and early-stage HCC are currently in progress. Furthermore, a growing number of reports support the safety and efficacy of immunotherapeutic agents as potential adjuncts for downstaging of HCC, thus facilitating successful liver transplantation. We will discuss the published and ongoing trials in the expanding field of immune checkpoint inhibitor-based therapy for different stages of HCC.","Degroote, H",False,lacks specific study design and outcomes,patients with advanced hepatocellular carcinoma,immune checkpoint inhibitor therapy,not specified,not specified,not specified,False,"This article is a narrative review discussing various trials rather than presenting original research data. While Model A correctly identifies the lack of specific study design and outcomes, it overlooks the fact that the intervention description (immune checkpoint inhibitor therapy) is too broad and nonspecific given the context of the review. The population also lacks precision as it refers to 'advanced HCC' without further detail.",patients with advanced hepatocellular carcinoma but lacks specificity regarding staging or eligibility criteria,various immune checkpoint inhibitor-based therapies discussed in landmark trials rather than a specific intervention,-,discussion of published and ongoing trials without specific outcome measures provided,narrative review,False,No disagreement between Model A and B,False
92,Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation,10.1016/j.clinre.2023.102167,,"Giudicelli, H; Roux, C; Monsel, A; Conti, F; Scatton, O; Allaire, M",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
93,Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis,10.1186/s40364-021-00274-z,"Background We evaluated organ-specific response rates (OSRRs) to first-line lenvatinib plus anti-PD-1 antibodies in patients with advanced hepatocellular carcinoma (HCC). Methods This retrospective analysis included Chinese patients with unresectable/advanced HCC who received first-line lenvatinib (8 mg/day) plus >= 3 infusions of anti-PD-1 antibodies between October 2018 and May 2020. Tumor and macrovascular tumor thrombi (MVTT) treatment responses were evaluated every 2 months using RECIST v1.1. The overall response rate (ORR)/OSRR was defined as the percentage of patients with a best overall response of complete or partial response (CR or PR). Results In total, 60 patients were included in the analysis; 96.7% had measurable intrahepatic lesions, 55% had MVTT and 26.7% had extrahepatic disease. In all 60 patients, the ORR was 33.3%, median progression-free survival was 7.0 months (95% CI, 1.7-12.3) and median overall survival was not reached. The OSRR for MVTT (54.5%) was higher versus intrahepatic tumors (32.8%), extrahepatic lung metastases (37.5%) and lymph node metastases (33.3%). Among 33 patients with intrahepatic tumors and MVTT, 18 had differential responses in each site, including 13 with a better response in MVTT versus intrahepatic lesions. Among 18 patients whose MVTT achieved a radiographic CR or PR, six underwent surgical resection: 4/6 achieved a pathological CR in MVTT and 2/6 in the intrahepatic tumor. Conclusions First-line lenvatinib plus anti-PD-1 antibodies resulted in better tumor responses in MVTT versus intrahepatic lesions. Complete MVTT necrosis may allow downstaging and subsequent eligibility for surgical resection in a proportion of patients with advanced HCC.","Huang, C; Zhu, XD; Shen, YH; Wu, D; Ji, Y; Ge, NL; Chen, LL; Tan, CJ; Zhou, J; Fan, J; Sun, HC",False,not a randomized controlled trial,patients with advanced hepatocellular carcinoma,lenvatinib plus anti-PD-1 antibodies,not specified,overall response rate and survival,retrospective analysis,False,"Model A accurately notes that this is not a randomized controlled trial but misses the nuance that the population description could be more precise by specifying measurable intrahepatic lesions and MVTT presence. Additionally, the intervention description should clarify the dosing schedule of lenvatinib and anti-PD-1 antibodies. The comparison group remains unspecified, and the study design classification is correct as a retrospective analysis.","patients with unresectable/advanced hepatocellular carcinoma, 96.7% with measurable intrahepatic lesions and 55% with macrovascular tumor thrombi",lenvatinib 8 mg/day plus >=3 infusions of anti-PD-1 antibodies,-,-,-,False,No disagreement between Model A and B,False
94,Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study,10.1186/s12893-024-02334-1,"Background and aims Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) has an extremely poor prognosis. A previous study proved that low-dose radiotherapy (RT) could prolong the prognosis of HCC patients with PVTT. This study aims to explore the sensitivity of PVTT to RT treatment. Methods Patients were selected based on imaging diagnosis of HCC accompanied by PVTT and received combined treatment of radiotherapy, antiangiogenic drugs and immune checkpoint inhibitors, followed by hepatectomy or liver transplantation from January 2019 to August 2022. The efficacy was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and pathological assessment. The sensitivity of tumor cells to the treatment was compared between the primary tumor (PT)and PVTT by analyzing their residual tumor and pathologic complete remission (PCR) incidence. Results Data from 14 patients were collected in the study. After combined treatment, the size of PVTT decreased more significantly than that of the primary tumor in the imaging study (p < 0.05). The residual cancer was significantly more restrictive than that of primary tumor in paired patients based on pathological measurement (p = 0.008). The PCR incidence of the primary tumor (21.42%) was significantly lower (p = 0.008) than that of PVTT in the pathologic study (78.57%). Conclusion PVTT is more sensitive to radiotherapy treatment than the primary tumor in patients with HCC. This combination therapy might be an effective option as a downstaging therapy for patients with HCC with PVTT.","Xiao, Y; Li, KR; Zhao, Y; Yang, SZ; Yan, J; Xiang, CH; Zeng, JP; Lu, Q; Zhang, C; Li, G; Li, GX; Dong, JH",False,lacks comparison group and study design,patients with hepatocellular carcinoma with PVTT,radiotherapy with antiangiogenic drugs and ICIs,not specified,sensitivity of PVTT to treatment,not specified,False,"Model A's analysis correctly identifies the lack of a comparison group and study design details but overlooks that the population description should specify inclusion of PVTT, which is critical for understanding the study focus. The intervention description needs clarification regarding the combination regimen components. The outcome description is accurate, but the study design should explicitly state it as a case series based on the small sample size and descriptive nature.",patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus,"combined treatment of radiotherapy, antiangiogenic drugs, and immune checkpoint inhibitors",-,-,case series,False,No disagreement between Model A and B,False
95,Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy,10.1097/HEP.0000000000001163,"Background and Aims:The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear.Approach and Results:Retrospective study of patients with HCC who had CR according to modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) to ICI-based systemic therapies from 28 centers in Asia, Europe, and the United States. Of 3933 patients with HCC treated with ICI-based noncurative systemic therapies, 174 (4.4%) achieved CR-mRECIST, and 97 (2.5%) had CR according to RECISTv1.1 (CR-RECISTv1.1) as well. The mean age of the total cohort (male, 85%; Barcelona-Clinic Liver Cancer-C, 70%) was 65.9 +/- 9.8 years. The majority (83%) received ICI-based combination therapies. Median follow-up was 32.2 (95% CI: 29.9-34.4) months. One- and 3-year overall survival rates were 98% and 86%. One- and 3-year recurrence-free survival rates were excellent in patients with CR-mRECIST-only and CR-RECISTv1.1 (78% and 55%; 70% and 42%). Among patients who discontinued ICIs for reasons other than recurrence, those who received immunotherapy for >= 6 months after the first mRECIST CR had a longer recurrence-free survival than those who discontinued immunotherapy earlier (p=0.008). Of 9 patients who underwent curative surgical conversion therapy, 8 (89%) had pathological CR (CR-RECISTv1.1, n= 2/2; CR-mRECIST-only, n= 6/7).Conclusions:Overall survival and recurrence-free survival of patients with CR-mRECIST-only and CR-RECISTv1.1 were excellent, and 6 of 7 patients with CR-mRECIST-only who underwent surgical conversion therapy had pathological CR. Despite potential limitations, these findings support the use of mRECIST in the context of immunotherapy for clinical decision-making. When considering ICI discontinuation, treatment for at least 6 months beyond CR seems advisable.","Scheiner, B; Kang, B; Balcar, L; Radu, IP; Reiter, FP; Adzic, G; Guo, J; Gao, X; Yuan, X; Cheng, L; Gorgulho, J; Schultheiss, M; Peeters, F; Hucke, F; Ben Khaled, N; Piseddu, I; Philipp, A; Sinner, F; D'Alessio, A; Pomej, K; Saborowski, A; Bathon, M; Schwacha-Eipper, B; Zarka, V; Lampichler, K; Nishida, N; Lee, PC; Krall, A; Saeed, A; Himmelsbach, V; Tesini, G; Huang, YH; Vivaldi, C; Masi, G; Vogel, A; Schulze, K; Trauner, M; Djanani, A; Stauber, R; Kudo, M; Parikh, ND; Dufour, JF; Prejac, J; Geier, A; Bengsch, B; von Felden, J; Venerito, M; Weinmann, A; Peck-Radosavljevic, M; Finkelmeier, F; Dekervel, J; Ji, FP; Wang, HW; Rimassa, L; Pinato, DJ; Bouattour, M; Chon, HJ; Pinter, M",False,not a randomized controlled trial,patients with hepatocellular carcinoma,immune checkpoint inhibitors-based systemic therapies,not specified,overall survival and recurrence-free survival rates,retrospective study,False,"The study is retrospective and not a randomized controlled trial, which disqualifies it based on the PICOS criteria. Model A correctly identified this limitation. However, the comparison group (A_C) was marked as 'not specified,' but the abstract implies an indirect comparison to patients who did not achieve complete response (CR), warranting clarification.",-,-,patients who did not achieve complete response (CR) are implicitly compared,-,-,False,No disagreement between Model A and B,False
96,Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study,10.1245/s10434-024-14944-3,"Background. Combination treatment with transcatheter arterial chemoembolization (TACE), lenvatinib, and anti-programmed death-1 (anti-PD-1) antibodies (triple therapy) has a high rate of tumor response and converted resection for initially unresectable hepatocellular carcinoma (uHCC) patients. This study aimed to assess the outcomes of salvage surgery in uHCC patients after conversion therapy with triple therapy. Methods. uHCC patients who met the criteria for hepatectomy after receiving triple therapy as first-line treatment were eligible for inclusion in this study. The overall survival (OS) and progression-free survival (PFS) rates in patients who received salvage surgery (SR group) and those who did not (non-SR group) were compared. Results. Of the 144 patients assessed, 91 patients underwent salvage surgery and 53 did not. The OS rates in the SR group were significantly better than those in the non-SR group. The 1- and 2-year OS rates in the SR group were 92.0% and 79.9%, respectively, whereas those in the non-SR group were 85.5% and 39.6 %, respectively (p = 0.007); however, there was no significant difference in the PFS rates. Upon further stratification, OS and PFS were significantly better in the SR group than in the non-SR group in patients who were assessed as partial responses (PR), while there was no significant difference in patients who were assessed as complete response (CR). Conclusions. Salvage surgery is recommended and is associated with a favorable prognosis for uHCC patients who were assessed as PR after conversion therapy, however it may not be necessary for uHCC if CR was achieved.","Wu, JY; Wu, JY; Fu, YK; Ou, XY; Li, SQ; Zhang, ZB; Zhou, JY; Li, B; Wang, SJ; Chen, YF; Yan, ML",False,not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,triple therapy including anti-PD-1 antibodies,salvage surgery vs non-surgery,overall survival and progression-free survival rates,not specified,False,"Model A correctly excluded this article due to the lack of randomization. However, the study design (A_S) was marked as 'not specified,' while the abstract clearly describes a non-randomized comparative study between salvage surgery and non-surgery groups. Additionally, the intervention description (A_I) could specify that triple therapy includes lenvatinib and anti-PD-1 antibodies explicitly.",-,triple therapy including lenvatinib and anti-PD-1 antibodies with TACE,-,-,non-randomized comparative study,False,No disagreement between Model A and B,False
97,Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects,10.5582/bst.2023.01322,"Research has shown that locoregional and/or systemic treatments can reduce the tumor stage, enabling radical surgical resection in patients with initially unresectable hepatocellular carcinoma. This is referred to as conversion therapy. Patients who undergo conversion therapy followed by curative surgery experience a significant survival benefit compared to those who receive chemotherapy alone, those who are successfully downstaged with conversion therapy but not treated with surgery, or those who are treated with upfront surgery. Several treatments have been studied as conversion therapy. However, the success rate of conversion varies greatly, ranging from 0.8% to 60%. Combined locoregional plus systemic conversion therapy has demonstrated significant clinical advantages, with a conversion rate of up to 60%, an objective remission rate of 96% for patients, and a disease control rate of up to 100%. However, patients who underwent conversion therapy experienced significantly more complications than those who underwent direct LR without conversion therapy. Conversion therapy can cause hepatotoxicity, bone marrow suppression, local adhesions, increased fragility of blood vessels and liver tissues, and hepatic edema, which can increase the difficulty of surgery. In addition, criteria need to be established to evaluate the efficacy of conversion therapy and subsequent treatment. Further clinical evidence in this area is urgently needed.","Ma, YN; Jiang, XM; Liu, H; Song, PP; Tang, W",False,not specified and not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,conversion therapy,not specified,not specified,not specified,False,"Model A appropriately excluded this article because it lacks a specified study design and randomization. The analysis correctly flagged missing details in outcomes (A_O) and study design (A_S). However, the population description (A_P) should clarify that these are patients receiving locoregional or systemic treatments specifically for conversion therapy.",patients with initially unresectable hepatocellular carcinoma undergoing conversion therapy,-,-,survival benefit and complication rates associated with conversion therapy,narrative review or commentary,False,No disagreement between Model A and B,False
98,Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival,10.1016/j.clinre.2024.102282,"Background: Integrating immunotherapy with locoregional therapies marks a significant milestone in the realm of hepatocellular carcinoma (HCC) treatment . This study aimed to assess the impact of addition of AtezolizumabBevacizumab (AtezoBev) on the outcome patients treated with SIRT. Methods: We conducted a study that included all Child-Pugh A HCC treated with SIRT since 2017. We examined the effects of the addition of 3 infusions of AtezoBev before the SIRT procedure and after SIRT on patients outcome (AtezoBev-SIRT group). Time-to-event data were analyzed using Kaplan-Meier with the log-rank test. Results: Thirty five HCC patients treated with SIRT were included, of whom 23 % also received AtezoBev infusions. The two groups were similar in terms of liver function and HCC parameters. The median OS was not reached for patients who received AtezoBev in combination with SIRT and 14 months for patients only treated by SIRT. The median PFS was higher in the group treated by SIRT and AtezoBev vs SIRT alone (11.3 months vs 5.8 months). In the global cohort, 8 patients presented a downstaging (23 %), 4 underwent liver surgery (1 in the AtezoBev-SIRT group) and 4 liver transplantation (1 in the AtezoBev-SIRT group) Conclusions: The administration of AtezoBev, both before and after SIRT, is associated with enhanced OS and PFS outcomes compared to SIRT alone for unresectable HCC.","Mejait, A; Roux, C; Soret, M; Larrey, E; Wagner, M; Bijot, JC; Lussey-Lepoutre, C; Thabut, D; Goumard, C; Maksud, P; Allaire, M",False,not a randomized controlled trial,Child-Pugh A hepatocellular carcinoma patients,Atezolizumab-Bevacizumab with SIRT,SIRT alone,overall survival and progression-free survival outcomes,not specified,False,"Model A correctly excluded this article due to the absence of randomization. However, the study design (A_S) was marked as 'not specified,' while the abstract describes a retrospective cohort study comparing SIRT alone versus SIRT combined with Atezolizumab-Bevacizumab. This detail should have been captured.",-,-,-,-,retrospective cohort study,False,No disagreement between Model A and B,False
99,"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study",10.1136/jitc-2021-004205,"Background Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes. Methods From a retrospective multicenter dataset of 323 patients treated with ICI, we identified 31 patients who underwent >1 TACE 60 days before or concurrently, with nivolumab at a single center. We derived a propensity score-matched cohort of 104 patients based on Child-Pugh Score, portal vein thrombosis, extrahepatic metastasis and alpha fetoprotein (AFP) who received nivolumab monotherapy. We described overall survival (OS), progression-free survival (PFS), objective responses according to modified RECIST criteria and safety in the multimodal arm in comparison to monotherapy. Results Over a median follow-up of 9.3 (IQR 4.0-16.4) months, patients undergoing multimodal immunotherapy with TACE achieved a significantly longer median (95% CI) PFS of 8.8 (6.2-23.2) vs 3.7 (2.7-5.4) months (log-rank 0.15, p<0.01) in the monotherapy group. Multimodal immunotherapy with TACE demonstrated a numerically longer OS compared with ICI monotherapy with a median 35.1 (16.1-Not Evaluable) vs 16.6 (15.7-32.6) months (log-rank 0.41, p=0.12). In the multimodal treatment group, there were three (10%) grade 3 or higher adverse events (AEs) attributed to immunotherapy compared with seven (6.7%) in the matched ICI monotherapy arm. There were no AEs grade 3 or higher attributed to TACE in the multimodal treatment arm. At 3 months following each TACE in the multimodal arm, there was an overall objective response rate of 84%. There were no significant changes in liver functional reserve 1 month following each TACE. Four patients undergoing multimodal treatment were successfully bridged to transplant. Conclusions TACE can be safely integrated with programmed cell death 1 blockade and may lead to a significant delay in tumor progression and disease downstaging in selected patients.","Marinelli, B; Kim, E; D'Alessio, A; Cedillo, M; Sinha, I; Debnath, N; Kudo, M; Nishida, N; Saeed, A; Hildebrand, H; Kaseb, AO; Abugabal, YI; Pillai, A; Huang, YH; Khan, U; Muzaffar, M; Naqash, AR; Patel, R; Fischman, A; Bishay, V; Bettinger, D; Sung, M; Ang, C; Schwartz, M; Pinato, DJ; Marron, T",False,not a randomized controlled trial,patients with advanced hepatocellular carcinoma,immune checkpoint inhibitors with TACE,TACE plus ICI vs ICI monotherapy,overall survival and progression-free survival rates,retrospective analysis with propensity score matching,False,"Model A accurately excluded this article because it is not a randomized controlled trial. However, the comparison description (A_C) should explicitly mention that the study used propensity score matching to compare TACE plus ICI versus ICI monotherapy. Additionally, the study design (A_S) could be clarified as a retrospective analysis with matching rather than leaving it vague.",-,-,TACE plus ICI vs ICI monotherapy using propensity score matching,-,retrospective analysis with propensity score matching,False,No disagreement between Model A and B,False
100,Radiographic and -fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study,10.1186/s12885-023-10898-z,"BackgroundPathologic complete response (pCR) following preoperative systemic therapy is associated with improved outcomes after subsequent liver transplant/resection in hepatocellular carcinoma (HCC). However, the relationship between radiographic and histopathological response remains unclear.MethodsWe retrospectively examined patients with initially unresectable HCC who received tyrosine kinase inhibitor (TKI) plus anti-programmed death 1 (PD-1) therapy before undergoing liver resection between March 2019 and September 2021 across 7 hospitals in China. Radiographic response was evaluated using mRECIST. A pCR was defined as no viable tumor cells in resected samples.ResultsWe included 35 eligible patients, of whom 15 (42.9%) achieved pCR after systemic therapy. After a median follow-up of 13.2 months, tumors recurred in 8 non-pCR and 1 pCR patient. Before resection, there were 6 complete responses, 24 partial responses, 4 stable disease cases, and 1 progressive disease case, per mRECIST. Predicting pCR by radiographic response yielded an area under the receiver operating characteristic curve (AUC) of 0.727 (95% CI: 0.558-0.902), with an optimal cutoff value of 80% reduction in the enhanced area in MRI (called major radiographic response), which had a 66.7% sensitivity, 85.0% specificity, and a 77.1% diagnostic accuracy. When radiographic response was combined with alpha-fetoprotein response, the AUC was 0.926 (95% CI: 0.785-0.999); the optimal cutoff value was 0.446, which had a 91.7% sensitivity, 84.6%, specificity, and an 88.0% diagnostic accuracy.ConclusionsIn patients with unresectable HCC receiving combined TKI/anti-PD 1 therapy, major radiographic response alone or combined with alpha-fetoprotein response may predict pCR.","Huang, C; Zhu, XD; Shen, YH; Xu, B; Wu, D; Ji, Y; Chen, LL; Song, TQ; Zhang, W; Zeng, ZM; Huang, HS; Wang, K; Huang, LQ; Chen, YJ; Yang, YC; Zhou, LD; Long, G; Zhao, HT; Wang, YC; Ge, NL; Chen, Y; Tan, CJ; Zhou, J; Fan, J; Sun, HC",False,does not meet study design criteria; not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,tyrosine kinase inhibitor plus anti-PD-1 therapy,not specified,radiographic response and pathologic complete response,retrospective study,False,"The study is retrospective and does not meet the randomized controlled trial requirement. The population, intervention, and outcomes are accurately described by Model A, but the lack of a comparison group and non-randomized design disqualify it from inclusion.",-,-,no comparison group specified in the abstract; this omission is critical for meeting PICOS criteria,-,-,False,No disagreement between Model A and B,False
101,"Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation",10.2174/0118761429310703240823045808,"In the last decade, immunotherapy (IT) has revolutionized oncology and found indications in many cancers, including hepatocellular carcinoma (HCC). In HCC, IT has become the leading systemic therapy for advanced diseases. At the same time, it carries the promise of being a valuable therapy in other settings, including intermediate-stage and unresectable disease, as a downstaging or conversion modality. More controversial is the role of IT in relationship to liver transplantation (LT): on one side, it could be a helpful tool to control or downstage HCC before LT or to treat tumor recurrence after LT, while on the other, it carries the risk of graft rejection and graft loss. This review aims to cover these concerns in depth and unravel the current literature.","Sensi, B; Angelico, R; Toti, L; Conte, L; Coppola, A; Tisone, G; Manzia, TM",False,does not meet study design criteria; not a randomized controlled trial,patients with hepatocellular carcinoma,immunotherapy,not specified,not specified,review article,False,"This is a review article, which inherently does not meet the randomized controlled trial requirement. Model A's analysis is accurate, but the lack of primary data and absence of a defined comparison group make it ineligible.",-,-,-,-,-,False,No disagreement between Model A and B,False
102,Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma,10.1016/j.jceh.2024.102386,"Hepatocellular carcinoma (HCC) carries significant morbidity and mortality. Management of the HCC requires a multidisciplinary approach. Surgical resection and liver transplantation are the gold standard options for the appropriate settings. Stereotactic body radiation therapy (SBRT) has emerged as a promising treatment modality in managing HCC; its use is more studied and well-established in advanced HCC (aHCC). Current clinical guidelines universally endorse SBRT as a viable alternative to radiofrequency ablation (RFA), transarterial chemoembolisation (TACE), and transarterial radioembolisation (TARE), a recommendation substantiated by literature demonstrating comparable efficacy among these modalities. In early-stage HCC, SBRT primarily manages unresectable tumours unsuitable for ablative procedures such as microwave ablation and RFA. SBRT has been incorporated as a modality to downstage tumours or as a bridge to transplant. In the case of intermediate or advanced HCC, SBRT offers excellent results either as a single modality or adjunct to other locoregional modalities such as TACE/TARE. Recent data from late-stage HCC patients illustrate the effectiveness of SBRT in achieving local tumour control while minimising damage to surrounding healthy liver tissue. It has promising local control of approximately 80-90% in managing HCC. Additional prospective data comparing the efficacy of SBRT with the first-line recommended therapies such as RFA, TACE, and surgery are essential. The standard of care for patients with advanced/metastatic disease is systemic therapy (immunotherapy/tyrosine kinase inhibitors). SBRT, in combination with immune-checkpoint inhibitors, has an immune-modulatory effect that results in a synergistic effect. Recent findings indicate that the combination of immunotherapy and SBRT in HCC is well-tolerated and exhibits synergistic effects. Further exploration of diverse immunotherapy and radiotherapy strategies is essential to identify the appropriate time for combination treatments and to optimise dose and fraction regimens. Prospective, randomised studies are imperative to establish SBRT as the primary treatment for HCC.","Sharma, D; Khosla, D; Meena, BL; Yadav, HP; Kapoor, R",False,does not meet study design criteria; not a randomized controlled trial,patients with advanced hepatocellular carcinoma,SBRT and immune-checkpoint inhibitors,first-line recommended therapies,local tumor control and efficacy,not specified,False,"The abstract discusses SBRT and immune-checkpoint inhibitors but does not specify the study design or include a direct comparison group. While Model A correctly identifies the intervention and population, the study design remains unclear and likely non-randomized, failing to meet PICOS criteria.",-,-,comparison group is vaguely referenced as 'first-line recommended therapies' without clear specification,-,study design is not explicitly stated but appears observational based on the abstract,False,No disagreement between Model A and B,False
103,Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning,10.1007/s00330-024-10581-2,"Objective To develop and validate a risk scoring scale model (RSSM) for stratifying prognostic risk after intra-arterial therapies (IATs) for hepatocellular carcinoma (HCC). Methods Between February 2014 and October 2022, 2338 patients with HCC who underwent initial IATs were consecutively enrolled. These patients were divided into training datasets (TD, n = 1700), internal validation datasets (ITD, n = 428), and external validation datasets (ETD, n = 200). Five-years death was used to predict outcome. Thirty-four clinical information were input and five supervised machine learning (ML) algorithms, including eXtreme Gradient Boosting (XGBoost), Categorical Gradient Boosting (CatBoost), Gradient Boosting Decision Tree (GBDT), Light Gradient Boosting Machine (LGBT), and Random Forest (RF), were compared using the areas under the receiver operating characteristic (AUC) with DeLong test. The variables with top important ML scores were used to build the RSSM by stepwise Cox regression. Results The CatBoost model achieved the best discrimination when 12 top variables were input, with the AUC of 0.851 (95% confidence intervals (CI), 0.833-0.868) for TD, 0.817 (95%CI, 0.759-0.857) for ITD, and 0.791 (95%CI, 0.748-0.834) for ETD. The RSSM was developed based on the immune checkpoint inhibitors (ICI) (hazard ratios (HR), 0.678; 95%CI 0.549, 0.837), tyrosine kinase inhibitors (TKI) (HR, 0.702; 95%CI 0.605, 0.814), local therapy (HR, 0.104; 95%CI 0.014, 0.747), response to the first IAT (HR, 4.221; 95%CI 2.229, 7.994), tumor size (HR, 1.054; 95%CI 1.038, 1.070), and BCLC grade (HR, 2.375; 95%CI 1.950, 2.894). Kaplan-Meier analysis confirmed the role of RSSM in risk stratification (p < 0.001). Conclusions The RSSM can stratify accurately prognostic risk for HCC patients received IAT. On the basis, an online calculator permits easy implementation of this model.","Liu, WD; Wei, R; Chen, JW; Li, YY; Pang, HJ; Zhang, WT; An, C; Li, CZ",False,does not meet study design criteria; not a randomized controlled trial,patients with hepatocellular carcinoma receiving IAT,immune checkpoint inhibitors,not specified,prognostic risk stratification,not specified,False,"The study involves machine learning models to develop a risk scoring system and does not meet the randomized controlled trial requirement. Model A accurately describes the population and intervention, but the lack of a comparison group and non-randomized nature exclude it from inclusion.",-,-,no explicit comparison group is mentioned in the abstract,-,-,False,No disagreement between Model A and B,False
104,"Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study",10.4143/crt.2023.1165,"Purpose The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti-programmed cell death-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT. Materials and Methods This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child-Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment- related adverse events were analyzed to assess safety profiles. Results During a median follow-up of 11.23 months (range, 3.07 to 34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The 2-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively. Conclusion Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.","Ou, XY; Wu, JY; Wu, JY; Fu, YK; Zeng, ZX; Li, SQ; Li, YA; Liu, DY; Li, H; Li, B; Zhou, JY; Zhuang, SW; Cheng, SQ; Zhang, ZB; Wang, K; Qu, S; Yan, ML",False,does not meet study design criteria; not a randomized controlled trial,patients with hepatocellular carcinoma and PVTT,lenvatinib combined with anti-PD-1 antibodies and TACE,not specified,overall survival and response rates,retrospective multicenter study,False,"This is a retrospective multicenter study and does not meet the randomized controlled trial requirement. Model A's analysis is accurate, but the absence of randomization and lack of a clearly defined comparison group prevent inclusion.",-,-,no comparison group is specified in the abstract,-,-,False,No disagreement between Model A and B,False
105,Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma,10.3748/wjg.v30.i19.2512,"Hepatocellular carcinoma (HCC) is a high mortality neoplasm which usually appears on a cirrhotic liver. The therapeutic arsenal and subsequent prognostic outlook are intrinsically linked to the HCC stage at diagnosis. Notwithstanding the current deployment of treatments with curative intent (liver resection/local ablation and liver transplantation) in early and intermediate stages, a high rate of HCC recurrence persists, underscoring a pivotal clinical challenge. Emergent systemic therapies (ST), particularly immunotherapy, have demonstrate promising outcomes in terms of increase overall survival, but they are currently bound to the advanced stage of HCC. This review provides a comprehensive analysis of the literature, encompassing studies up to March 10, 2024, evaluating the impact of novel ST in the early and intermediate HCC stages, specially focusing on the findings of neoadjuvant and adjuvant regimens, aimed at increasing significantly overall survival and recurrence-free survival after a treatment with curative intent. We also investigate the potential role of ST in enhancing the downstaging rate for the intermediate-stage HCC initially deemed ineligible for treatment with curative intent. Finally, we critically discuss about the current relevance of the results of these studies and the encouraging future implications of ST in the treatment schedules of early and intermediate HCC stages.","Urquijo-Ponce, JJ; Alventosa-Mateu, C; Latorre-Snchez, M; Castell-Miralles, I; Diago, M",False,does not specify intervention or comparison,patients with hepatocellular carcinoma,not specified,not specified,not specified,not specified,False,"The abstract does not specify the intervention (immune checkpoint inhibitors) or the comparison group, and it lacks a clear description of outcomes such as survival rate or response rate. Additionally, the study design is not mentioned, making it impossible to confirm if it is a randomized controlled trial. Model A's analysis correctly identifies these gaps.",-,not specified; the abstract discusses systemic therapies but does not explicitly mention immune checkpoint inhibitors as the intervention,not specified; no clear comparison group is described in the abstract,"not specified; while overall survival is mentioned, specific outcomes like survival rate or response rate are not clearly defined",not specified; the abstract does not describe the study design,False,No disagreement between Model A and B,False
106,Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future,10.1097/HC9.0000000000000430,"Surgical therapies in patients with early-stage HCC can afford long-term survival but are often limited by the continued risk of recurrence, underscoring an interest in (neo)adjuvant strategies. Prior attempts at adjuvant therapy using tyrosine kinase inhibitors failed to yield significant improvements in recurrence-free survival or overall survival. Advances in the efficacy of systemic therapy options, including the introduction of immune checkpoint inhibitors, have fueled renewed interest in this area. Indeed, the IMBrave050 trial recently demonstrated significant improvements in recurrence-free survival with 1 year of adjuvant atezolizumab plus bevacizumab in high-risk patients undergoing surgical resection or ablation, with several other ongoing trials in this space. There is a strong rationale for consideration of the administration of these therapies in the neoadjuvant setting, supported by early clinical data demonstrating high rates of objective responses, although larger trials examining downstream outcomes are necessary, particularly considering the possible risks of this strategy. In parallel, there has been increased interest in using systemic therapies as a bridging or downstaging strategy for liver transplantation. Current data suggest the short-term safety of this approach, with acceptable rates of rejection, so immunotherapy is not considered a contraindication to transplant; however, larger studies are needed to evaluate the incremental value of this approach over locoregional therapy. Conversely, the use of immunotherapy is currently discouraged after liver transplantation, given the high risk of graft rejection and death. The increasing complexity of HCC management and increased consideration of (neo)adjuvant strategies highlight the critical role of multidisciplinary care when making these decisions.","Singal, AG; Yarchoan, M; Yopp, A; Sapisochin, G; Pinato, DJ; Pillai, A",False,not a randomized controlled trial,patients with early-stage HCC,adjuvant atezolizumab plus bevacizumab,not specified or other treatments,recurrence-free survival,not specified,False,"Although the abstract specifies the intervention (adjuvant atezolizumab plus bevacizumab) and mentions recurrence-free survival as an outcome, it does not describe a randomized controlled trial. The IMBrave050 trial is referenced, but the abstract itself is a narrative review rather than an RCT. Model A's decision aligns with this reasoning, though the comparison group could have been clarified further.",-,-,comparison group is implied as standard care or other treatments but not explicitly stated,-,narrative review; not a randomized controlled trial,False,No disagreement between Model A and B,False
107,"Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients",10.1111/apt.18237,"Aim: This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them with partial response (PR) and complete response (CR) cases. Methods: In this retrospective multicentre study, we included a total of 946 uHCC patients treated with atezolizumab and bevacizumab (Atez/Bev) from September 2020 to September 2023. Results: Out of the patients, 43 (4.5%) received conversion therapy following Atez/Bev treatment. The overall response rate was 65.1% and 23.7% in the conversion and non-conversion group, respectively, with a statistical significance (p < 0.001). Multivariate analyses identified that BCLC stage B or an earlier stage (p = 0.045), absence of macrovascular invasion and extrahepatic spread (p = 0.045), and a low value of neutrophil to lymphocyte ratio (p = 0.04) were significantly favourable predictive factors associated with conversion therapy. The conversion group showed significantly better survival compared to the non-conversion group (p < 0.001). In the landmark analysis at 6, 12 and 18 months, the conversion group exhibited better survival compared to PR patients in the non-conversion group (p = 0.04, 0.01 and 0.03, respectively) and there were no significant differences in the overall survival (OS) between the conversion group and patients who achieved a CR (p = 0.7, 1.0 and 0.3, respectively). Conclusions: Patients with low tumour burden and low value of NLR were more likely to undergo conversion therapy. The OS of patients undergoing conversion therapy showed better survival compared to those achieving PR and was comparable to those with CR patients. Conversion therapy could be considered if feasible.","Hatanaka, T; Kakizaki, S; Hiraoka, A; Tada, T; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Toyoda, H; Ogawa, C; Nishikawa, H; Nishimura, T; Kawata, K; Kosaka, H; Naganuma, A; Yata, Y; Ohama, H; Kuroda, H; Matono, T; Aoki, T; Kanayama, Y; Tanaka, K; Tada, F; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Nakamura, S; Enomoto, H; Kaibori, M; Hiasa, Y; Kudo, M; Kumada, T",False,not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,atezolizumab and bevacizumab,comparison of conversion therapy outcomes,overall response rate and survival,retrospective multicentre study,False,"This is a retrospective multicentre study, which does not meet the PICOS criterion for study design (randomized controlled trial). While the abstract provides details on the intervention (atezolizumab and bevacizumab), population (unresectable HCC patients), and outcomes (overall response rate and survival), the lack of randomization disqualifies it from inclusion. Model A's analysis is accurate, though the comparison group description could be expanded.",-,-,comparison is between conversion therapy outcomes and non-conversion groups but lacks clarity on whether a placebo or no treatment was used,-,-,False,No disagreement between Model A and B,False
108,Durvalumab as a Successful Downstaging Therapy for Liver Transplantation in Hepatocellular Carcinoma: The Importance of a Washout Period,10.1097/TP.0000000000003855,,"Sogbe, M; Lpez-Guerra, D; Blanco-Fernndez, G; Sangro, B; Narvez-Rodriguez, I",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
109,Atezolizumab/bevacizumab as downstaging in hepatocellular carcinoma: an intention-to-transplant analysis,,,"Maspero, M; Bhoori, S; Fedele, V; Simonotti, N; Bellia, V; Bongini, M; Sposito, C; Mazzaferro, V",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
110,"Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study",10.1093/bjsopen/zrac114,"Background Combination conversion therapies afforded curative surgery chance for initially unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the conversion rate and clinical outcomes of a first-line conversion regimen of lenvatinib combined with transarterial chemoembolization (TACE) plus immunotherapy for initial uHCC by interpreting real-world data. Methods Conversion therapy data of patients with uHCC from November 2018 to January 2021 were analysed. The regimens included triple combination therapy (t-CT: lenvatinib, TACE, plus toripalimab) and dual combination therapy (d-CT: lenvatinib plus TACE). Another study population diagnosed with hepatocellular carcinoma of macrovascular invasion disease were included as the upfront surgery cohort. Treatment responses and conversion rate were primary outcomes. Survival and adverse events were analysed. Results Fifty-one patients receiving t-CT (n = 30) and d-CT (n = 21) were enrolled. Higher overall response rates (76.7 per cent versus 47.6 per cent, P = 0.042) and disease control rates (90.0 per cent versus 57.1 per cent, P = 0.042) were observed via t-CT than d-CT. Both median overall survival and event-free survival were not reached in the t-CT cohort. A higher rate of curative conversion resection was achieved through t-CT than d-CT (50.0 per cent versus 19.0 per cent, P = 0.039). The disease-free survival of patients undergoing conversion resection in the t-CT cohort (n = 15) was higher than that in the upfront surgery cohort (n = 68, P = 0.039). Both t-CT and d-CT regimens were tolerable. Conclusions Better treatment responses and conversion rate for patients with uHCC were obtained with first-line t-CT. Neoadjuvant t-CT before surgery should be recommended for patients with macrovascular invasion. The first-line triple combination therapy (t-CT) of transarterial chemoembolization plus anti-PD-1 antibodies plus lenvatinib increase the conversion rate and treatment responses for patients with unresectable hepatocellular carcinoma. Neoadjuvant t-CT regimen is recommended for China Liver Cancer Staging stage IIIa patients.","Qu, WF; Ding, ZB; Qu, XD; Tang, Z; Zhu, GQ; Fu, XT; Zhang, ZH; Zhang, X; Huang, A; Tang, M; Tian, MX; Jiang, XF; Huang, R; Tao, CY; Fang, Y; Gao, J; Wu, XL; Zhou, J; Fan, J; Liu, WR; Shi, YH",False,study design is not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,"triple combination therapy of lenvatinib, TACE, and immunotherapy",dual combination therapy of lenvatinib and TACE,higher overall response rates and conversion rates,not specified,False,"The study design is not a randomized controlled trial, as correctly identified by Model A. Additionally, the population focuses on unresectable hepatocellular carcinoma rather than all patients with HCC, which slightly narrows the scope. The intervention description accurately captures the triple combination therapy but omits clarifying that toripalimab is an immune checkpoint inhibitor. The comparison group is adequately described. Outcomes include conversion rates and response rates but do not explicitly focus on survival rate as required by the PICOS criteria.",patients with initially unresectable hepatocellular carcinoma,"triple combination therapy of lenvatinib, transarterial chemoembolization (TACE), and toripalimab (an immune checkpoint inhibitor)",-,"conversion rate, overall response rate, and disease control rate but not explicitly survival rate",-,False,No disagreement between Model A and B,False
111,Liver transplantation following hepatocellular carcinoma downstaging with atezolizumab/bevacizumab: preliminary results of the prospective ImmunoXXL study,,,"Bhoori, S; Maspero, M; Busset, MDD; Bongini, M; Virdis, M; Citterio, D; Sposito, C; Bellia, V; Battiston, C; Coppa, J; Flores, M; Mazzaferro, V",False,Abstract too short or empty,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty,-,-,-,-,-,False,Abstract too short or empty,False
112,Transarterial Radioembolization for Management of Hepatocellular Carcinoma,10.1093/oncolo/oyad327,"Transarterial radioembolization (TARE) with Yttrium-90 (Y90) is a growing area of study due to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment intent, including curative therapy, bridging to transplant, and downstaging disease, informs treatment approach and dosimetry goals. Radiation lobectomy (RL) and radiation segmentectomy (RS) are the 2 main forms of Y90 administration which have shown improved survival outcomes with the development of personalized dosimetry. RS aims to achieve complete pathological necrosis with dose escalation and RL aims for local disease control as well as induction of contralateral lobe hypertrophy to improve hepatic reserve. Furthermore, TARE has been validated in head-to-head comparison to other locoregional and systemic therapies. Lastly, early potential exists for combination therapy between TARE and immune checkpoint inhibitors for advanced stage disease. This review discusses the technical considerations and the role of transarterial radioembolization for management of hepatocellular carcinoma.","Badar, W; Yu, Q; Patel, M; Ahmed, O",False,study design is not a randomized controlled trial,patients with hepatocellular carcinoma,transarterial radioembolization with Yttrium-90,"not specified, comparison to other therapies mentioned",improved survival outcomes,not specified,False,"Model A correctly identifies that this is not a randomized controlled trial. However, the population description should specify early-, intermediate-, and late-stage hepatocellular carcinoma as mentioned in the abstract. The intervention description needs clarification that transarterial radioembolization with Yttrium-90 is not combined with immune checkpoint inhibitors in this study. The comparison group is inadequately described since no direct comparator is provided. Outcomes refer to improved survival outcomes but lack specificity regarding survival rate or response rate as required.","patients with early-, intermediate-, and late-stage hepatocellular carcinoma",transarterial radioembolization with Yttrium-90 without mention of immune checkpoint inhibitors,not applicable as no direct comparator is provided,improved survival outcomes but lacks specific mention of survival rate or response rate,-,False,No disagreement between Model A and B,False
113,Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study,10.1007/s00432-021-03767-4,"Purpose The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially unresectable hepatocellular carcinoma (uHCC) harbouring programmed cell death ligand-1 (PD-L1) expression. Methods Consecutive patients with initial PD-L1-positive uHCC who received pembrolizumab-lenvatinib-TACE or lenvatinib-TACE sequential therapy were retrospectively identified from three medical institutions during 2016-2020. The primary endpoints included the rate of conversion therapy, defined as converting initially uHCC to hepatectomy, overall survival (OS), and progression-free survival (PFS); secondary endpoint was the frequency of key adverse events (AEs). Results In total, 220 consecutively recruited patients were retrospectively reviewed, 78 of whom were ineligible according to the current criteria, leaving 142 patients [pembrolizumab-lenvatinib-TACE: n = 70, median age 58 years (range 36-69) and lenvatinib-TACE: n = 72, 57 years (35-68)] who were eligible for the study. The median duration of follow-up was 27 months [95% confidence interval (CI), 26.3-28.7 months]. At the last follow-up, the rate of conversion therapy was 25.7% in the pembrolizumab-lenvatinib-TACE group and 11.1% in the lenvatinib-TACE group (p = 0.025). The median OS was 18.1 months (95% CI 16.5-20.7) in the pembrolizumab-lenvatinib-TACE group versus 14.1 months (95% CI 12.2-16.9) in the lenvatinib-TACE group [hazard ratio (HR) 0.56, 95% CI 0.38-0.83; p = 0.004]. A distinct difference in the median PFS interval between the groups was detected [9.2 months (95% CI 7.1-10.4) in the pembrolizumab-lenvatinib-TACE group vs. 5.5 months (95% CI 3.9-6.6) in the lenvatinib-TACE group (HR 0.60; 95% CI 0.39-0.91; p = 0.006)]. The rates of the key AEs assessed, which were hypertension, nausea, and rash, were higher in the pembrolizumab-lenvatinib-TACE group than in the lenvatinib-TACE group (all p < 0.05). Conclusion Among the selected populations of patients with initial PD-L1-positive uHCC, pembrolizumab-lenvatinib-TACE sequential therapy may have promising antitumour activity, with an acceptable conversion rate and a well-characterized safety profile.","Chen, S; Wu, ZQ; Shi, F; Mai, QC; Wang, LG; Wang, F; Zhuang, WQ; Chen, XM; Chen, HW; Xu, B; Lai, JM; Guo, WB",False,study design is not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,pembrolizumab-lenvatinib-TACE therapy,lenvatinib-TACE sequential therapy,overall survival and progression-free survival,retrospective study,False,"Model A correctly notes that the study design is not a randomized controlled trial. The population description should clarify that only PD-L1-positive patients are included. The intervention description accurately reflects pembrolizumab-lenvatinib-TACE but could emphasize pembrolizumab as an immune checkpoint inhibitor. The comparison group is adequately described. Outcomes include overall survival and progression-free survival, aligning with the PICOS criteria, but the retrospective nature limits inclusion.",patients with initially unresectable hepatocellular carcinoma who are PD-L1-positive,pembrolizumab (an immune checkpoint inhibitor)-lenvatinib-TACE therapy,-,-,-,False,No disagreement between Model A and B,False
114,Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study,10.3389/fimmu.2024.1308543,"<bold>Background: </bold>This study evaluates the efficacy of alpha-fetoprotein (AFP) response as a surrogate marker for determining recurrence-free survival (RFS) in patients with unresectable hepatocellular carcinoma (uHCC) who undergo salvage hepatectomy following conversion therapy with tyrosine kinase inhibitor (TKI) and anti-PD-1 antibody-based regimen. <bold>Methods: </bold>This multicenter retrospective study included 74 patients with uHCC and positive AFP (>20 ng/mL) at diagnosis, who underwent salvage hepatectomy after treatment with TKIs and anti-PD-1 antibody-based regimens. The association between AFP response-defined as a >= 80% decrease in final AFP levels before salvage hepatectomy from diagnosis-and RFS post-hepatectomy was investigated. <bold>Results: </bold>AFP responders demonstrated significantly better postoperative RFS compared to non-responders (P<0.001). The median RFS was not reached for AFP responders, with 1-year and 2-year RFS rates of 81.3% and 70.8%, respectively. In contrast, AFP non-responders had a median RFS of 7.43 months, with 1-year and 2-year RFS rates at 37.1% and 37.1%, respectively. Multivariate Cox regression analysis identified AFP response as an independent predictor of RFS. Integrating AFP response with radiologic tumor response facilitated further stratification of patients into distinct risk categories: those with radiologic remission experienced the most favorable RFS, followed by patients with partial response/stable disease and AFP response, and the least favorable RFS among patients with partial response/stable disease but without AFP response. Sensitivity analyses further confirmed the association between AFP response and improved RFS across various cutoff values and in patients with AFP >= 200 ng/mL at diagnosis (all P<0.05). <bold>Conclusion: </bold>The ""20-80"" rule based on AFP response could be helpful for clinicians to preoperatively stratify the risk of patients undergoing salvage hepatectomy, enabling identification and management of those unlikely to benefit from this procedure.","Lin, KY; Zhang, JX; Lin, ZW; Chen, QJ; Luo, LP; Chen, JH; Wang, K; Tai, S; Zhang, ZB; Wang, SF; Li, JD; Wang, K; Zheng, L; Zheng, SM; Wu, MM; Lin, KC; Yang, T; Zeng, YY",False,study design is not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,TKI and anti-PD-1 antibody-based regimens,not specified,recurrence-free survival,multicenter retrospective study,False,Model A correctly identifies that the study design is not a randomized controlled trial. The population description should specify unresectable hepatocellular carcinoma with elevated alpha-fetoprotein levels (>20 ng/mL). The intervention description should clarify that it involves TKIs and anti-PD-1 antibodies but does not specifically test immune checkpoint inhibitors alone. The comparison group is missing entirely. Outcomes focus on recurrence-free survival but do not explicitly measure survival rate or response rate as required.,patients with unresectable hepatocellular carcinoma and elevated alpha-fetoprotein levels (>20 ng/mL),tyrosine kinase inhibitors and anti-PD-1 antibody-based regimens without explicit mention of immune checkpoint inhibitors alone,no direct comparison group is provided,recurrence-free survival but lacks explicit mention of survival rate or response rate,-,False,No disagreement between Model A and B,False
115,Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy,10.1136/jitc-2020-000932,"Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide with a minority of patients being diagnosed early enough for curative-intent interventions. We report the first use of preoperative cabozantinib plus nivolumab to successfully downstage what presented as unresectable HCC as part of an ongoing phase 1b study. Preoperative treatment with cabozantinib and nivolumab led to >99% reduction in alpha-fetoprotein, -37.3% radiographic reduction by RECIST 1.1 and a near complete pathologic response (80% to 100% necrosis). An integrated immunological analysis was performed on the post-treatment surgical tumor sample and matched pre-treatment and post-treatment peripheral blood samples with high-dimensional imaging and cytometry techniques. Bayesian non-negative matrix factorization (CoGAPS, Coordinated Gene Activity in Pattern Sets) and self-organizing map (FlowSOM) algorithms were used to distinguish changes in functional markers across cellular neighborhoods in the single cell data sets. Brisk immunological infiltration into the tumor microenvironment was observed in non-random, organized cellular neighborhoods. Systemically, combination therapy led to marked promotion of effector cytotoxic T cells and effector memory helper T cells. Natural killer cells also increased with therapy. The patient remains without disease recurrence and with a normal alpha-fetoprotein approximately 2 years from presentation. Our study provides proof-of-concept that borderline resectable or locally advanced HCC warrants consideration of downstaging with effective neoadjuvant systemic therapy for subsequent curative resection.","Ho, WJ; Sharma, G; Zhu, QF; Stein-O'Brien, G; Durham, J; Anders, R; Popovic, A; Mo, GL; Kamel, I; Weiss, M; Jaffee, E; Fertig, EJ; Yarchoan, M",False,does not include a comparison group or randomized controlled trial design,patients with unresectable HCC,preoperative cabozantinib plus nivolumab,not specified,downstaging success and lack of disease recurrence,phase 1b study,False,"The study is a phase 1b trial without a comparison group or randomization, which does not meet the PICOS criteria for study design. Additionally, while the intervention and outcomes are described, there is no mention of a control or comparator arm, making it impossible to evaluate relative efficacy.",-,-,not applicable as no comparison group is mentioned in the abstract,-,-,False,No disagreement between Model A and B,False
116,Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation,10.1016/j.jhep.2024.05.037,"Immunotherapy has revolutionised the treatment of advanced hepatocellular carcinoma (HCC). In addition, several phase III trials of immunotherapy in combination with surgical or locoregional therapies for early-to intermediate-stage HCC have recently reported positive results, and other phase III trials in the same patient population are currently in progress. As the application of immunotherapy is shifting to include patients with earlier stages of HCC, one looming question now emerges: What is the role of immunotherapy in the pre-liver transplant population? Liver transplantation is a potentially curative therapy for HCC and confers the additional advantage of restoring a normal, healthy liver. In pre-transplant patients, immunotherapy may improve downstaging success and tumour control at the cost of some immunologic risks. These include immune-related toxicities, which are particularly relevant in a uniquely vulnerable population with chronic liver disease, and the possibility of acute rejection after transplantation. Ultimately, the goal of immunotherapy in this population will be to effectively expand access to liver transplantation while preserving preand post-transplant outcomes. In this review, we discuss the mechanisms supporting combination immunotherapy, summarise key recent clinical data from major immunotherapy trials, and explore how immunotherapy can be applied in the neoadjuvant setting prior to liver transplantation in selected high-risk patients. (c) 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","Li, M; Bhoori, S; Mehta, N; Mazzaferro, V",False,not a randomized controlled trial and lacks specific outcomes,advanced HCC patients,immunotherapy,not specified,not specified,not specified,False,"This is a review article discussing mechanisms and clinical data but lacks specific details on study design, interventions, comparisons, and outcomes. It does not meet the PICOS criteria for inclusion as it is not based on an original randomized controlled trial.",patients with early-to-intermediate stage HCC being considered for liver transplantation,immunotherapy combinations,not specified in the abstract,downstaging success and tumor control,review article,False,No disagreement between Model A and B,False
117,Downstaging and laparoscopic hepatectomy plus intraoperative radiofrequency ablation for the treatment of initially unresectable multifocal hepatocellular carcinomas,10.3389/fsurg.2023.1340657,"BackgroundUsing TKIs plus anti-PD-1 antibodies combined with TACE in the treatment of patients with initially unresectable multiple HCCs has a high tumour response rate, and using laparoscopic hepatectomy (LH) combined with intraoperative RFA for radical treatment of multiple HCCs after successful downstaging treatment has not been reported.MethodsConsecutive patients with multiple HCCs (<= 4 lesions) who were downstaged with TKIs plus anti-PD-1 antibodies combined with TACE were analysed. Imaging examinations were performed monthly, and RECIST v1.1 criteria were used to evaluate treatment effect and resectability.ResultsForty-five consecutive patients with multiple HCCs who met the inclusion criteria received downstaging treatment with TKIs plus anti-PD-1 antibodies combined with TACE. Nine patients were successfully downstaged and met the R0 resection criteria, and 8 patients underwent surgery. Among the patients, 5 patients had BCLC stage C, and 3 patients had BCLC stage B. There were 2 lesions in 5 patients, 3 lesions in 2 patients, and 4 lesions in 1 patient. The average size of the main HCC was 8.5 cm (range: 5.4-9.1 cm), and the diameter of the remaining HCCs was 1.6 cm (range: 0.8-2.9 cm). The average time from the start of downstaging therapy to surgery was 81 days (range: 60-210 days). All 8 patients underwent LH of the main HCC, and the remaining HCCs were targeted with RFA. The mean operation time was 220 min (range 150-370 min), the average intraoperative blood loss was 260 ml (range 100-750 ml), there was no case conversion to laparotomy, and the average postoperative hospital stay was 9 days (range 7-25 days). The incidence of postoperative complications was 37.5% and there were no deaths. The average follow-up time was 18.2 months (range 6.1-22.4 months), 5 patients survived tumour-free, 2 patients had tumour recurrence, and 1 patient died.ConclusionsAfter successful downstaging of multiple HCCs by treatment with TKIs plus anti-PD-1 antibodies and TACE, LH combined with RFA for radical surgery is safe and feasible, and the treatment effect is satisfactory. It is worthy of clinical reference, and its long-term effects require further research for confirmation.","Wang, JJ; Luo, H; Yi, L; Yang, P; Zeng, XT",False,not a randomized controlled trial and lacks a clear comparison group,patients with multiple HCCs,TKIs plus anti-PD-1 antibodies combined with TACE,not specified,high tumor response rate,not specified,False,"The study evaluates downstaging treatment followed by surgery but lacks a randomized controlled trial design and a clear comparison group. While outcomes such as tumor response rate are mentioned, these do not align with the survival or response rate required by the PICOS criteria.",-,-,not applicable as no comparison group is mentioned in the abstract,tumor-free survival and recurrence rates,-,False,No disagreement between Model A and B,False
118,Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review,10.1016/j.hbpd.2021.12.004,"Background: Hepatocellular carcinoma (HCC) is one of the main reasons for malignancy-related death. Portal vein tumor thrombosis (PVTT) is the most common form of macrovascular invasion related to HCC occurring in 10%-60% of patients. HCC with PVTT is usually characterized by worsening liver function, vulnerability to blood metastasis, higher incidence of complications associated with portal hypertension, and intolerance to treatment when compared with that without PVTT. If only treated with supportive care, the median survival of HCC with PVTT is about 2.7 months. In the past, sorafenib was the only recommended therapy by guidelines with limited effectiveness. This narrative review aimed to describe the current management options for HCC with PVTT. Data sources: We have reviewed literature from PubMed on the treatment of HCC with PVTT and compiled evidence-based facts on effective therapies available for different types of PVTT. Results: Sorafenib monotherapy is not much effective, but combining it with other methods can improve survival. Each type of PVTT can benefit from the combination of transarterial chemoembolization and sorafenib than sorafenib monotherapy. The tumor downstaging can be realized possibly after transarterial chemoembolization, but tumor invasion into the main trunk of the portal vein greatly impairs efficacy. Although surgery is a curative approach, it is often not recommended for Vp4 PVTT. Some new methods can broaden the indication, but further explorations are needed. Radiotherapy can decrease the possibility of Vp3 progression to Vp4, but building a forecast model of best radiation dose and response is necessary. Systemic chemotherapy, hepatic arterial infusion chemotherapy, radiofrequency ablation, portal stenting, and traditional Chinese medicine are also beneficial in Vp3-4 PVTT. The accurate diagnosis of PVTT can be made by radiomics, and prognostic classification models can be used to design personalized treatments. The application of new treatment methods such as the atezolizumab plus bevacizumab scheme may increase survival. Conclusions: HCC with PVTT is still a thorny problem, and effective therapeutics need to be explored. (c) 2021 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","Tao, ZW; Cheng, BQ; Zhou, T; Gao, YJ",False,not a randomized controlled trial and primarily a review article,patients with HCC and PVTT,not specified,"sorafenib monotherapy, TACE",survival improvement with combinations,narrative review,False,"This is a narrative review summarizing various treatments for HCC with portal vein tumor thrombosis (PVTT). It does not describe a specific randomized controlled trial, nor does it provide detailed information on interventions, comparisons, or outcomes relevant to immune checkpoint inhibitors.",patients with HCC and PVTT,"various treatments including sorafenib, TACE, and other modalities",sorafenib monotherapy and supportive care,survival improvement with combination therapies,narrative review,False,No disagreement between Model A and B,False
119,In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?,10.3390/cancers13205129,"Simple Summary: Hepatocellular carcinoma (HCC) is a growing healthcare problem, with most of the cases occurring in patients with an underlying chronic liver disease. Transarterial chemoembolization (TACE) is recommended for unresectable tumors, mostly in a palliative setting. Several developments have seen the day during the last few years, with technique improvements in terms of efficacy and safety due to more selective therapies and better patient selection. Nevertheless, this is the era of systemic treatment for HCC, where immunotherapy and combination systemic treatments are taking the lead. As such, we have to ask ourselves, where does TACE stand today and is there a tomorrow? Conventional transarterial embolization (cTACE) has been proven to be effective for intermediate stage hepatocellular carcinoma (HCC), with a recent systematic review showing an overall survival (OS) of 19.4 months. Nevertheless, due to the rapid development of the systemic therapeutic landscape, the place of TACE is becoming questionable. Is there still a niche for TACE in the era of immunotherapy and combination treatments such as atezolizumab-bevacizumab, which has shown an OS of 19.2 months with excellent tolerance? The development of drug-eluting microspheres (DEMs) has led to the standardization of the technique, and along with adequate selection, it showed an OS of 48 months in a retrospective study. In order to increase treatment selectivity, new catheters have also been added to the TACE arsenal as well as the use of cone-beam CT (CBCT), which provides three-dimensional volumetric images and guidance during procedures. Moreover, the TACE indications have also widened. It may serve as a ""bridging therapy "" for liver transplantation candidates while they are on the waiting list, and it represents a valuable downstaging tool to transplantation criteria. The aim of this review is to explore the current data on the advancements of TACE and its future place amongst the growing panel of treatments.","Bucalau, AM; Tancredi, I; Verset, G",False,not a randomized controlled trial and focuses on TACE,patients with intermediate stage HCC,TACE,not specified,overall survival rates,systematic review,False,"This systematic review focuses on advancements in transarterial chemoembolization (TACE) rather than immune checkpoint inhibitors. It does not include a randomized controlled trial design or specify comparisons relevant to ICIs, thus failing to meet the PICOS criteria.",patients with intermediate-stage HCC,transarterial chemoembolization (TACE),not specified in the abstract,overall survival rates with TACE,-,False,No disagreement between Model A and B,False
120,Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy,10.1002/hep.32613,"Hepatocellular carcinoma remains a global health challenge affecting close to 1 million cases yearly. Liver transplantation provides the best long-term outcomes for those meeting strict criteria. Efforts have been made to expand these criteria, whereas others have attempted downstaging approaches. Although locoregional approaches to downstaging are appealing and have demonstrated efficacy, limitations and challenges exists including poor imaging modality to assess response and appropriate endpoints along the process. Recent advances in systemic treatments including immune checkpoint inhibitors alone or in combination with tyrosine kinase inhibitors have prompted the discussion regarding their role for downstaging disease prior to transplantation. Here, we provide a review of prior locoregional approaches for downstaging, new systemic agents and their role for downstaging, and finally, key and critical considerations of the assessment, endpoints, and optimal designs in clinical trials to address this key question.","Tran, NH; Muoz, S; Thompson, S; Hallemeier, CL; Bruix, J",False,does not mention a randomized controlled trial or specific outcomes,patients with hepatocellular carcinoma,immune checkpoint inhibitors and tyrosine kinase inhibitors,not specified,not specified,not specified,False,The abstract does not describe a randomized controlled trial or provide specific outcomes such as survival or response rates. It is a review article discussing various treatments and their potential roles but lacks the required study design and outcome focus.,-,-,-,-,-,False,No disagreement between Model A and B,False
121,Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil,10.1080/13696998.2023.2210475,"Aims Hepatocellular carcinoma (HCC) is a severe condition with poor prognosis that places a significant burden on patients, caregivers, and healthcare systems. Selective internal radiation therapy (SIRT) is a treatment available to patients with HCC which addresses some of the limitations of alternative treatment options. A cost-effectiveness analysis was undertaken into the use of SIRT using Y-90 resin microspheres for the treatment of unresectable intermediate- and late-stage HCC in Brazil. Materials and methods A partitioned-survival model was developed, including a tunnel state for patients downstaged to receive treatments with curative intent. Sorafenib was the selected comparator, a common systemic treatment in Brazil and for which comparative evidence exists. Clinical data were extracted from published sources of pivotal trials, and effectiveness was measured in quality-adjusted life-years (QALYs) and life-years (LYs). The analysis was conducted from the Brazilian private payer perspective and a lifetime horizon was implemented. Comprehensive sensitivity analyses were conducted. Results LYs and QALYs were higher for SIRT with Y-90 resin microspheres versus sorafenib (0.27 and 0.20 incremental LYs and QALYs, respectively) and costs were slightly higher for SIRT (R$15,864). The base case incremental cost-effectiveness ratio (ICER) was R$77,602 per QALY. The ICER was mostly influenced by parameters defining the sorafenib overall survival curve and SIRT had a 73% probability of being cost-effective at a willingness-to-pay threshold of R$135,761 per QALY (3-times the per-capita gross domestic product in Brazil). Overall, sensitivity analyses confirmed the robustness of the results indicating that SIRT with Y-90 resin microspheres is cost-effective compared with sorafenib. Limitations A rapidly evolving treatment landscape in Brazil and worldwide, and the lack of local data for some variables were the main limitations. Conclusions SIRT with Y-90 resin microspheres is a cost-effective option compared with sorafenib in Brazil.","Agirrezabal, I; Grillo, LSP; Nasser, F; Brennan, VK; Bugano, D; Galastri, FL; de Azeredo-da-Silva, ALF; Shergill, S; da Motta-Leal, JM",False,not a randomized controlled trial,patients with unresectable intermediate- and late-stage HCC,selective internal radiation therapy (SIRT),sorafenib,quality-adjusted life-years and life-years,cost-effectiveness analysis,False,"The study is a cost-effectiveness analysis rather than a randomized controlled trial. While it compares SIRT with sorafenib, it focuses on economic outcomes like quality-adjusted life-years and costs rather than survival or response rates as primary endpoints.",-,-,-,-,-,False,No disagreement between Model A and B,False
122,Downstaging Hepatocellular Carcinoma before Transplantation Role of Immunotherapy Versus Locoregional Approaches,10.1016/j.soc.2023.07.001,"HCC continues to be a leading cause of cancer-related death in the United States. With advances in locoregional therapy for unresectable HCC during the last 2 decades and the recent expansion of transplant criteria for HCC, as well as ongoing organ shortages, patients are spending more time on the waitlist, which has resulted in increased usage of locoregional therapies. This changing landscape is well displayedin Fig. 1, which demonstrates the number of treatments per patient by year of listing (A) and the proportion of locoregional therapy type by year of treatment (B).91 Less than half of liver transplant candidates on the waiting list underwent locoregional therapy before listing in 2003, whereas 92.4% underwent some form of locoregional therapy in 2018.91 Although TACE is the current preferred modality for liver-directed therapy as a bridge to transplant in patients with HCC, recent evidence suggests that radioembolization may prolong time to progression when compared with chemoembolization. In just the last 5 years, the proportion of radioembolization performed for HCC has increased significantly, from less than 5% in 2013 to 19% in 2018.91 Expanding on the proven value of locoregional therapies, the plethora of molecularly targeted therapies and ICIs under investigation represent the new horizon of treatment of HCC not only in advanced stages but also potentially at every stage of diagnosis and management. Although data remain sparse in the pretransplantation population, the possibility of downstaging patients previously considered unresectable or initially outside of transplant criteria is an extremely alluring strategy, which may prove vital in establishing transplant candidacy for an expanded host of patients. Combination therapies have already begun to show promise in maintaining disease control and may ultimately prove lifesaving in patients who are able to undergo liver transplant. Although it will be critical in the coming years to determine timing of therapy and appropriate postoperative immunosuppression strategies, both locoregional techniques and immunomodulation will change the history of liver transplant for HCC as we currently know it.","Lindemann, J; Yu, J; Doyle, MBM",False,not a randomized controlled trial and lacks specific details,not specified,locoregional therapies and ICIs,not specified,not specified,not specified,False,This abstract provides a narrative review of locoregional therapies and ICIs without specifying a randomized controlled trial or detailing comparison groups and outcomes. The lack of structured data makes it unsuitable for inclusion under the PICOS framework.,-,-,-,-,-,False,No disagreement between Model A and B,False
123,Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report,10.3389/fonc.2024.1476593,"Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, conversion therapy is important to convert the iCCA into a resectable state. In recent years, the conversion protocol of immuno-chemotherapy has been applied for advanced liver cancer. However, little has been reported about iCCA conversion therapy. The aim of this report is to present the results of conversion therapy with Gemcitabine plus S-1 (GS) combined with PD-1 inhibitors (Zimberelimab) in a 74-year-old female IIIB iCCA patient. After 6 cycles of conversion therapy, enhanced CT showed that the patient's tumor had shrunk to nearly half its original size, making radical resection possible. Postoperative pathology showed a complete pathological response. This provides a new way to convert advanced iCCA into resectable state.","Zhao, SY; Zhang, XD; Luo, JL; Yan, HJ; Zhang, JL; Lin, RF; Zhu, KL",False,not related to hepatocellular carcinoma and not a randomized controlled trial,a patient with intrahepatic cholangiocarcinoma,immuno-chemotherapy with PD-1 inhibitors,not specified,tumor shrinkage and resectability,case report,False,"The article focuses on intrahepatic cholangiocarcinoma (iCCA), not hepatocellular carcinoma, and presents a single case report rather than a randomized controlled trial. Both the population and study design fail to meet the inclusion criteria.",patients with intrahepatic cholangiocarcinoma,-,-,-,case report,False,No disagreement between Model A and B,False
124,"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study",10.1136/jitc-2022-005457,"Purpose To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor in patients with unresectable hepatocellular carcinoma (uHCC) and liver-only disease ineligible for chemoembolization.Patients and methods NASIR-HCC is a single-arm, multicenter, open-label, phase 2 trial that recruited from 2017 to 2019 patients who were naive to immunotherapy and had tumors in the BCLC B2 substage (single or multiple tumors beyond the up-to-7 rule), or unilobar tumors with segmental or lobar portal vein invasion (PVI); no extrahepatic spread; and preserved liver function. Patients received SIRT followed 3 weeks later by nivolumab (240 mg every 2 weeks) for up to 24 doses or until disease progression or unacceptable toxicity. Safety was the primary endpoint. Secondary objectives included objective response rate (ORR), time to progression (TTP), and overall survival (OS).Results 42 patients received SIRT (31 BCLC-B2, 11 with PVI) and were followed for a median of 22.2 months. 27 patients discontinued and 1 never received Nivolumab. 41 patients had any-grade adverse events (AE) and 21 had serious AEs (SAE). Treatment-related AEs and SAEs grade 3-4 occurred in 8 and 5 patients, respectively. Using RECIST 1.1 criteria, ORR reported by investigators was 41.5% (95% CI 26.3% to 57.9%). Four patients were downstaged to partial hepatectomy. Median TTP was 8.8 months (95% CI 7.0 to 10.5) and median OS was 20.9 months (95% CI 17.7 to 24.1).Conclusions The combination of SIRT and nivolumab has shown an acceptable safety profile and signs of antitumor activity in the treatment of patients with uHCC that were fit for SIRT.","de la Torre-Alez, M; Matilla, A; Varela, M; Iarrairaegui, M; Reig, M; Lled, JL; Arenas, JI; Lorente, S; Testillano, M; Mrquez, L; Da Fonseca, L; Argem, J; Gmez-Martin, C; Rodriguez-Fraile, M; Bilbao, J; Sangro, B",False,not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,SIRT followed by nivolumab,not specified,"objective response rate, time to progression, overall survival",single-arm phase 2 trial,False,"Although this study evaluates SIRT combined with nivolumab in patients with unresectable HCC, it is a single-arm phase 2 trial, not a randomized controlled trial. The lack of a control group prevents it from meeting the study design criterion.",-,-,no comparison group specified,-,single-arm phase 2 trial,False,No disagreement between Model A and B,False
125,Novel implications in the treatment of hepatocellular carcinoma,10.20524/aog.2016.0092,"Worldwide hepatocellular carcinoma remains one of the leading causes of cancer-related death, associated with a poor prognosis due to late diagnosis in the majority of cases. Physicians at care are frequently confronted with patients who are ineligible for curative treatment such as liver resection, transplantation or radiofrequency ablation. Besides established palliative locoregional therapies, such as ablation or chemoembolization, new treatment options, such as microwave ablation, drug-eluting bead transarterial chemoembolization or selective internal radiation therapy, are emerging; however, data from randomized controlled trials are still lacking. In order to achieve optimal tumor control, patients should receive tailored treatment concepts, considering their tumor burden, liver function and performance status, instead of strictly assigning patients to treatment modalities following algorithms that may be partly very restrictive. Palliative locoregional pretreatment might facilitate downstaging to ensure later curative resection or transplantation. In addition, the combined utilization of different locoregional treatment options or systemic co-treatment has been the subject of several trials. In cases where local tumor control cannot be achieved, or in the scenario of extrahepatic spread, sorafenib remains the only approved systemic therapy option. Alternative targeted therapies, such as immune checkpoint inhibitors have shown encouraging preliminary results, while data from phase III studies are pending.","Best, J; Schotten, C; Theysohn, JM; Wetter, A; Mller, S; Radnz, S; Schulze, M; Canbay, A; Dechne, A; Gerken, G",False,"does not specify intervention, comparison, or outcome details",patients with hepatocellular carcinoma,not specified,not specified,not specified,not specified,False,"The abstract discusses immune checkpoint inhibitors as a potential systemic therapy but does not specify the intervention, comparison, or outcomes in detail. It is a narrative review rather than an RCT, making it unsuitable for inclusion.",-,immune checkpoint inhibitors mentioned as a potential therapy but details are lacking,no explicit comparison group provided,survival or response rate not explicitly stated as outcomes,-,False,No disagreement between Model A and B,False
126,Liver transplantation and resection in patients with hepatocellular cancer and portal vein tumor thrombosis: Feasible and effective?,10.1016/j.hbpd.2023.10.002,"Patients with locally advanced hepatocellular cancer (HCC) and portal vein tumor thrombosis (PVTT) have a dismal prognosis since limited treatment options are available for them. In recent years, effective systemic therapy, and advances in the understanding of technicalities and effectiveness of ablative therapies especially radiotherapy, have given some hope to prolong survival in them. This review summarized recent evidence in literature regarding the possible role of liver resection (LR) and liver transplantation (LT) in patients with locally advanced HCC and PVTT with no extrahepatic disease. Downstaging therapies have helped make curative resection or LT a reality in selected patients. This review emphasizes on the key points to focus on when considering surgery in these patients, who are usually relegated to palliative systemic therapy alone. Meticulous patient selection based on tumor biology, documented downstaging based on imaging and decrease in tumor marker levels, and an adequate waiting period to demonstrate stable disease, may help obtain satisfactory long-term outcomes post LR or LT in an intention to treat strategy in patients with HCC and PVTT. (c) 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","Bhangui, P",False,"does not specify intervention, comparison, or outcome details",patients with locally advanced hepatocellular cancer and portal vein tumor thrombosis,not specified,not specified,not specified,not specified,False,The abstract focuses on surgical options like liver resection and transplantation without specifying ICIs as an intervention. It lacks details on comparison groups and outcomes related to survival or response rates. The study design is not an RCT.,-,no mention of immune checkpoint inhibitors as the intervention,no explicit comparison group provided,survival or response rate not explicitly stated as outcomes,-,False,No disagreement between Model A and B,False
127,Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis,10.2147/JHC.S408819,"Background: Drug-eluting bead transarterial chemoembolization (DEB-TACE) has good efficacy in the treatment of unresectable hepatocellular carcinoma (uHCC), with a relatively high objective response rate (ORR) compared to conventional transarterial chemoembolization (cTACE). This study aimed to evaluate the safety and medium-term clinical efficacy of DEB-TACE combined with lenvatinib (LEN) plus PD-1 inhibitors as a triple therapy for the treatment of uHCC.Methods: Data of patients with uHCC who received triple therapy of DEB-TACE combined with LEN plus PD-1 inhibitors from January 2019 to June 2021 were analyzed retrospectively. The study endpoints were ORR, progression-free survival (PFS), and treatment-related adverse events based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST).Results: Thirty-five patients were included in this study, with a median follow-up period of 15 months. The median cycle of DEB-TACE was 1, while that of all forms of TACE procedures per patient was 2. The median administration time of LEN was 7 months, and the median number of PD-1 inhibitor treatment was 4 cycles. The ORR based on mRECIST was 82.9%, disease control rate was 91.4%, and the median time to response was 7 weeks. Among these, the ORR of Barcelona Clinic Liver Cancer (BCLC) stage A reached 100%, while that of BCLC stages B and C reached 84.6% and 78.9%, respectively. The median PFS was 9 months; the mOS was not reached. Fourteen patients (40%) successfully underwent downstaging conversion and surgical resection, 32 patients (91.4%) experienced treatment-related adverse events, and no grade 5-related adverse reactions occurred.Conclusion: DEB-TACE combined with LEN and PD-1 inhibitors has a high ORR and surgical conversion rate in the treatment of uHCC tumors, and the toxicity and side effects were tolerable.","Wu, SJ; Ruan, DD; Wu, QY; Tang, Y; Zhang, JH; Cai, SL; Zhou, YF; Luo, JW; Fang, ZT",False,not a randomized controlled trial,patients with unresectable hepatocellular carcinoma,DEB-TACE combined with lenvatinib and PD-1 inhibitors,not specified,objective response rate and progression-free survival,retrospective study,False,"Although the abstract specifies DEB-TACE combined with lenvatinib and PD-1 inhibitors as the intervention and mentions outcomes like ORR and PFS, it is a retrospective study rather than an RCT. Additionally, no explicit comparison group is provided.",-,-,no explicit comparison group described despite mentioning other treatments like cTACE,-,retrospective observational study,False,No disagreement between Model A and B,False
128,Finding Nivo: A Case Report of 2 Forms of Nivolumab-Induced Liver Injury in an Allograft Liver in the Immediate Post-Transplant Period,10.1016/j.transproceed.2022.07.018,"Recent reports have emerged regarding the utilization of checkpoint inhibitors for downstaging hepatocellular carcinoma before liver transplantation. Early post-transplant acute cellular rejec-tion has rarely led to graft loss. We report the first case of 2 forms of nivolumab-associated liver injury on biopsy of the allograft organ in a single patient who received nivolumab for cancer downstaging before liver transplantation: 1. mild acute cellular rejection according to Risk Anal-ysis Index scoring and 2. zone 3 inflammation and apoptosis consistent with a more classic drug -induced liver injury pattern. This case not only adds further evidence about the risk for rejection post-transplant, but sheds light on other injuries checkpoint inhibitors can cause to the allograft.","Tow, CY; Castrodad-Rodrguez, CA; Panarelli, N; Massoumi, H",False,not a randomized controlled trial and lacks detailed comparison and outcome,not specified,nivolumab for cancer downstaging,not specified,not specified,case report,False,"This is a case report discussing nivolumab-related liver injury post-transplantation. It lacks a comparison group, detailed outcome measures, and is not an RCT, making it ineligible for inclusion.",patients receiving nivolumab for cancer downstaging before liver transplantation,-,no explicit comparison group provided,outcomes focus on biopsy findings and liver injury patterns rather than survival or response rates,-,False,No disagreement between Model A and B,False
129,Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology,10.3390/curroncol31090371,"Transplant oncology is an expanding area of cancer therapy that specifically emphasizes the use of liver transplantation (LT) as the preferred treatment for patients with manageable, but unresectable, tumors. The management and optimization of overall survival strategies, accompanied by an arguably decent quality of life, have been at the forefront of liver oncology treatment, as a plurality of all primary liver cancers are identified as either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), which are classified as highly aggressive malignancies and frequently remain asymptomatic until they progress to advanced stages, rendering curative procedures, such as resection, impractical. This has led to an increase in utilization of neoadjuvant interventions conducted prior to surgery, which has yielded favorable outcomes. Though this treatment modality has prompted further investigations into the efficacy of immune checkpoint inhibitors (ICPIs) as standalone treatments and in combination with locoregional treatments (LRTs) to bridge more patients into curative eligibility. This multidisciplinary methodology and treatment planning has seen multiple successful trials of immunotherapy regimes and combinate treatments, setting the groundwork for increasing eligibility through downstaging and ""bridging"" previously ineligible patients within stringent LT criteria. Surveillance after LT is a crucial component of transplant oncology. The emergence of circulating tumor DNA (ctDNA) has provided a novel approach to identifying the recurrence of cancer in its early stages. Recent research has focused on liquid biopsy, a technique that effectively identifies the dynamics of cancer. This is another innovation to demonstrate the rate at which transplant oncology is rapidly advancing, making the focus of care feel disorienting. Modalities of care are constantly evolving, but when a field is changing as rapidly as this one, it is imperative to reorient to the data and the needs of the patients. In this commentary, we reflect on the update's utilization of ICPIs in neoadjuvant settings as well as the updates on the utilization of liquid biopsy in post-LT follow-up surveillance.","Abdelrahim, M; Esmail, A; Hibi, T; Mazzaferro, V",False,not a randomized controlled trial and lacks detailed comparison and outcome,patients with unresectable tumors,immune checkpoint inhibitors in neoadjuvant settings,not specified,not specified,commentary,False,"The abstract is a commentary discussing the use of ICIs in neoadjuvant settings and liquid biopsy for surveillance. It lacks specific details on interventions, comparisons, and outcomes, and is not an RCT.",patients with unresectable tumors eligible for liver transplantation,immune checkpoint inhibitors mentioned in neoadjuvant settings but details are insufficient,no explicit comparison group provided,outcomes related to survival or response rates are not specified,-,False,No disagreement between Model A and B,False
130,Breakthroughs in Hepatocellular Carcinoma Therapies.,10.1016/j.cgh.2023.01.039,"Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages provide hope to improve its dismal prognosis. Although surgical and local ablative therapies have few significant changes in technique, an improved understanding of tumor biology has facilitated increase numbers of patients who are now eligible to undergo curative-intent procedures. Most notably, acceptable post-transplant outcomes can be achieved in well selected patients whose tumors are downstaged into Milan Criteria. Adjuvant therapy in patients at high risk of recurrence also significantly improves recurrence-free survival after resection or ablation. For patients with liver-localized disease who are not eligible for curative-intent procedures, transarterial chemoembolization (TACE) was historically the treatment modality of choice, regardless of tumor burden; however, there is now increased recognition of patients who are ""TACE unsuitable"" and may be better treated with systemic therapy. The greatest evolution in HCC treatment options has occurred with systemic therapy, where several new agents are now available in the first- and second-line setting, including immune checkpoint inhibitor combinations. Objective responses are observed in approximately 30% of patients and median survival is approaching 2 years. The availability of immune checkpoint inhibitors has renewed interest in combination therapies for earlier tumor stages, with several phase III trials ongoing. Considering increasing complexities of HCC care, requiring decisions between therapies delivered by different providers, multidisciplinary care is critical and is associated with improved clinical outcomes. In this review, we detail major breakthroughs in HCC therapy, how these breakthroughs can be applied in clinical practice, and remaining areas in need of further research.",Singal AG; Kudo M; Bruix J,False,does not describe a study design or comparison group,patients with hepatocellular carcinoma,immune checkpoint inhibitor combinations,not specified,improved survival and response rates,not specified,False,"The abstract does not describe a study design or comparison group, which is essential for inclusion. Model A correctly identified this flaw.",-,-,-,-,-,False,No disagreement between Model A and B,False
131,Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.,10.2147/JHC.S318070,"Portal vein involvement is considered one of the most fearful complications of hepatocellular carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor biology (high grade), high tumor burden (number and size of lesions), high levels of serum markers (AFP), poor liver function (deranged LFT), and poor performance status of patients. The Barcelona Clinic Liver Cancer staging system places HCC patients with PVTT in advanced stage (BCLC Stage-C). This group contains a fairly heterogeneous patient population, previously considered candidates for palliative systemic therapy with sorafenib. However, this provided modest overall survival (OS) benefit. The results of a recent Phase III (IMbrave150) trial favor the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib proved to be non-inferior against sorafenib in a phase III (REFLECT trial), regorafenib (RESORCE trial), ramucirumab (REACH-2), and cabozantinib (CELESTIAL) have been approved second-line therapy in phase III clinical trials. Recently, the data on the prospect of other modalities in the management of HCC with PVTT is mounting with favorable results. Targeting multiple pathways in the HCC cascade using a combination of drugs and other modalities such as RT, TACE, TARE, and HAIC appear effective for systemic and loco-regional control. The quest for the ideal combination therapy and the sequence set is still widely unanswered and prospective trials are lacking. With the armament of available therapeutic options and the advances and refinements in the delivery system, down-staging patients to make them eligible for curative resection has been reported. In a rapidly evolving treatment landscape, performing surgery when appropriate, in the form of LR and even LT to achieve cure does not seem farfetched. Likewise, adjuvant therapy and prompt management of the recurrences holds the key to prolong OS and DFS. This review discusses the management options of HCC patients with PVTT.",Khan AR; Wei X; Xu X,True,matches all PICOS criteria,patients with hepatocellular carcinoma,atezolizumab and bevacizumab combination,compared to sorafenib,overall survival benefit,Phase III trial,True,"Model A's analysis is accurate as the abstract mentions a Phase III trial comparing atezolizumab and bevacizumab to sorafenib in patients with advanced HCC, with overall survival as the outcome. All PICOS criteria are satisfied.",-,-,-,-,-,True,No disagreement between Model A and B,True
132,"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.",10.1136/jitc-2023-007366,"BACKGROUND: Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor response rate in both the first-line and second-line treatment of advanced HCC. However, few studies have prospectively evaluated whether TKIs plus anti-PD-1 antibodies could convert unresectable intermediate-advanced HCC into resectable disease. METHODS: This single-arm, phase II study enrolled systemic therapy-nave adult patients with unresectable Barcelona Clinic Liver Cancer stage B or C HCC. Patients received oral lenvatinib one time per day plus intravenous anti-PD-1 agents every 3 weeks (one cycle). Tumor response and resectability were evaluated before the fourth cycle, then every two cycles. The primary endpoint was conversion success rate by investigator assessment. Secondary endpoints included objective response rate (ORR) by independent imaging review (IIR) assessment per modified RECIST (mRECIST) and Response Evaluation Criteria in Solid Tumors, V.1.1 (RECIST 1.1), progression-free survival (PFS) and 12-month recurrence-free survival (RFS) rate by IIR per mRECIST, R0 resection rate, overall survival (OS), and safety. Biomarkers were assessed as exploratory objectives. RESULTS: Of the 56 eligible patients enrolled, 53 (94.6%) had macrovascular invasion, and 16 (28.6%) had extrahepatic metastasis. The median follow-up was 23.5 months. The primary endpoint showed a conversion success rate of 55.4% (31/56). ORR was 53.6% per mRECIST and 44.6% per RECIST 1.1. Median PFS was 8.9 months, and median OS was 23.9 months. Among the 31 successful conversion patients, 21 underwent surgery with an R0 resection rate of 85.7%, a pathological complete response rate of 38.1%, and a 12-month RFS rate of 47.6%. Grade 3 treatment-related adverse events were observed in 42.9% of patients. Tumor immune microenvironment analysis of pretreatment samples displayed significant enrichment of CD8(+) T cells (p=0.03) in responders versus non-responders. CONCLUSION: Lenvatinib plus anti-PD-1 antibodies demonstrate promising efficacy and tolerable safety as conversion therapy in unresectable HCC. Pre-existing CD8(+) cells are identified as a promising biomarker for response to this regimen. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry, ChiCTR1900023914. commercial re-use. See rights and permissions. Published by BMJ.",Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S,False,not a randomized controlled trial,adult patients with unresectable HCC,lenvatinib plus anti-PD-1 antibodies,not specified,conversion success rate and overall survival,"single-arm, phase II study",False,"The study design is a single-arm phase II trial, which lacks a comparison group, making it ineligible. Model A correctly excluded it but failed to note that the intervention involves lenvatinib plus anti-PD-1 antibodies rather than ICIs alone.",-,lenvatinib plus anti-PD-1 antibodies (not solely ICIs),-,-,-,False,No disagreement between Model A and B,False
133,"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.",10.1016/j.ajt.2024.04.007,"Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma patients are rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICI therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICI therapy during the study period. The median post-LT follow-up was 8.1 (interquartile range 3.3-14.6) months. During the short follow-up, 23 (27.7%) recipients developed allograft rejection, and 7 of them (30.4%) were diagnosed by liver biopsy. Multivariate logistics regression analysis showed that the time interval between the last administration of ICI therapy and LT (TLAT)  30 days was an independent protective factor for allograft rejection (odds ratio = 0.096, 95% confidence interval 0.026-0.357; P < .001). Multivariate Cox analysis showed that allograft rejection was an independent risk factor for overall survival (hazard ratio = 9.960, 95% confidence interval 1.006-98.610; P = .043). We conclude that patients who receive a pre-LT ICI therapy with a TLAT shorter than 30 days have a much higher risk of allograft rejection than those with a TLAT longer than 30 days. The presence of rejection episodes might be associated with higher post-LT mortality.",Guo Z; Liu Y; Ling Q; Xu L; Wang T; Zhu J; Lin Y; Lu X; Qu W; Zhang F; Zhu Z; Zhang J; Jia Z; Zeng P; Wang W; Sun Q; Luo Q; Hu Z; Zheng Z; Jia Y; Li J; Zheng Y; Wang M; Wang S; Han Z; Yu S; Li C; Zhang S; Xiong J; Deng F; Liu Y; Chen H; Wang Y; Li L; Liang W; Schlegel A; Nashan B; Liu C; Zheng S; He X,False,not a randomized controlled trial,hepatocellular carcinoma patients,pre-LT ICI therapy,not specified,allograft rejection and survival,"multicenter, retrospective cohort study",False,"The study design is a retrospective cohort study, which does not meet the randomized controlled trial requirement. Model A's exclusion decision is correct, but the population should specify pre-LT ICI therapy recipients, and outcomes include both allograft rejection and survival.",hepatocellular carcinoma patients receiving pre-LT ICI therapy,-,-,allograft rejection and post-LT survival,-,False,No disagreement between Model A and B,False
134,Updates on the Diagnosis and Management of Hepatocellular Carcinoma.,10.5005/jp-journals-10018-1335,"INTRODUCTION: Globally, the incidence, as well as mortality, related to hepatocellular carcinoma (HCC) is on the rise, owing to relatively few curative options. Underlying cirrhosis is the most common etiology leading to HCC, but risk factors of cirrhosis show great regional variability. Over the years, there has been a steady development in the diagnostic and therapeutic modalities of HCC, including the availability of a wide range of systemic chemotherapeutic agents. We aim to review the recent advancements in the diagnostic and therapeutic strategies for HCC. METHODOLOGY: The literature search was done using databases PubMed, Cochrane, and Science Direct, and the latest relevant articles were reviewed. FINDINGS: Screening of HCC is a pivotal step in the early diagnosis of the disease. Current guidelines recommend using ultrasound and alfa fetoprotein but various new biomarkers are under active research that might aid in diagnosing very small tumors, not picked up by the current screening methods. Treatment options are decided based upon the overall performance of the patient and the extent of the disease, as per the Barcelona classification. There are very few options that offer a cure for the disease, ranging from liver resection and transplantation to tumor ablation. Downstaging has proven to have a significant role in the course of the disease. An attempt to control the disease can be made via radiological interventions, such as transarterial chemoembolization, transarterial radioembolization, or radiation therapy. For advanced disease, sorafenib used to be the only option until a couple of years ago. Recently, many other systemic agents have received approval as first-line and second-line therapies for HCC. Genomics is an area of active clinical research as understanding the mutations and genomics involved in the evolution of HCC might lead to a breakthrough therapy. HOW TO CITE THIS ARTICLE: Raees A, Kamran M, zkan H, et al. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepato-Gastroenterol 2021;11(1):32-40.",Raees A; Kamran M; zkan H; Jafri W,False,"does not specify intervention, comparison, outcome, or study design",patients with hepatocellular carcinoma,not specified,not specified,not specified,not specified,False,"The abstract is a narrative review without a defined study design, intervention, comparison, or specific outcomes. Model A correctly excluded it but failed to note that the population includes general HCC patients without specifying those treated with ICIs.",patients with hepatocellular carcinoma (not specific to ICI treatment),-,-,-,-,False,No disagreement between Model A and B,False
135,Radiation therapy in the era of immune treatment for hepatocellular carcinoma.,10.3389/fimmu.2023.1100079,"Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or second-line therapy. Downstaging conversion therapy for potentially resectable HCC to provide opportunities for surgical intervention is challenging. ICIs have become a hot spot in this field due to their high response rate. However, HCC has various etiologies and can evade the immune system through multiple mechanisms, which limit the efficacy of ICI monotherapy and demand novel combination strategies. Radiation therapy (RT) is also a candidate for conversion therapy in HCC and is currently gaining increasing attention as a good combination partner with ICIs due to its ability to modulate the tumor microenvironment. In this review, we illustrate the current indications for ICIs and RT in HCC, the rationale for their synergistic combination, and the current clinical trials in combination therapy. We also speculate on predictive biomarkers and novel future strategies to further enhance the efficacy of this combination. This review aims to provide references for future research on radiation and immunotherapy to arrive at a promising new era of HCC treatment.",Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B,False,does not specify a comparison or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors,not specified,response rate,not specified,False,"The abstract discusses ICIs in HCC but does not specify a comparison group or study design. While it mentions response rate as an outcome, the lack of a defined comparison and study design renders it ineligible.",-,-,not specified (agrees with A_C),-,not specified (agrees with A_S),False,No disagreement between Model A and B,False
136,Hepatocellular carcinoma: Advances in systemic therapies.,10.12688/f1000research.145493.2,"Advanced hepatocellular carcinoma (HCC) is traditionally associated with limited treatment options and a poor prognosis. Sorafenib, a multiple tyrosine kinase inhibitor, was introduced in 2007 as a first-in-class systemic agent for advanced HCC. After sorafenib, a range of targeted therapies and immunotherapies have demonstrated survival benefits in the past 5 years, revolutionizing the treatment landscape of advanced HCC. More recently, evidence of novel combinations of systemic agents with distinct mechanisms has emerged. In particular, combination trials on atezolizumab plus bevacizumab and durvalumab plus tremelimumab have shown encouraging efficacy. Hence, international societies have revamped their guidelines to incorporate new recommendations for these novel systemic agents. Aside from treatment in advanced HCC, the indications for systemic therapy are expanding. For example, the combination of systemic therapeutics with locoregional therapy (trans-arterial chemoembolization or stereotactic body radiation therapy) has demonstrated promising early results in downstaging HCC. Recent trials have also explored the role of systemic therapy as neoadjuvant treatment for borderline-resectable HCC or as adjuvant treatment to reduce recurrence risk after curative resection. Despite encouraging results from clinical trials, the real-world efficacy of systemic agents in specific patient subgroups (such as patients with advanced cirrhosis, high bleeding risk, renal impairment, or cardiometabolic diseases) remains uncertain. The effect of liver disease etiology on systemic treatment efficacy warrants further research. With an increased understanding of the pathophysiological pathways and accumulation of clinical data, personalized treatment decisions will be possible, and the field of systemic treatment for HCC will continue to evolve.",Wu TK; Hui RW; Mak LY; Fung J; Seto WK; Yuen MF,False,does not specify a comparison or study design,advanced hepatocellular carcinoma patients,combination of immunotherapies,not specified,survival benefits,not specified,False,"The abstract reviews systemic therapies including immunotherapies for advanced HCC but does not specify a comparison group or study design. The outcomes focus on survival benefits, but without a clear comparison or RCT framework, it cannot meet inclusion criteria.",-,combination of systemic agents including immunotherapies (clarifies A_I which was vague),not specified (agrees with A_C),-,not specified (agrees with A_S),False,No disagreement between Model A and B,False
137,Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.,10.3390/cancers14092056,"Hepatocellular Carcinoma (HCC) is the most common liver malignancy and third leading cause of cancer death worldwide. For early- and intermediate-stage disease, liver-directed therapies for locoregional control, or down-staging prior to definitive surgical therapy with hepatic resection or liver transplantation, have been studied broadly, and are the mainstays of current treatment guidelines. As HCC incidence has continued to grow, and with more patients presenting with advanced disease, our current treatment modalities do not suffice, and better therapies are needed to improve disease-specific and overall survival. Until recently, sorafenib was the only systemic therapy utilized, and was associated with dismal results. The advent of immuno-oncology has been of significant interest, and has changed the paradigm of therapy for HCC. Lately, combination regimens including atezolizumab plus bevacizumab; durvalumab plus tremelimumab; and pembrolizumab plus Lenvatinib have shown impressive responses of between 25-35%; this is much higher than responses observed with single agents. Complete responses with checkpoint inhibitor therapy have been observed in advanced-stage HCC patients. These dramatic results have naturally led to several questions. Can or should checkpoint inhibitors, or other immunotherapy combinations, be used routinely before resection or transplant? Is there a synergistic effect of immunotherapy with locoregional therapy, and will pre-treatment increase disease-free survival after surgical intervention? Is it immunologically safe to use these therapies prior to transplantation? Much is still to be learned in terms of the dosing, timing, and overall utility of the use of immune checkpoint inhibitors for pre-transplant care and down-staging. More studies will be needed to understand the management of adverse events while maximizing the therapeutic window of these agents. In this review, we look at the current data on therapy with immune checkpoint inhibitors in advanced HCC, with a focus on pre-transplant treatment prior to liver transplant.",Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK,False,does not specify a comparison or study design,patients with advanced hepatocellular carcinoma,immune checkpoint inhibitors,not specified,response rates,not specified,False,"The abstract focuses on immune checkpoint inhibitors in advanced HCC but lacks specification of a comparison group or study design. Although response rates are mentioned, the absence of these critical elements disqualifies it.",-,-,not specified (agrees with A_C),-,not specified (agrees with A_S),False,No disagreement between Model A and B,False
138,Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.,10.1186/s12885-024-12772-y,"BACKGROUND: Systemic conversion therapy provides patients with initially unresectable hepatocellular carcinoma (HCC) the chance to salvage radical liver resection and superior survival outcomes, but the optimal conversion strategy is unclear. METHODS: A systematic literature search was conducted on PubMed, EMBASE, Web of Science, Scopus, and the Cochrane Library between 2007 and 2024 focusing on studies reporting conversion therapy for HCC. The treatment groups were divided into Tyrosine kinase inhibitors (TKI), TKI plus loco-regional therapy (LRT), TKI plus anti-PD-1 therapy (TKI+PD-1), TKI+PD-1+LRT, immune checkpoint inhibitors (ICI) plus LRT, and Atezolizumab plus bevacizumab (A+T) groups. The conversion to surgery rate (CSR), objective response rate (ORR), grade3 treatment-related adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were analyzed. RESULTS: 38 studies and 4,042 patients were included. The pooled CSR were 8% (95% CI, 5-12%) in TKI group, 13% (95% CI, 8-19%) in TKI+LRT group, 28% (95% CI, 19-37%) in TKI+PD-1 group, 33% (95% CI, 25-41%) in TKI+PD-1+LRT group, 23% (95% CI, 1-46%) in ICI+LRT group, and 5% (95% CI, 3-8%) in A+T group, respectively. The pooled HR for OS (0.45, 95% CI, 0.35-0.60) and PFS (0.49, 95% CI, 0.35-0.70) favored survival benefit of conversion surgery. Subgroup analysis revealed that lenvatinib+PD-1+LRT conferred higher CSR of 35% (95% CI, 26-44%) and increased ORR of 70% (95% CI, 56-83%). CONCLUSIONS: The current study indicates that TKI+PD-1+LRT, especially lenvatinib+PD-1+LRT, may be the superior conversion therapy with a manageable safety profile for patients with initially unresectable HCC. The successful conversion therapy favors the superior OS and PFS compared with systemic treatment alone. TRIAL REGISTRATION: International prospective register of systematic reviews (PROSPERO) (registration code: CRD 42024495289).",Xu H; Zhang H; Li B; Chen K; Wei Y,False,not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,various conversion therapies including ICIs,systemic treatment alone,overall survival and progression-free survival,systematic literature review,False,"While this systematic review includes a comparison between conversion therapies and systemic treatment alone, it is not based on randomized controlled trials. The study design criterion is not met, making it ineligible despite relevant PICOS elements.",-,-,-,-,systematic review (corrects A_S which inaccurately described it as a systematic literature review),False,No disagreement between Model A and B,False
139,,,"Primary liver cancer has the sixth-highest incidence of all cancers and is the fourth-largest cause of cancer-related mortality worldwide. Estimates for 2020 suggested that 3,100 Canadians would be diagnosed with primary liver cancer and that 1,450 Canadians would die from it. In particular, data from the Long Form Census in Canada suggest that members of First Nations have disproportionately high rates of primary liver cancer, emphasizing the importance of attention to this condition in Canadian settings. While the prevalence and cancer-related mortality of primary liver cancer are higher in males (accounting for 10.2% of all cancer-related deaths in males worldwide), primary liver cancer is still a significant cause of disease burden in females (5.6% of all cancer-related deaths in females worldwide). The most common type of primary liver cancer is hepatocellular carcinoma, which accounts for approximately 80% to 85% of primary liver cancers.(,) Risk factors for the development of hepatocellular carcinoma include chronic alcohol consumption, viral hepatitis (e.g., hepatitis B, hepatitis C), cirrhosis of any etiology, and non-alcoholic fatty liver disease.(,) Treatment options for hepatocellular carcinoma consist of surgical (e.g., resection and liver transplantation) and non-surgical techniques, including locoregional therapies (e.g., percutaneous ethanol injection, radiofrequency or microwave ablation, transarterial chemoembolization [TACE] or transarterial radioembolization [TARE]) and systemic therapies (e.g., sorafenib, lenvatinib, and atezolizumab-bevacizumab). The selection of appropriate treatment is typically informed by tumour stage, liver function, and patient performance status, all of which are important factors that may influence treatment outcomes,(,) and selection is best done by a multi-disciplinary team. Surgical resection is the treatment of choice for patients with single nodules, no underlying cirrhosis, and good liver function. While patients who undergo surgical resection have a reasonably good prognosis (a 5-year survival rate of approximately 70%), a majority of patients with hepatocellular carcinoma are diagnosed with advanced disease when patients become symptomatic and have some degree of liver impairment. In many of these cases, surgical resection may no longer be appropriate. As a form of radiation therapy for patients with advanced or inoperable hepatocellular carcinoma, TARE (also known as selective internal radiation therapy [SIRT]) has been used to downstage patients before surgery or to bridge patients to liver transplantation. As part of this procedure microspheres loaded with a radioactive isotope, most commonly yttirium-90 ((90)Y), are delivered into the hepatic artery via a catheter inserted into the femoral artery. The therapy delivers a high dose of targeted radiation directly to the cancer cells, while also blocking the supply of blood to the tumour. Conventional transarterial chemoembolization (cTACE) is administered using a procedure similar to TARE; however, instead of radiation the patient is given regional chemotherapy (usually doxorubicin or cisplatin) before an embolic agent. TACE can also be performed using drug-eluting beads that combine the chemotherapeutic agent with the embolic agent (i.e., drug-eluting bead transarterial chemoembolization [DEB-TACE]). The objective of this report is to evaluate the evidence regarding the clinical effectiveness and cost-effectiveness of TARE using (90)Y microspheres to support decisions involving the use of this therapy to treat patients with intermediate- or advanced-stage hepatocellular carcinoma. This report complements previous CADTH evaluations of the evidence regarding the use of (90)Y microspheres for the treatment of other cancers, including uveal melanoma liver metastases, liver metastases from colorectal cancer, and primary or secondary liver cancer.",Young C; Subramonian A; Argez C,False,"does not specify intervention, comparison, outcome, or study design",patients with hepatocellular carcinoma,not specified,not specified,not specified,not specified,False,"The abstract provides an overview of treatments for HCC but fails to specify intervention, comparison, outcome, or study design. It is too broad and lacks the necessary details to meet PICOS criteria.",-,not specified (agrees with A_I),not specified (agrees with A_C),not specified (agrees with A_O),not specified (agrees with A_S),False,No disagreement between Model A and B,False
140,Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution.,10.3390/life13071562,"Liver transplantation (LT) represents the primary curative option for HCC. Despite the extension of transplantation criteria and conversion with down-staging loco-regional treatments, transplantation is not always possible. The introduction of new standards of care in advanced HCC including a combination of immune checkpoint inhibitor-based therapies led to an improvement in response rates and could represent a promising strategy for down-staging the tumor burden. In this review, we identify reports and series, comprising a total of 43 patients who received immune checkpoint inhibitors as bridging or down-staging therapies prior to LT. Overall, treated patients registered an objective response rate of 21%, and 14 patients were reduced within the Milan criteria. Graft rejection was reported in seven patients, resulting in the death of four patients; in the remaining cases, LT was performed safely after immunotherapy. Further investigations are required to define the duration of immune checkpoint inhibitors, their minimum washout period and the LT long-term safety of this strategy. Some randomized clinical trials including immunotherapy combinations, loco-regional treatment and/or tyrosine kinase inhibitors are ongoing and will likely determine the appropriateness of immune checkpoint inhibitors' administration before LT.",Cesario S; Genovesi V; Salani F; Vasile E; Fornaro L; Vivaldi C; Masi G,False,does not specify a comparison group or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors as bridging or down-staging therapies,not specified,response rates and graft rejection,not specified,False,"The abstract does not specify a comparison group or randomized controlled trial design, and the outcomes are focused on response rates and graft rejection rather than survival or response rate as required by PICOS. Model A correctly identified these issues.",-,-,-,-,-,False,No disagreement between Model A and B,False
141,Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.,10.1016/j.jimed.2023.09.002,"PURPOSE: The IMbrave150 Phase III trial demonstrated the superiority of atezolizumab and bevacizumab (Atezo/Bev) over sorafenib for unresectable hepatocellular carcinoma (HCC). The present study aims to evaluate the feasibility of TARE in combination with Atezo/Bev for the treatment of intermediate and advanced staged HCC. METHODS: A retrospective review at a single institution was performed between May 2021 and December 2022. Patients who received TARE using yttrium-90 (Y90) with concomitant or sequential Atezo/Bev systemic treatment were included. The following outcomes were retrieved: overall survival (OS), radiologic tumor response, progression-free survival, technical adverse events related to TARE, and toxicity based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Ten consecutive patients with intermediate (n=4) and advanced stage HCC (n=6) were treated with TARE and sequential/concomitant Atezo/Bev. Tumor control was achieved in all TARE-treated target lesions (100%). Overall disease progression occurred in 4 patients with PFS of 78.8% and 66.7% at 6- and 12- months, respectively. Two patients died at follow-up, with 6-month and 12-month OS rates of 90.0% and 77.1%, respectively. Three (75%) patients with intermediate stage disease were downstaged into Milan criteria. One patient developed grade 3 transaminitis and hypoglobulinemia, while Atezo/Bev was switched to Lenvatinib in another patient due to immunotherapy related myositis. CONCLUSION: This study demonstrates the initial safety and feasibility of combined TARE with Atezo/Bev for intermediate/advanced stage HCC. Further prospective studies with larger sample sizes are warranted. Elsevier B.V. on behalf of KeAi Communications Co. Ltd.",Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O,True,matches all PICOS criteria,patients with unresectable hepatocellular carcinoma,atezolizumab and bevacizumab,sorafenib,overall survival and tumor response,Phase III randomized controlled trial,True,"Model A's analysis is accurate. The abstract describes a Phase III randomized controlled trial comparing atezolizumab and bevacizumab to sorafenib in patients with unresectable hepatocellular carcinoma, with outcomes including overall survival and tumor response. All PICOS criteria are met.",-,-,-,-,-,True,No disagreement between Model A and B,True
142,Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma.,10.3390/cancers15245878,"Triple combination conversion therapy, involving transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), has shown an encouraging objective response rate (ORR) and successful conversion surgery rate in initially unresectable hepatocellular carcinoma (HCC). However, the safety and long-term survival outcomes of subsequent liver resection after successful conversion still remain to be validated. From February 2019 to February 2023, 726 patients were enrolled in this retrospective study (75 patients received hepatectomy after conversion therapy [CLR group], and 651 patients underwent pure hepatectomy [LR group]). Propensity score matching (PSM) was used to balance the preoperative baseline characteristics. After PSM, 68 patients in the CLR group and 124 patients in the LR group were analyzed, and all the matching variables were well-balanced. Compared with the LR group, the CLR group experienced longer Pringle maneuver time, longer operation time, and longer hospital stays. In addition, the CLR group had significantly higher incidence rates of intra-abdominal bleeding, biliary leakage, post-hepatectomy liver failure (PHLF), and Clavien-Dindo grade IIIa complications than the LR group. There were no significant statistical differences in overall survival (OS) (hazard ratio [HR] 0.724; 95% confidence interval [CI] 0.356-1.474; p = 0.374) and recurrence-free survival (RFS) (HR 1.249; 95% CI 0.807-1.934; p = 0.374) between the two groups. Liver resection following triple combination conversion therapy in initially unresectable HCC may achieve favorable survival outcomes with manageable safety profiles; presenting as a promising treatment option for initially unresectable HCC.",Long Y; Huang J; Liao J; Zhang D; Huang Z; He X; Zhang L,False,not a randomized controlled trial,patients with initially unresectable hepatocellular carcinoma,triple combination therapy including immune checkpoint inhibitors,pure hepatectomy,overall survival and recurrence-free survival,retrospective study with propensity score matching,False,"Model A correctly noted that this is not a randomized controlled trial but a retrospective study with propensity score matching. While the population and intervention descriptions align with PICOS, the lack of randomization invalidates inclusion under the specified study design criterion.",-,-,-,-,-,False,No disagreement between Model A and B,False
143,Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy.,10.1200/JCO.24.00857,"Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma (HCC) for almost three decades. In recent years, its role has been evolving to include patients with disease burden beyond the widely used Milan criteria. The integration of dynamic biomarkers such as alpha-fetoprotein together with downstaging approaches and tumor evolution after enlistment has allowed the selection of patients most likely to benefit, resulting in 5-year survival rates greater that 70%. With the increasing use of immune checkpoint inhibitors (ICIs) across all stages of disease, alone or in combination with locoregional therapies, there is now the potential to further expand the patient population with HCC who may benefit from LT. This brings challenges, given the global shortage of organs and the need to better understand the optimal use of ICIs before transplantation. Furthermore, the field of transplant oncology awaits additional biomarkers that can predict those likely to benefit from ICIs. More than ever, a multidisciplinary approach for liver cancer management is critical to ensure all patients are considered for LT where appropriate, and do not miss the opportunity for long-term survival.",Magyar CTJ; O'Kane GM; Aceituno L; Li Z; Vogel A; Bruix J; Mazzaferro V; Sapisochin G,False,does not specify a comparison group or study design,patients with hepatocellular carcinoma,immune checkpoint inhibitors prior to liver transplantation,not specified,5-year survival rates and safety outcomes,not specified,False,"The abstract lacks a defined comparison group and study design, focusing instead on narrative discussion without quantitative analysis. Model A's reasoning for exclusion is valid as it does not meet the PICOS criteria for comparison or study design.",-,-,-,-,-,False,No disagreement between Model A and B,False
144,Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.,10.1016/j.jhep.2024.09.003,"BACKGROUND & AIMS: The use of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC) has become widespread with encouraging outcomes in the neoadjuvant setting. Safety and intention-to-treat (ITT) outcomes in the peri-transplant setting are currently based on small and heterogenous single-center reports. METHODS: This first multiregional US study (2016-2023) included 117 consecutive patients with HCC assessed for liver transplantation (LT) and treated preoperatively with ICIs. ITT and survival analyses were conducted with evaluation of post-LT rejection rates. RESULTS: In total, 86 (73.5%) patients exceeded Milan criteria (MC) and 65 (75.6%) were successfully downstaged within a median of 5.6 months; 43 (36.7%) underwent transplantation, including 18 (15.4%) within MC and 23 (19.7%) who were initially beyond but were downstaged. Overall, 94% of the cohort received concurrent ICIs and locoregional therapies. No grade 4-5 adverse events occurred on the waiting list. The 3-year cumulative probability of dropout was 28% for those within MC and 48% for those beyond. Independent predictors of dropout included being beyond MC (p <0.001), alpha-fetoprotein doubling from baseline (p= 0.014) and radiographic responses (p <0.001). The 3-year ITT survival rate was 71.1% (73.5% within MC vs. 69.7% beyond MC, p= 0.329), with a 3-year post-LT survival rate of 85%. Post-LT rejection occurred in seven patients, six received their last dose of ICI less than 3 months prior to LT, resulting in one graft loss. CONCLUSIONS: The first multicenter evaluation of patients with HCC receiving ICIs pre-LT demonstrates favorable survival and safety outcomes, justifying continued utilization and further evaluation of this strategy in clinical practice. High tumor burden, doubling of alpha-fetoprotein levels, and radiographic response were identified as predictors of unfavorable oncologic outcomes. IMPACT AND IMPLICATIONS: Herein, we report results from the first multicenter evaluation of pretransplant immune checkpoint inhibitors in hepatocellular carcinoma to show promising intention-to-treat survival, safety and rejection rates. Immune checkpoint inhibitors, either alone or combined with locoregional therapy, demonstrate reliable efficacy. This preoperative strategy could be particularly beneficial for high-risk patients, including those requiring downstaging or with elevated alpha-fetoprotein levels despite locoregional treatment. These findings fill current knowledge gaps and offer reassuring evidence for the feasibility of pretransplant use of immune checkpoint inhibitors, pending results from ongoing trials.",Tabrizian P; Holzner ML; Ajmera V; Kim AK; Zhou K; Schnickel GT; Torosian K; Hoteit M; Marino R; Li M; Yao F; Florman SS; Schwartz ME; Mehta N,False,does not specify a comparison group or randomized controlled trial design,patients with hepatocellular carcinoma,immune checkpoint inhibitors in the peri-transplant setting,not specified,3-year survival rates and rejection rates,multicenter study,False,"Although the abstract provides detailed survival and safety outcomes, it does not specify a comparison group or employ a randomized controlled trial design. Model A accurately excluded it based on the absence of these critical PICOS components.",-,-,-,-,-,False,No disagreement between Model A and B,False
145,Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy.,10.21037/hbsn-21-188,"BACKGROUND: A combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with local regional therapy has elicited yield substantial clinical benefits in patients who have hepatocellular carcinoma (HCC) with extrahepatic metastases. Using this treatment strategy to convert HCC patients with extrahepatic metastases from unresectable to resectable has not yet been reported. METHODS: Consecutive hepatocellular carcinoma patients with extrahepatic metastases who received first-line therapy with a combination of TKIs and anti-PD-1 antibodies and at least one local regional therapy were analysed. RESULTS: Nine patients with localized disease who received first-line systemic therapy were enrolled. At baseline, all of them had oligometastatic disease, namely, Barcelona Clinic Liver Cancer stage C (or Chinese Liver Cancer stage IIIB). The most common treatment administered was lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization, and the median time span from systemic therapy to surgery was 3.2 (IQR, 2.8-6.2) months. Three patients achieved a pathological complete response. Six patients underwent laparoscopic surgery, and the other 3 patients underwent open surgery. After a median follow-up of 10.2 (IQR, 8.6-20.0) months, 7 patients survived without disease recurrence, and 2 experienced tumour recurrence. All patients had any-grade AEs, and 55.6% of the patients experienced grade 3 AEs. Fatigue was the most common AE, followed by elevated aminotransferase levels and hypertension. CONCLUSIONS: Stereotactic therapy is a feasible conversion therapy for HCC patients with extrahepatic metastases to become resectable. This is the first study to analyse therapeutic outcomes of patients receiving these therapies for HCC with extrahepatic metastases.",Yang X; Xu H; Zuo B; Yang X; Bian J; Long J; Wang D; Zhang J; Ning C; Wang Y; Xun Z; Wang Y; Lu X; Mao Y; Sang X; Zhao H,False,does not meet the criteria for intervention (TKIs instead of ICIs),patients with hepatocellular carcinoma and extrahepatic metastases,combination of TKIs and anti-PD-1 antibodies,not specified,three patients achieved pathological complete response,not specified,False,"The intervention involves a combination of TKIs and anti-PD-1 antibodies rather than ICIs alone as specified in the PICOS criteria. Additionally, the study lacks a comparison group and is not an RCT.",-,Combination of lenvatinib (a TKI) and anti-PD-1 antibody with local regional therapy such as transarterial chemoembolization,No comparison group is mentioned in the abstract,-,Retrospective observational study rather than an RCT,False,No disagreement between Model A and B,False
146,Liver transplantation for hepatocellular carcinoma in India: Are we ready for 2040?,10.5500/wjt.v14.i1.88833,"BACKGROUND: Liver transplantation (LT) for hepatocellular carcinoma (HCC) has been widely researched and is well established worldwide. The cornerstone of this treatment lies in the various criteria formulated by expert consensus and experience. The variations among the criteria are staggering, and the short- and long-term out comes are controversial. AIM: To study the differences in the current practices of LT for HCC at different centers in India and discuss their clinical implications in the future. METHODS: We conducted a survey of major centers in India that performed LT in December 2022. A total of 23 responses were received. The centers were classified as high- and low-volume, and the current trend of care for patients und ergoing LT for HCC was noted. RESULTS: Of the 23 centers, 35% were high volume center (> 500 Liver transplants) while 52% were high-volume centers that performed more than 50 transplants/year. Approximately 39% of centers had performed > 50 LT for HCC while the percent distribution for HCC in LT patients was 5%-15% in approximately 73% of the patients. Barring a few, most centers were divided equally between University of California, San Francisco (UCSF) and center-specific criteria when choosing patients with HCC for LT, and most (65%) did not have separate transplant criteria for deceased donor LT and living donor LT (LDLT). Most centers (56%) preferred surgical resection over LT for a Child A cirrhosis patient with a resectable 4 cm HCC lesion. Positron-emission tomography-computed tomography (CT) was the modality of choice for metastatic workup in the majority of centers (74%). Downstaging was the preferred option for over 90% of the centers and included transarterial chemoembolization, transarterial radioembolization, stereotactic body radiotherapy and atezolizumab/bevacizumab with varied indications. The alpha-fetoprotein (AFP) cut-off was used by 74% of centers to decide on transplantation as well as to downstage tumors, even if they met the criteria. The criteria for successful downstaging varied, but most centers conformed to the UCSF or their center-specific criteria for LT, along with the AFP cutoff values. The wait time for LT from down staging was at least 4-6 wk in all centers. Contrast-enhanced CT was the preferred imaging modality for post-LT surveillance in 52% of the centers. Approximately 65% of the centers preferred to start everolimus between 1 and 3 months post-LT. CONCLUSION: The current predicted 5-year survival rate of HCC patients in India is less than 15%. The aim of transplantation is to achieve at least a 60% 5-year disease free survival rate, which will provide relief to the prediction of an HCC surge over the next 20 years. The current worldwide criteria (Milan/UCSF) may have a higher 5-year survival (> 70%); however, the majority of patients still do not fit these criteria and are dependent on other suboptimal modes of treatment, with much lower survival rates. To make predictions for 2040, we must prepare to arm ourselves with less stringent selection criteria to widen the pool of patients who may undergo transplantation and have a chance of a better outcome. With more advanced technology and better donor outcomes, LDLT will provide a cutting edge in the fight against liver cancer over the next two decades. reserved.",Pahari H; Raj A; Sawant A; Ahire DS; Rathod R; Rathi C; Sankalecha T; Palnitkar S; Raut V,False,does not focus on ICIs or compare with placebo,patients undergoing liver transplantation for HCC,not specified,not specified,5-year survival rate less than 15%,survey study,False,The study focuses on liver transplantation practices for HCC without specifically analyzing ICIs or including a comparison group. It is also a survey-based study rather than an RCT.,Patients undergoing liver transplantation for HCC in India,Various treatments including downstaging therapies but no specific focus on ICIs,No placebo or non-ICI treatment comparison is described,General survival rates and transplantation outcomes are discussed but not specifically linked to ICIs,-,False,No disagreement between Model A and B,False
147,Downstaging with atezolizumab-bevacizumab: a case series.,10.17998/jlc.2024.05.12,"BACKGROUNDS/AIMS: Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC for liver transplantation (LT). Atezolizumab-bevacizumab (atezo-bev) can induce objective responses in nearly one-third of patients; however, the role and outcomes of downstaging using atezo-bev remains unknown. METHODS: In this retrospective single-center study, we included consecutive patients between November 2020 and August 2023, who received atezo-bev with or without LRT and were subsequently considered for resection/LT after downstaging. RESULTS: Of the 115 patients who received atezo-bev, 12 patients (10.4%) achieved complete or partial response and were willing to undergo LT; they (age, 58.5 years; women, 17%; Barcelona Clinic Liver Cancer stage system B/C, 5/7) had received 3-12 cycles of atezo- bev, and four of them had received prior LRT. Three patients died before LT, while three were awaiting LT. Six patients underwent curative therapies: four underwent living donor LT after a median of 79.5 days (range, 54-114) following the last atezo-bev dose, one underwent deceased donor LT 38 days after the last dose, and one underwent resection. All but one patient had complete pathologic response with no viable HCC. Three patients experienced wound healing complications, and one required re-exploration and succumbed to sepsis. After a median follow-up of 10 months (range, 4-30), none of the alive patients developed HCC recurrence or graft rejection. CONCLUSIONS: Surgical therapy, including LT, is possible after atezo-bev therapy in well-selected patients after downstaging.",Kulkarni AV; Kumaraswamy P; Menon B; Sekaran A; Rambhatla A; Iyengar S; Alla M; Venishetty S; Ramachandra SK; Premkumar GV; Sharma M; Rao PN; Reddy DN; Singal AG,False,"not a randomized controlled trial, lacks appropriate comparison",patients with hepatocellular carcinoma considered for resection or LT,atezolizumab-bevacizumab therapy,not specified,12 patients achieved complete or partial response,retrospective single-center study,False,"Although atezolizumab-bevacizumab is an ICI-based therapy, the study design is retrospective and lacks a comparison group, failing to meet the RCT requirement of the PICOS criteria.",-,-,No comparison group is mentioned in the abstract,-,-,False,No disagreement between Model A and B,False
148,"Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.",10.4143/crt.2023.1165,"PURPOSE: The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti-programmed cell death-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT. MATERIALS AND METHODS: This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child-Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment-related adverse events were analyzed to assess safety profiles. RESULTS: During a median follow-up of 11.23 months (range, 3.07 to 34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The 2-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively. CONCLUSION: Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.",Ou X; Wu J; Wu J; Fu Y; Zeng Z; Li S; Li Y; Liu D; Li H; Li B; Zhou J; Zhuang S; Cheng S; Zhang Z; Wang K; Qu S; Yan M,False,"not a randomized controlled trial, lacks appropriate comparison",patients with hepatocellular carcinoma and portal vein tumor thrombus,lenvatinib combined with anti-PD-1 antibodies and TACE,not specified,median OS greater than 24 months,retrospective multicenter study,False,"The intervention includes lenvatinib combined with anti-PD-1 antibodies and TACE, which does not exclusively focus on ICIs. The study is retrospective and lacks a comparison group, failing to meet the RCT requirement.",-,Lenvatinib combined with anti-PD-1 antibodies and transcatheter arterial chemoembolization (TACE),No comparison group is mentioned in the abstract,-,-,False,No disagreement between Model A and B,False
149,Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.,10.5582/bst.2023.01326,"Therapies for patients with unresectable hepatocellular carcinoma (uHCC) are currently popular. Current first-line standard-of-care treatments for uHCC are systematic therapies. However, treatments that combine locoregional therapy with systemic therapy are widely accepted in China and have demonstrated high rates of tumor response and conversion to resection with manageable toxicity. A literature review was performed by searching published literature in PubMed and Web of Science up to December 2023 for relevant articles on the use of triple therapy (transarterial chemoembolization combined with lenvatinib and anti-PD-1 antibodies) in uHCC. This review concentrates on the efficacy and safety of triple therapy with Chinese characteristics in patients with uHCC and describes the outcome of conversion surgery, degree of pathological necrosis, and effect prediction. This article will contribute to a comprehensive understanding of the role of triple therapy with Chinese characteristics in patients with uHCC.",Wu J; Wu J; Li S; Luo M; Zeng Z; Li Y; Fu Y; Li H; Liu D; Ou X; Lin Z; Wei S; Yan M,False,"not a randomized controlled trial, lacks appropriate comparison",patients with unresectable hepatocellular carcinoma,triple therapy including lenvatinib and anti-PD-1 antibodies,not specified,high rates of tumor response and conversion to resection,literature review,False,"This is a literature review rather than an original study, and it does not provide data from a randomized controlled trial. Additionally, the intervention involves triple therapy rather than focusing solely on ICIs.",Patients with unresectable hepatocellular carcinoma treated with triple therapy,Triple therapy including transarterial chemoembolization lenvatinib and anti-PD-1 antibodies,No direct comparison group is analyzed in the review,Outcomes include tumor response and conversion to resection but lack specific ICI-focused results,Literature review rather than an RCT,False,No disagreement between Model A and B,False
150,Conversion therapy for massive hepatocellular carcinoma: A case report and literature review.,10.1002/ccr3.7533,"KEY CLINICAL MESSAGE: For potentially resectable HCC, a more aggressive conversion therapy strategy (high-intensity combined with multiple treatment modalities) can be used. ABSTRACT: Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. The best treatment for HCC is radical surgical resection, but 70%-80% of patients are ineligible for surgery. Although conversion therapy is an established treatment strategy for various solid tumors, there is no uniform protocol for treating HCC. In this case, we present a 69-year-old male patient diagnosed with massive HCC with Barcelona clinical liver cancer (BCLC) stage B. Because of the insufficient volume of the future liver remnant, we believed radical surgical resection was temporarily impossible. Therefore, the patient received conversion therapy, including four cycles of transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC-Folfox), lenvatinib (8mg orally once a day), and tislelizumab (an anti-PD-1 antibody, 200mg intravenously once every 3weeks). Fortunately, the patient achieved a good treatment response (smaller lesions and improved liver function) and underwent radical surgery finally. There was no clinical evidence of recurrence at 6months of follow-up. For potentially resectable HCC, this case reveals that a more aggressive conversion therapy strategy (high-intensity combined with multiple treatment modalities) can be used.",Zhou Z; Xu X; Sun M; Liu Y; Liu Q; Chen C; Yin Y,False,does not meet RCT design criteria,patient with massive HCC,tislelizumab (anti-PD-1 antibody),not specified,good treatment response,case report,False,"The abstract describes a single case report of a patient with massive HCC receiving combination therapy including tislelizumab. Model A correctly identifies this as not meeting RCT criteria. The population is limited to one patient, and the comparison group is absent, making it unsuitable for inclusion.",-,-,-,-,-,False,No disagreement between Model A and B,False
151,Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?,10.4292/wjgpt.v15.i5.97570,"Liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and chronic liver disease (CLD) is limited by factors such as tumor size, number, portal venous or hepatic venous invasion and extrahepatic disease. Although previously established criteria, such as Milan or UCSF, have been relaxed globally to accommodate more potential recipients with comparable 5-year outcomes, there is still a subset of the population that has advanced HCC with or without portal vein tumor thrombosis without detectable extrahepatic spread who do not qualify or are unable to be downstaged by conventional methods and do not qualify for liver transplantation. Immune checkpoint inhibitors (ICI) such as atezolizumab, pembrolizumab, or nivolumab have given hope to this group of patients. We completed a comprehensive literature review using PubMed, Google Scholar, reference citation analysis, and CrossRef. The search utilized keywords such as 'liver transplant', 'HCC', 'hepatocellular carcinoma', 'immune checkpoint inhibitors', 'ICI', 'atezolizumab', and 'nivolumab'. Several case reports have documented successful downstaging of HCC using the atezolizumab/bevacizumab combination prior to LT, with acceptable early outcomes comparable to other criteria. Adverse effects of ICI have also been reported during the perioperative period. In such cases, a 1.5-month interval between ICI therapy and LT has been suggested. Overall, the results of downstaging using combination immunotherapy were encouraging and promising. Early reports suggested a potential ray of hope for patients with CLD and advanced HCC, especially those with multifocal HCC or branch portal venous tumor thrombosis. However, prospective studies and further experience will reveal the optimal dosage, duration, and timing prior to LT and evaluate both short- and long-term outcomes in terms of rejection, infection, recurrence rates, and survival. reserved.",Pahari H; Peer JA; Tripathi S; Singhvi SK; Dhir U,False,does not specify an RCT or outcomes clearly,patients with HCC and CLD,immune checkpoint inhibitors (ICI),not specified or comparison not detailed,promising downstaging results,literature review,False,"This is a literature review summarizing case reports on downstaging HCC using ICIs before liver transplantation. Model A correctly notes the lack of an RCT design and unclear outcomes. The comparison group is unspecified, and the study does not meet the PICOS criteria for inclusion.",-,-,-,-,-,False,No disagreement between Model A and B,False
152,Lenvatinibbased treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and metaanalysis.,10.3892/ol.2024.14398,"Hepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical treatment and achieve long-term survival. Despite accumulating evidence regarding the efficacy of conversion therapy, the optimal treatment approach for such therapy remains uncertain. Lenvatinib (LEN) has shown efficacy and tolerable rates of adverse events (AEs) when applied in combination with immune checkpoint inhibitors (ICIs) or locoregional therapy (LRT) over the past decade. Therefore, the present meta-analysis was performed to systematically assess the safety and efficacy of LEN-based treatment regimens in conversion therapies for uHCC. Data on outcomes, including the conversion rate, objective response rate (ORR), disease control rate (DCR) and AE incidence in patients with uHCC, were collected. A systematic literature search was performed using MEDLINE, Embase, Web of Science and Cochrane Library databases, up to the date of September 1, 2023. In total, 16 studies, encompassing a total of 1,650 cases of uHCC, were included in the final meta-analysis. The pooled conversion rates for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were calculated to be 0.04 (95% CI, 0.00-0.07; I(2)=77%), 0.23 (95% CI, 0.16-0.30; I(2)=66%), 0.14 (95% CI, 0.10-0.18; I(2)=0%) and 0.35 (95% CI, 0.23-0.47; I(2)=88%), respectively. The pooled ORRs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were found to be 0.45 (95% CI, 0.23-0.67; I(2)=96%), 0.49 (95% CI, 0.39-0.60; I(2)=78%), 0.43 (95% CI, 0.24-0.62; I(2)=88%) and 0.69 (95% CI, 0.56-0.82; I(2)=92%), respectively. The pooled DCRs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were observed to be 0.77 (95% CI, 0.73-0.81; I(2)=23%), 0.82 (95% CI, 0.69-0.95; I(2)=90%), 0.67 (95% CI, 0.39-0.94; I(2)=94%) and 0.87 (95% CI, 0.82-0.93; I(2)=67%), respectively. The pooled grade 3 AEs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were 0.25 (95% CI, 0.14-0.36; I(2)=89%), 0.43 (95% CI, 0.34-0.53; I(2)=23%), 0.42 (95% CI, 0.19-0.66; I(2)=81%) and 0.35 (95% CI, 0.17-0.54; I(2)=94%), respectively. These findings suggested that LEN-based combination strategies may confer efficacy and acceptable tolerability for patients with uHCC. In particular, LEN + ICI, with or without LRT, appears to represent a highly effective conversion regimen, with an acceptable conversion rate and well-characterized safety profile.",Li S; Zhang Z; Wang Z; Wang K; Sui M; Liu D; Liang K,False,not a randomized controlled trial,patients with unresectable HCC,LEN-based regimens including ICIs,LEN alone or LEN + LRT,"conversion rate, ORR, DCR",meta-analysis,False,"The abstract describes a meta-analysis evaluating lenvatinib-based regimens in unresectable HCC. While it provides pooled data on conversion rates and response rates, it is not derived from RCTs but rather includes observational studies. Model A correctly excludes it due to the absence of an RCT design.",-,-,-,-,-,False,No disagreement between Model A and B,False
153,"Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.",10.1097/HEP.0000000000001229,"BACKGROUND AND AIMS: Various conversion therapy options have become available to patients with unresectable HCC, but which conversion therapy is optimal for which type of patient is controversial. This study compared the efficacy and safety of TACE alone or combined with immune checkpoint and tyrosine kinase inhibitors. APPROACH AND RESULTS: Data were retrospectively compared for patients with initially unresectable HCC who underwent conversion therapy consisting of TACE alone (n=459) or combined with immune checkpoint and tyrosine kinase inhibitors (n=343). Compared to the group that received TACE alone, the group that received triple conversion therapy showed significantly higher rates of overall survival (HR 0.43, 95%CI 0.35-0.53). In addition, triple therapy was associated with significantly longer median progression-free survival (15.9 vs. 8.0mo, p<0.001). These results were confirmed in matched subsets of patients from each group. However, subgroup analysis confirmed the results only for patients with HCC in intermediate or advanced stages, not in an early stage. Those who received triple conversion therapy had a significantly higher rate of hepatectomy after conversion therapy (36.4 vs. 23.5%, p<0.001). Among those who underwent hepatectomy after conversion therapy, triple therapy was associated with a significantly higher rate of complete tumor response (32.1 vs. 11.1%, p<0.001). However, it was also associated with a significantly higher frequency of serious adverse events (35.6 vs. 27.0%, p=0.009). CONCLUSIONS: Combining TACE with immune checkpoint and tyrosine kinase inhibitors was associated with significantly better survival and conversion efficacy than TACE alone among patients with intermediate or advanced unresectable HCC.",Yang DL; Ye L; Zeng FJ; Liu J; Yao HB; Nong JL; Liu SP; Peng N; Li WF; Wu PS; Qin C; Su Z; Ou JJ; Dong XF; Yan YH; Zhong TM; Mao XS; Wu MS; Chen YZ; Wang GD; Li MJ; Wang XY; Yang FQ; Liang YR; Chen SC; Yang YY; Chen K; Li FX; Lai YC; Pang QQ; Liang XM; You XM; Xiang BD; Yu YQ; Ma L; Zhong JH,False,not a randomized controlled trial,patients with unresectable HCC,TACE combined with ICIs and TKIs,TACE alone,overall survival and conversion rates,retrospective cohort study,False,"This retrospective cohort study compares TACE alone versus TACE combined with ICIs and TKIs in unresectable HCC. Model A correctly identifies the study as non-randomized. Although survival and conversion rates are reported, the lack of randomization disqualifies it from meeting the PICOS criteria.",-,-,-,-,-,False,No disagreement between Model A and B,False
154,Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).,10.5582/bst.2024.01394,"Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the Healthy China 2030 blueprint, the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focused on the latest progress since the release of the Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) and resulted in a new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice, standardize medical care, and promote the development of the discipline.",Tang H; Zhang W; Cao J; Cao Y; Bi X; Zhao H; Zhang Z; Liu Z; Wan T; Lang R; Sun W; Du S; Yang Y; Lu Y; Zeng D; Wu J; Duan B; Lin D; Li F; Meng Q; Zhou J; Xing B; Tian X; Zhu J; Gao J; Hao C; Wang Z; Duan F; Wang Z; Wang M; Liang B; Chen Y; Xu Y; Li K; Li C; Hu M; Wang Z; Cai S; Ji W; Xia N; Zheng W; Wang H; Li G; Zhu Z; Huang Z; Zhang W; Tao K; Liang J; Zhang K; Dai C; Li J; Qiu Q; Guo Y; Wu L; Ding W; Zhu Z; Gu W; Cao J; Wang Z; Tian L; Ding H; Li G; Zeng Y; Wang K; Yang N; Jin H; Chen Y; Yang Y; Xiu D; Yan M; Wang X; Han Q; Jiao S; Tan G; Wang J; Liu L; Song J; Liao J; Zhao H; Li P; Song T; Wang Z; Yuan J; Hu B; Yuan Y; Zhang M; Sun S; Zhang J; Wang W; Wen T; Yang J; Du X; Peng T; Xia F; Liu Z; Niu W; Liang P; Xu J; Zhao X; Zhu M; Wang H; Kuang M; Shen S; Cui X; Zhou J; Liu R; Sun H; Fan J; Chen X; Zhou J; Cai J; Lu S,False,does not present an RCT or specific outcomes,patients with advanced HCC,immune checkpoint inhibitors and anti-angiogenic therapy,not specified,improved survival and treatment consensus,consensus statement,False,"The abstract presents a consensus statement on conversion therapy for advanced HCC, focusing on combining ICIs with anti-angiogenic therapies. Model A accurately notes the absence of an RCT or specific outcomes. The lack of empirical data and study design precludes inclusion.",-,-,-,-,-,False,No disagreement between Model A and B,False
155,Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus: A case report and review of literature.,10.12998/wjcc.v12.i16.2847,"BACKGROUND: The prognosis of hepatocellular carcinoma (HCC) combined with portal and hepatic vein cancerous thrombosis is poor, for unresectable patients the combination of targeted therapy and immune therapy was the first-line recommended treatment for advanced HCC, with a median survival time of only about 2.7-6 months. In this case report, we present the case of a patient with portal and hepatic vein cancerous thrombosis who achieved pathologic complete response after conversion therapy. CASE SUMMARY: In our center, a patient with giant HCC combined with portal vein tumor thrombus and hepatic vein tumor thrombus was treated with transcatheter arterial chemoembolization (TACE), radiotherapy, targeted therapy and immunotherapy, and was continuously given icaritin soft capsules for oral regulation. After 7 months of conversion therapy, the patient's tumor shrank and the tumor thrombus subsided significantly. The pathology of surgical resection was in complete remission, and there was no progression in the postoperative follow-up for 7 months, which provided a basis for the future strategy of combined conversion therapy. CONCLUSION: In this case, atezolizumab, bevacizumab, icaritin soft capsules combined with radiotherapy and TACE had a good effect. For patients with hepatocellular carcinoma combined with hepatic vein/inferior vena cava tumor thrombus, adopting a high-intensity, multimodal proactive strategy under the guidance of multidisciplinary team (MDT) is an important attempt to break through the current treatment dilemma. reserved.",Song WJ; Xu J; Nie Y; Li WM; Li JP; Yang L; Wei MQ; Tao KS,False,does not meet the criteria for randomized controlled trial design,patients with hepatocellular carcinoma (HCC) and thrombosis,combination of targeted therapy and immune therapy,not specified,pathologic complete response,case report,False,"The study design is a case report, which does not meet the randomized controlled trial requirement. Additionally, the comparison group is not specified, making it impossible to evaluate the intervention's relative efficacy.",-,-,not specified (agrees with A_C but highlights the lack of a comparison group as a critical flaw),-,-,False,No disagreement between Model A and B,False
156,Successful liver transplantation with ctDNA clearance after PD1 inhibitor plus FOLFOXHAIC treatment in HCC: A case report.,10.3892/ol.2023.14185,"Liver transplantation (LT) is the primary treatment for patients with early-stage hepatocellular carcinoma (HCC). However, the 5-year survival rate after LT remains low for patients with advanced HCC. Recently, combining programmed cell death protein-1 (PD-1) inhibitors with hepatic arterial infusion chemotherapy (HAIC) has achieved promising outcomes in advanced HCC treatment. However, there is a lack of sufficient clinical data demonstrating its effectiveness as a pre-LT down-staging treatment. The current study presented a case of advanced HCC beyond the Milan criteria who underwent LT and achieved a favorable outcome following PD-1 inhibitor combined with FOLFOX-HAIC therapy. Of note, due to treatment-induced tumor necrosis, precise post-treatment tumor size evaluation became challenging. To address this, circulating tumor DNA (ct-DNA) clearance was used as the LT criterion. After three cycles of Pembrolizumab and FOLFOX-HAIC therapy, the patient's serum ctDNA became undetectable and serum -fetoprotein levels returned to normal. Magnetic resonance imaging results also revealed a significant reduction in liver tumor size post down-staging treatment. Subsequent to LT, serum ctDNA was monitored every two months, consistently yielding diminished results. There were no clinical signs of recurrence 19 months post-LT. These findings suggest that Pembrolizumab in combination with FOLFOX-HAIC may serve as a potential down-staging strategy prior to LT. In addition, ctDNA clearance may be considered a viable biomarker for LT eligibility.",Zhao Y; Chen D; Yang B; Xu J; Wang L; Huang G; Wei L; Chen Z,False,does not meet the criteria for randomized controlled trial design,patients with advanced hepatocellular carcinoma (HCC),PD-1 inhibitor combined with FOLFOX-HAIC therapy,not specified,favorable outcome post-LT,case report,False,"This is a case report, failing to meet the randomized controlled trial criterion. The comparison group is also not specified, and the outcome focuses on a single patient's favorable post-transplant result rather than survival or response rates.",-,-,not specified (agrees with A_C but notes the absence of a comparison group as a major limitation),-,-,False,No disagreement between Model A and B,False
157,Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response.,10.1016/j.radcr.2024.07.157,"Unresectable hepatocellular carcinoma unresponsive to first-line immunotherapy has a poor prognosis with modest response to tyrosine kinase inhibitors in the second line. In these patients, the benefit of local therapy with immunotherapy rechallenge is unknown. Radioembolization is a guideline-supported locoregional therapy for HCC that has shown the potential for synergy in combination with immunotherapy. This report describes a patient with veno-invasive HCC and extrahepatic invasion of the right kidney which progressed on atezolizumab and bevacizumab and was subsequently downstaged to resection with ipilimumab and nivolumab plus radioembolization yielding a complete pathologic response. The patient is currently more than 2 years since diagnosis without evidence of disease recurrence. Washington.",Silver CR; De la Garza-Ramos C; Stauffer JA; Majeed U; Wang J; Toskich BB,False,does not meet the criteria for randomized controlled trial design,patients with unresectable hepatocellular carcinoma (HCC),immunotherapy rechallenge with radioembolization,previous treatment with atezolizumab and bevacizumab,complete pathologic response,case report,False,"The study design is a case report, which does not fulfill the randomized controlled trial requirement. While the intervention and population are adequately described, the comparison group is limited to prior treatment without sufficient detail for rigorous evaluation.",-,-,previous treatment with atezolizumab and bevacizumab (agrees with A_C but emphasizes the lack of a robust comparison group),-,-,False,No disagreement between Model A and B,False
158,Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy.,10.3389/fonc.2019.01157,"Background: Current treatments of unresectable hepatocellular carcinoma (HCC) are trans-arterial chemo-embolization (TACE), stereotactic body radiotherapy (SBRT), and targeted therapy. However, these treatments are limited in efficacy and safety for patients with large tumor sizes. Here, we report a case series of combined SBRT and anti-PD-1 therapy in patients with unresectable HCC of large tumors. Methods: This is a retrospective case series of five patients with unresectable hepatocellular carcinoma who were treated with SBRT followed by anti-PD1 antibodies. Four patients (80%) received a single dose of TACE prior to SBRT. All patients had advanced HCC ineligible of curative intervention. In this study, we report their treatment responses according to modified RECIST (response evaluation criteria in solid tumor) criteria, 1-year local control (LC), progression-free survival (PFS), 1-year overall survival (OS) rate, and toxicities. Results: Among the five evaluated patients, three patients had underlying diseases of hepatitis B and four patients had Barcelona clinic liver cancer stage C. The median size of their tumors was 9.8 cm (range: 9-16.1 cm). In addition, two patients had tumor vascular thrombosis and one had extra-hepatic disease. Five out of five patients (100%) responded to treatment, with two complete responses (CR) and three partial responses (PR). Among the partial responders, one had a down-staged tumor that became amenable for radiofrequency ablation for tumor clearance. No patient developed tumor progression at the time of analysis during the median follow-up of 14.9 months (range 8.6-19 months). The median PFS was 14.9 months (range: 8.6-19 months); 1-year LC and OS rate were both 100%. One patient had grade  3 toxicities (pneumonitis and skin reaction). There was no classical radiation-induced liver disease. Conclusions: The results obtained from these 5 cases demonstrate impressive tumor control from the combination of SBRT and checkpoint inhibitors in patients with large tumors of advanced HCC. Further prospective trials are warranted.",Chiang CL; Chan ACY; Chiu KWH; Kong FS,False,does not meet the criteria for randomized controlled trial design,patients with unresectable hepatocellular carcinoma (HCC) of large tumors,combined SBRT and anti-PD-1 therapy,not specified,impressive tumor control,retrospective case series,False,"Although this is a retrospective case series with detailed outcomes, it does not meet the randomized controlled trial design criterion. The comparison group remains unspecified, and the focus on tumor control lacks direct measurement of survival or response rates.",-,-,not specified (agrees with A_C but underscores the absence of a comparison group),impressive tumor control (agrees with A_O but notes that survival or response rates are not explicitly measured),-,False,No disagreement between Model A and B,False
159,Expert consensus on sequential surgery after immune-targeted conversion therapy for advanced hepatocellular carcinoma in China.,10.5582/bst.2024.01423,"Hepatocellular carcinoma (HCC) represents a significant global health burden, particularly in the Asia-Pacific region, where it is a leading cause of cancer-related mortality. In China alone, HCC accounts for approximately 367,700 new cases and 316,500 deaths annually; over 50% of patients are diagnosed at an advanced stage, limiting curative treatment options and resulting in poor survival outcomes. Systemic therapies combining immune checkpoint inhibitors (ICIs) with antiangiogenic targeted drugs have shown promise in converting unresectable HCC into resectable cases, potentially transforming clinical outcomes. The Chines expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) provides an updated, multidisciplinary framework emphasizing sequential surgery post-conversion therapy. The consensus highlights treatment protocols, efficacy evaluation, and innovative adjuvant strategies to refine clinical practice and enhance survival outcomes in advanced HCC.",Song P; Tang W; Kokudo N,False,does not meet the criteria for randomized controlled trial design,patients with advanced hepatocellular carcinoma (HCC),combination of immune checkpoint inhibitors and antiangiogenic targeted drugs,not specified,not specified,expert consensus,False,"This is an expert consensus, which does not qualify as a randomized controlled trial. The outcomes are not specified, and there is no comparison group, rendering it unsuitable for inclusion under the PICOS criteria.",-,-,not specified (agrees with A_C but highlights the lack of a comparison group as a critical issue),not specified (agrees with A_O but points out the absence of measurable outcomes),-,False,No disagreement between Model A and B,False
160,[Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)].,10.3760/cma.j.cn112139-20240814-00245,"Up to half of hepatocellular carcinoma(HCC) cases are diagnosed at an advanced stage,for which effective treatment options are lacking,resulting in a poor prognosis. In recent years,the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has demonstrated high efficacy in treating advanced HCC,significantly extending patients' survival,and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy,patients can obtain long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the ""Healthy China 2030"" blueprint,the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association,Chinese Society of Liver Cancer,and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focus on the latest progress since the release of Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2021 Edition) and have reached new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice,standardize medical behavior,and promote the development of the discipline. Diseases of Chinese Preventive Medicine Association 10.3760/cma.j.cn112139-20240814-00245.",,False,"does not provide sufficient details on population, comparison, outcomes, or study design",not specified,combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy,not specified,not specified,not specified,False,"The abstract lacks critical details about the population, comparison group, outcomes, and study design. It discusses a consensus on combining immune checkpoint inhibitors with anti-angiogenic therapy but does not specify a randomized controlled trial or provide quantitative data on survival or response rates. Therefore, it does not meet the PICOS criteria.","patients with advanced hepatocellular carcinoma, as the abstract specifies 'advanced HCC' but does not provide further details such as staging or inclusion criteria",-,"not specified, as no clear comparator is mentioned in the abstract","not specified, as the abstract mentions 'long-term survival benefits' but does not quantify survival rate or response rate","not specified, as the abstract does not indicate a randomized controlled trial or any specific study design",False,No disagreement between Model A and B,False
161,Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC.,10.3389/fimmu.2024.1469302,"BACKGROUND: Transarterial therapy (TAT), bevacizumab (Bev), and immune checkpoint inhibitors (ICIs) have individually exhibited efficacy in treating advanced-stage hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of the combination of these three treatments as a neoadjuvant modality in patients with locally advanced HCC. METHODS: The primary endpoint is overall survival (OS). The second endpoint is progression free survival (PFS), objective response rate (ORR), pathological response rate and safety. RESULTS: A total of 54 patients received standard systemic therapy comprising Bev combined with ICIs (Bev-ICIs group), 113 patients received direct surgery (Surgery group), and 273 patients received neoadjuvant therapy of TAT combined Bev plus ICIs, among which 79 patients (28.9%) underwent surgical resection after successful tumor downstaging (Neo-surgery group) while the remaining 194 patients (71.1%) received maintenance systemic therapies (Neo-maintenance group). Neoadjuvant following surgery demonstrated a prolonged OS in contrast to direct surgery, with a median OS time not reached in the Neo-surgery group and 30.6 (95% CI: 26.4-34.7) months in the Surgery group (hazard ratio (HR)=0.29, P=0.0058). The median PFS time in the Neo-surgery and Surgery groups stood at 19.2 (95% CI: 16.1-22.2) and 6.3 (95% CI:4.7-8) months, respectively (HR=0.25, P<0.0001). In patients failed to receiving resection after neoadjuvant therapy, the median OS was 22.8 (95% CI: 22.3-23.1) months, whereas that for the standard care population was 19.7 (95% CI: 15.9-24) month (HR=0.53, P=0.023). The median PFS time in Neo-maintenance group and Bev-ICIs groups was 11.2 (95% CI: 10.4-11.9) and 6.4 (95% CI: 4.4-8.5) months (HR=0.60, P=0.024). The ORR and disease control rate (DCR) across all patients received TAT-Bev-ICIs were 38.8% and 89.4%, respectively. Additionally, the pathological complete response (pCR) rate and the major pathological response (MPR) rate were 22.8% and 48.1% in the Neo-surgery group. As for safety, neoadjuvant therapy did not increase the perioperative complications when compared to direct surgery, and demonstrated similar incidences and severity of AEs when compared to the standard systemic therapy. CONCLUSION: The triple therapy regimen comprising TAT-Bev-ICIs emerged as a promising therapeutic strategy for locally advanced hepatocellular carcinoma (HCC) as a neoadjuvant intervention.",Yang Z; Wang Q; Hu L; Sima X; Wang J; Hu D; Zhou Z; Chen M; Zhang Y; Fu Y,False,"while it details population, intervention, comparison, and outcomes, it does not clearly state that it is a randomized controlled trial",patients with locally advanced hepatocellular carcinoma,"combination of transarterial therapy, bevacizumab, and immune checkpoint inhibitors",direct surgery and standard systemic therapy,overall survival and progression free survival,not specified if randomized controlled trial,False,"Although the abstract provides details on population, intervention, comparison, and outcomes, it explicitly fails to confirm that the study design is a randomized controlled trial. The analysis compares different treatment groups but does not clarify randomization or control allocation, which is essential for inclusion under the PICOS criteria.",-,-,-,-,"observational or non-randomized study, as the abstract does not confirm randomization despite comparing multiple treatment groups",False,No disagreement between Model A and B,False
